
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>aveo-ex101_345.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
aveo-ex101_345.htm
</title>
</head>
<!-- NG Converter v4.0.3.7 -->
<body>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="top"  style="width:70%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities&#160;and&#160;Exchange&#160;Commission.&#160;Double&#160;asterisks&#160;denote&#160;omissions.</p></td>
<td valign="top"  style="width:8.2%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p></td>
<td valign="top"  style="width:7.7%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:30%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION VERSION</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> COLLABORATION AND LICENSE AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">BY AND BETWEEN</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">canbridge LIFE SCIENCES LTD.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">aveo pharmaceuticalS, INC.</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">March 17, 2016</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 1&nbsp;&nbsp; DEFINITIONS</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 2&nbsp;&nbsp; GOVERNANCE; JOINT STEERING COMMITTEE</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Formation; Purposes and Principles</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specific Responsibilities</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Membership</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Meetings; Reports</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decision-Making; Escalation to Executive Officers</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alliance Managers</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 3&nbsp;&nbsp; LICENSE GRANTS</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO License Grant; Right of Reference</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CANbridge License Grant; Right of Reference</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicensing and Subcontracting</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusivity Covenant</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition Transactions</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reservation of Rights</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bankruptcy Code &#167; 365(n) Election</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Inconsistent Third Party Agreements</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 4&nbsp;&nbsp; DEVELOPMENT</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Responsibilities</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Authorities</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Diligence; Manner of Performance; Reports</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rights of First Negotiation</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Submissions and Regulatory Approvals</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Partners</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 5&nbsp;&nbsp; MANUFACTURE AND COMMERCIALIZATION</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology Transfer and Manufacture</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 6&nbsp;&nbsp; FINANCIAL PROVISIONS</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:18pt;;text-indent:-18pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront Payment; Reimbursement of Manufacturing Development Costs; Milestone Payments</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicense Revenue</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty Payments and Reports</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit Share Payments</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment Reductions</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement of Third Party Expenses</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.8</font></p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Audits</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.9</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Matters</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.10</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency of Payments</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 7&nbsp;&nbsp; INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS </p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ownership of Inventions</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prosecution and Maintenance of the Licensed Patents</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prosecution and Maintenance of the CANbridge Program Patents</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Infringement</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claimed Infringement</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU Unitary Patent System</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademarks</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 8&nbsp;&nbsp; CONFIDENTIALITY AND PUBLICITY</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Information</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publicity</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 9&nbsp;&nbsp; REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual Representations and Warranties</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Representations and Warranties of AVEO</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Debarment</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 10&nbsp;&nbsp; INDEMNIFICATION; DAMAGES</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by AVEO</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by CANbridge</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claims for Indemnification</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 11&nbsp;&nbsp; LIMITATION OF LIABILITY</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Consequential or Punitive Damages</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusion from Liability Limitation</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 12&nbsp;&nbsp; TERM AND TERMINATION</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early Termination</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of Termination</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 13&nbsp;&nbsp; DISPUTE RESOLUTION</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dispute Resolution Escalation</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arbitration</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jury Waiver</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:96.16%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 14&nbsp;&nbsp; MISCELLANEOUS</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment; Successors</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Choice of Law</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-ii-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3</font></p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.4</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Integration</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waivers and Amendments</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Independent Contractors; No Agency</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Affiliates</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.9</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.10</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Third Party Beneficiary Rights</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.11</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-exclusive Remedy</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.12</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interpretation</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.13</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further Assurances</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.14</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ambiguities; No Presumption</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.98%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.15</p></td>
<td valign="top"  style="width:90.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution in Counterparts; Facsimile Signatures</p></td>
<td valign="bottom"  style="width:3.84%;">
<p style="text-align:right;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LIST OF SCHEDULES and EXHIBITS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.60:&nbsp;&nbsp;Existing Third Party License Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.88:&nbsp;&nbsp;List of AVEO Individuals for Purposes of Knowledge </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.112:&nbsp;&nbsp;Information to be Included in the POC Study Data Package</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.3.4:&nbsp;&nbsp;Provisions Required by Existing Third Party License Agreements to be Included in Sublicense Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 4.2.1:&nbsp;&nbsp;POC Study Requirements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 7.1.2:&nbsp;&nbsp;EvoGenix Improvements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 9.2.1:&nbsp;&nbsp;Licensed Patents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A:&nbsp;&nbsp;POC Development Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B:&nbsp;&nbsp;Initial Press Release</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C:&nbsp;&nbsp;Technology Transfer Plan and Transfer of Regulatory Documents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-iii-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="text-decoration:underline;">COLLABORATION AND LICENSE AGREEMENT</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS COLLABORATION AND LICENSE AGREEMENT (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), entered into as of March 17, 2016 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), is entered into by and between CANbridge Life Sciences Ltd., a corporation organized and existing under the laws of the People&#8217;s Republic of China (&#8220;<font style="text-decoration:underline;">CANbridge</font>&#8221;), and AVEO Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (&#8220;<font style="text-decoration:underline;">AVEO</font>&#8221;). </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">INTRODUCTION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, prior to the Effective Date, AVEO has developed an ErbB3 (HER3) inhibitory Antibody Product candidate for the treatment of cancer;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, CANbridge wishes to obtain from AVEO and AVEO wishes to grant to CANbridge certain rights and licenses under Licensed Patents and Licensed Know-How to Develop, Manufacture and Commercialize the Product in the Licensed Territory (each as defined below); and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, CANbridge and AVEO therefore desire to provide for the development, manufacture and commercialization of the Product on and subject to the terms and conditions set forth herein.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, the Parties hereby agree as follows:</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445902988"></a><a name="DEFINITIONS"></a><a name="_Ref440468092"></a>ARTICLE 1<font style="color:#000000;"><br><a name="DEFINITIONS"></a><a name="_Ref440468092"></a>DEFINITIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this Agreement, the following terms will have the meanings set forth below:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443931794"></a>1.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Accounting Standards</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to a Person, generally accepted accounting principles as practiced in the United States (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">GAAP</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) or applicable international standards followed by such Person. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Acquirer</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.5.1</font><font style="font-family:Times New Roman;color:#000000;"> (Effect of Acquisition Transaction). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Acquired Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.5.1</font><font style="font-family:Times New Roman;color:#000000;"> (Effect of Acquisition Transaction).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Acquisition Transaction</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.5.1</font><font style="font-family:Times New Roman;color:#000000;"> (Effect of Acquisition Transaction).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Action</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Adverse Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AE</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in 21 C.F.R. &#167; 312.32 and generally means any untoward medical occurrence associated with the use of a product in human subjects, whether or not considered related to such product. An AE does not necessarily have a causal relationship with a product, that is, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of such product.</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Adverse Ruling</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443931034"></a>1.8<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;"><a name="_Ref443931034"></a> &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Affiliate</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to any Person, any Person controlling, controlled by or under common control with such first Person.&nbsp;&nbsp;For purposes of this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 1.8</font><font style="font-family:Times New Roman;color:#000000;"> (Affiliate), &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">control</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means (a) direct or indirect ownership of 50% or more of the stock or shares having the right to vote for the election of directors of such Person (or if the jurisdiction where such Person is domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted under such Laws; provided, however, that such ownership interest provides actual control over such Person), (b) status as a general partner in any partnership, or (c) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;"> &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Aggregate AVEO Third Party Royalty Obligation</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the aggregate effective royalty rate that AVEO is obligated to pay Third Parties on the sale of Products by AVEO, its Affiliates or Sublicensees in any Calendar Year pursuant to the terms of the Existing Third Party License Agreements, as such agreements exist as of the Effective Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Alliance Manager</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 2.6.1</font><font style="font-family:Times New Roman;color:#000000;"> (Appointment). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.11<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Antibody</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any immunoglobulin molecule (such as IgG) whether in monospecific, bispecific or any other form, and will include (a) any immunoglobulin fragment (such as Fv, Fab, F(ab')2) of any such immunoglobulin molecule containing one or more complementarity determining regions, (b) any fusion protein comprising any such immunoglobulin molecule or immunoglobulin fragment and any single chain antibody (such as scFv), and (c) any truncation or derivative of any of the foregoing. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Applicable Percentage</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.5</font><font style="font-family:Times New Roman;color:#000000;"> (Profit Share Payment).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO Indemnified Parties</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 10.2</font><font style="font-family:Times New Roman;color:#000000;"> (Indemnification by CANbridge). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.14<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO Invention</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.1.2</font><font style="font-family:Times New Roman;color:#000000;"> (Ownership).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.15<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Bankruptcy Code</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.7</font><font style="font-family:Times New Roman;color:#000000;"> (Bankruptcy Code &#167; 365(n) Election). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>1.16<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Biologics License Application</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">BLA</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a biologics license application (as defined in Title 21 of the United States Code of Federal Regulations, parts 211 and 601, as amended) submitted to the FDA containing complete details of the manufacturing processes, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">chemistry, pharmacology, clinical pharmacology and the medical effects of a given biologic product, for purposes of obtaining Regulatory Approval for such biologic product in the United States.</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.17<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Biosimilar Competition</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to any country in the Licensed Territory, that any one or more Third Parties sell Biosimilar Products in such country that have, in the aggregate, achieved [**]% or more of the aggregate market share of Products and Biosimilar Products (based on data provided by IMS Health Incorporated, Fairfield, Connecticut) in any Calendar Quarter as measured on an aggregate sales basis (in unit sales), or if such data is not available, a methodology to be mutually agreed upon by the Parties for estimating the percentage of aggregate sales (in unit sales) based on market share of Biosimilar Products in such country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Biosimilar Product</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, as to any Product, a biologic product that is licensed by a Regulatory Authority as a biosimilar or bioequivalent to such Product based upon high similarity to the Product notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between such biological product and the Product in terms of the safety, purity, and potency. For purposes of clarity, a biologic product will be deemed to be biosimilar or bioequivalent to a Product for purposes of this definition to the extent such Product is used as the reference product in the application or submission made with respect to such biologic product under applicable Laws (including under the Biologics Price Competition and Innovation Act of 2009 and/or the United States Patient Protection and Affordable Care Act); provided, that, a product licensed or produced by CANbridge will not be deemed to be a Biosimilar Product for purposes of this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Blocking Third Party Patent Rights</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to a Product in any country in the Licensed Territory, any Patent Rights owned or Controlled by a Third Party that are necessary to Manufacture, or necessary or useful to Develop or Commercialize, such Product in such country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Blocking Third Party Intellectual Property Costs</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any royalties paid to a Third Party who owns or Controls Blocking Third Party Patent Rights in order to license or otherwise acquire the relevant rights to such Blocking Third Party Patent Rights.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.21<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Breaching Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.22<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Business Day</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any day other than a Saturday or a Sunday on which the banks in New York, New York and Beijing, China are open for business.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Calendar Quarter</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means each of the three month periods ending on March 31, June 30, September 30, and December 31 of any Calendar Year.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.24<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Calendar Year</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means each 12 month period commencing on January 1, and ending on December 31.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Indemnified Parties</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 10.1</font><font style="font-family:Times New Roman;color:#000000;"> (Indemnification by AVEO). </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Invention</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.1.2</font><font style="font-family:Times New Roman;color:#000000;"> (Ownership).</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.27<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Program Know-How</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Safety Data and CMC Data Controlled by CANbridge or any of its Affiliates as of the Effective Date or during the Term that is necessary or useful to Exploit any Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.28<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Program Patents</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Patent Rights that are Controlled by CANbridge or any of its Affiliates as of the Effective Date or during the Term that Cover the Exploitation of any Product, but excluding CANbridge&#8217;s interest in the Joint Patent Rights. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Clinical Data</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any and all data (together with all clinical trial reports and the results of analyses thereof) derived or generated from any Clinical Study involving any Product conducted by or on behalf of a Party or from the testing of subjects or the analysis of samples used in any such Clinical Study.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Clinical Trial Application</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CTA</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 1.76</font><font style="font-family:Times New Roman;color:#000000;"> (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">IND</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.31<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CMC</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the Chemistry, Manufacturing and Controls portion of any Regulatory Filing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.32<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CMC Data</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any data included in the CMC portion of a Regulatory Filing and in the supporting development reports, with respect to any Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Clinical Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a study in which human subjects or patients are dosed with a drug, whether approved or investigational, including any Phase II Clinical Study, Phase IIa Clinical Study, Phase III Clinical Study, or Phase IIIb Clinical Study.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Code</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the Internal Revenue Code of 1986, as amended from time to time (or any corresponding provisions of succeeding law).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Collaboration Agreement</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.2(a)</font><font style="font-family:Times New Roman;color:#000000;"> (Exclusive Negotiation Period). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Combination Product</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any pharmaceutical product containing a Product and one or more other significantly active pharmaceutical ingredients.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commence</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commencement</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, when used to describe a Clinical Study of a Product, the first dosing of the first human subject with such Product in such Clinical Study.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commercialization</font><font style="font-family:Times New Roman;color:#000000;">&#8221;, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commercializing</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commercialize</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any and all activities related to the pre-marketing, launching, marketing, promotion (including advertising and detailing), labeling, pricing and reimbursement, distribution, storage, handling, offering for sale, selling, importing and exporting for sale, distribution, customer service and support, and post-marketing safety surveillance and reporting of a product (including a Product), but not including Manufacturing.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commercially Reasonable Efforts</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, in respect of a Party, the level of efforts and resources (measured as of the time that such efforts and resources are required to be used under this Agreement) that are commonly used by a company in the industry of a similar size and profile as such Party to Develop, Manufacture or Commercialize, as the case may be, a product owned by such company or to which it has rights, which product is at a similar stage in its development or product life and is of a similar market and profitability potential to Product and taking into account all relevant factors including the patent and other proprietary position of the product, product labeling or anticipated labeling, market potential, financial return, medical and clinical considerations, regulatory environments and competitive market conditions, and other technical legal, scientific, medical or commercial factors that such a company would reasonably deem to be relevant. </font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Competitive Program</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.5.1</font><font style="font-family:Times New Roman;color:#000000;"> (Effect of Acquisition Transaction).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.41<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means (a) all trade secrets or confidential or proprietary information or tangible materials of the disclosing Party or its Affiliates provided or disclosed to the other Party or any of its Affiliates pursuant to this Agreement, (b) &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">&#8221; (as defined in the Prior CDA) that was disclosed by a Party or any of its Affiliates to the other Party or any of its Affiliates under the Prior CDA, and (c) the terms and conditions of this Agreement; provided, however, that Confidential Information will not include information that:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">has been published by a Third Party or otherwise is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful act, fault or negligence on the part of the receiving Party or its Affiliates;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;">has been in the receiving Party&#8217;s or its Affiliates possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information (as evidenced by the receiving Party&#8217;s or such Affiliate&#8217;s written records or other competent evidence);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">is subsequently received by the receiving Party or its Affiliate from a Third Party without restriction and without breach of any agreement between such Third Party and the disclosing Party; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;">has been independently developed by or for the receiving Party or its Affiliates without reference to, or use or disclosure of, the disclosing Party&#8217;s Confidential Information (as evidenced by the receiving Party&#8217;s or such Affiliate&#8217;s written records or other competent evidence);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided, further, that clauses (ii) through (iv) above will not apply to the terms and conditions of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">All Regulatory Filings owned by a Party will be deemed to be the Confidential Information of such Party and such Party will be deemed to be the disclosing Party and the other Party will be deemed to be the receiving Party with respect thereto. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.42</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Contract Manufacturing Organization</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CMO</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a Third Party contract manufacturing organization. </font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.43<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Control</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Controlled</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to any Know-How, Patent Right, Regulatory Filing or other intellectual property right, the legal authority or right (whether by ownership, license (other than a license granted pursuant to this Agreement) or otherwise) of a Person or its Affiliate, to grant access, a license or a sublicense of or under such Know-How, Patent Right, Regulatory Filing or intellectual property right, without breaching the terms of any agreement with a Third Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.44<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Cost of Goods Sold</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">COGS</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to any Product Manufactured by CANbridge or its Affiliates under this Agreement, the reasonable internal and external costs of CANbridge or its Affiliates incurred in Manufacturing such Product, including: (a) to the extent such Product is Manufactured by CANbridge or its Affiliates, the cost of goods sold of such Product, consisting of direct materials and direct labor costs, plus overhead directly attributable to Product supplied (including pre-batch and post-batch specific cleaning, all directly incurred Manufacturing variances and a reasonable allocation of related Manufacturing administrative, facilities operations and facilities depreciation costs (to the extent not otherwise included as direct labor costs or overhead), which allocation will be mutually agreed in good faith by the Parties, but excluding facilities or plant start-up costs and costs associated with excess or idle capacity), all calculated in accordance with GAAP in the United States consistently applied, and (b) to the extent that such Product is Manufactured by a Third Party manufacturer (including a CMO), the actual fees paid by such Party or any of its Affiliates to the Third Party for the Manufacture, supply, testing, packaging, labeling and shipping of such Product, and any reasonable out-of-pocket and direct labor costs actually incurred by such Party or any of its Affiliates in managing or overseeing the Third Party relationship.&nbsp;&nbsp;For purposes of clarity, if any material used to make a Product may be used to Manufacture multiple batches of Product and/or other compounds or products, the cost of such material will be appropriately allocated to such batches and/or other products or compounds and amortized over the useful life of such material in accordance with CANbridge&#8217;s Accounting Standards.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.45<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Cover,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Covering</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Covered</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, when referring to a Product: (a) with respect to a patent, that, in the absence of a license granted to a Person under a claim included in such patent, the practice by such Person of a specified activity with respect to such Product would infringe such claim (without regard to the validity or enforceability of such claim), or (b) with respect to a patent application, that, in the absence of a license granted to a Person under a claim included in such patent application, the practice by such Person of a specified activity with respect to such Product would infringe such claim if such patent application were to issue as a patent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>1.46<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Develop</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means non-clinical and clinical drug research and development activities, whether before or after Regulatory Approval, including drug metabolism and pharmacokinetics, translational research, toxicology, pharmacology, test method development and stability testing, process and packaging development and improvement, process validation, process scale-up, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, conduct of Clinical Studies, regulatory affairs, and Regulatory Approval and Clinical Study regulatory activities. Development includes use and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">importation of the relevant compound or Product to conduct such Development activities.&nbsp;&nbsp;Development will not include Commercialization activities.</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.47<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Milestone Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.1.3</font><font style="font-family:Times New Roman;color:#000000;"> (Development Milestone Payments).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.48<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Milestone Payment</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.1.3</font><font style="font-family:Times New Roman;color:#000000;"> (Development Milestone Payments).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.49<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Report</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.3.4</font><font style="font-family:Times New Roman;color:#000000;"> (Development Records; Reports). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Distributor</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Third Party appointed by a Party or any of its Affiliates to distribute, market and sell any Product, with or without packaging rights, in one or more countries in its respective territory, where such Third Party purchases its requirements of such Product from such Party or its Affiliates for a transfer price but does not make any royalty, profit share or similar payment to such Party based on sales of such Product. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.51<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Effective Date</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in the preamble. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">EPO</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (In the North America Territory).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.53<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">EMA</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the European Medicines Agency or any successor agency thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.54<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ERBB3</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the human ErbB3 (aka HER3) polypeptide, including: (a) any species variants or homologs thereof; (b) any amino acid sequence variants or mutations of the foregoing, (c) any post-translational modifications of the foregoing; and (d) any derivative or fragment of the foregoing; provided, however, that the derivative or fragment elicits an Antibody that reacts with native human erbB3, when used as an antigen.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.55<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ERBB3 Antibody</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means an Antibody that binds to ERBB3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.56<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ESCC</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 1.113</font><font style="font-family:Times New Roman;color:#000000;"> (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.57<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">European Union</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">EU</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the countries of the European Union as constituted on the Effective Date and as it may be expanded or contracted from time to time after the Effective Date; provided, however, that the EU will always be deemed to include the United Kingdom, France, Germany, Italy and Spain.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exclusive Negotiation Period</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.2(a)</font><font style="font-family:Times New Roman;color:#000000;"> (Exclusive Negotiation Period).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443931693"></a><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>1.59<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Executive Officers</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means (a) with respect to AVEO, the Chief Executive Officer of AVEO, and (b) with respect to CANbridge, the Chief Executive Officer of CANbridge.&nbsp;&nbsp;If the position of any of the Executive Officers identified in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 1.59</font><font style="font-family:Times New Roman;color:#000000;"> (Executive Officers) no longer exists due to a corporate reorganization, corporate restructuring or the like that results in the elimination of the identified position, the applicable title of the Executive Officer set forth herein will be replaced with the title of another executive officer with responsibilities and seniority </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">comparable to the eliminated Executive Officer, and the relevant Party will promptly provide notice of such replacement title to the other Party.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443931715"></a>1.60<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Existing Third Party License Agreements</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the license agreements by and between AVEO and Third Parties listed on </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 1.60</font><font style="font-family:Times New Roman;color:#000000;"> attached hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.61<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Expanded License</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.2(a)</font><font style="font-family:Times New Roman;color:#000000;"> (Exclusive Negotiation Period).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exploit</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exploitation</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means to make, have made, import, export, use, have used, sell, have sold, offer for sale or otherwise exploit, including to Develop, Commercialize, register, modify, enhance, improve, Manufacture, have Manufactured, hold, or keep (whether for disposal or otherwise), or otherwise dispose of.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.63<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">FDA</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the United States Food and Drug Administration or any successor agency thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.64<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">FFDCA</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;301 et seq.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Field</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means with respect to the Product, the diagnosis, treatment or prevention of disease in humans and/or animals.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.66<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">First Commercial Sale</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means with respect to a Product in any country, the first sale for monetary value for use or consumption by the end user of such Product in such country after the receipt of the Marketing Authorization for such Product has been obtained in such country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.67<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Force Majeure Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 14.9</font><font style="font-family:Times New Roman;color:#000000;"> (Force Majeure). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.68<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">FTE</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the equivalent of the work of one duly qualified employee of CANbridge full time for one year (consisting of a total of [**] hours per year) carrying out work under any this Agreement. The portion of an FTE for an individual during a given accounting period will be determined by dividing the number of hours worked directly by said individual on the work to be conducted under this Agreement during such accounting period and the number of FTE hours applicable for such accounting period based on [**] working hours per Calendar Year. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.69<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">GAAP</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 1.1</font><font style="font-family:Times New Roman;color:#000000;"> (Accounting Standards). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>1.70<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">GCP</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Good Clinical Practice</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means all applicable then-current standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of Clinical Studies, including, as applicable, (a) as set forth in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal Products, (b) the Declaration of Helsinki (2013) as last amended at the 64th World Medical Association in October 2013 and any further amendments or clarifications thereto, (c) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">New Drug Application), and (d) the equivalent applicable Laws in any relevant country, in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.71<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">GLP</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Good Laboratory Practice</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means all applicable then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#8217;s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58 or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (OECD), and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which a Product is intended to be sold, to the extent such standards are not less stringent than United States Good Laboratory Practice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.72<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">GMP</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Good Manufacturing Practice</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means all applicable then-current standards for Manufacturing, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. &#167;&#167; 201, 211, 600 and 610 and all applicable FDA guidelines and requirements, (b) European Directive 2003/94/EC for medicines and investigational medicines for human use and the applicable guidelines stated in the Eudralex guidelines, (c) the principles detailed in the applicable ICH guidelines, (d) the conduct of an inspection by a Qualified Person and the execution by such Qualified Person of an appropriate certification of inspection; and (e) the equivalent applicable Laws in any relevant country, each as may be amended and applicable from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.73<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Governmental Authority</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any multinational, federal, national, state, provincial, local or other entity, office, commission, bureau, agency, political subdivision, instrumentality, branch, department, authority, board, court, arbitral or other tribunal, official or officer, exercising executive, judicial, legislative, police, regulatory, administrative or taxing authority or functions of any nature pertaining to government.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.74<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Government Order</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with any Governmental Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ICH</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443931405"></a>1.76<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">IND</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means an application filed with a Regulatory Authority for authorization to commence Clinical Studies, including (a) an Investigational New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA, (b) any equivalent of a United States IND in other countries or regulatory jurisdictions, including a Clinical Trial Application (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CTA</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) and (c) all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.77<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Indemnified Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a Person entitled to indemnification under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 10</font><font style="font-family:Times New Roman;color:#000000;"> (Indemnification; Damages).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.78<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Indemnifying Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a Party from whom indemnification is sought under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 10</font><font style="font-family:Times New Roman;color:#000000;"> (Indemnification; Damages).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.79</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Infringement Action</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.4.3</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the North America Territory).</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Infringement Claim</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.5</font><font style="font-family:Times New Roman;color:#000000;"> (Claimed Infringement).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Insolvent Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.7</font><font style="font-family:Times New Roman;color:#000000;"> (Bankruptcy Code &#167; 365(n) Election). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">International Chamber of Commerce</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ICC</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in Section 13.1 (Arbitration). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Invention</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.1.1</font><font style="font-family:Times New Roman;color:#000000;"> (Inventorship). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Joint Know-How</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Know-How that is first conceived or reduced to practice jointly by the Parties or their Affiliates or others acting on behalf of the Parties or their Affiliates in the conduct of Development, Manufacturing or Commercialization of the Product under this Agreement during the Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.85<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Joint Patent Rights</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Patent Rights that contain one or more claims that Cover Joint Know-How. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.86<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">JSC</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Formation; Purposes and Principles).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Know-How</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means all chemical and biological materials and other tangible materials, inventions, practices, methods, protocols, formulae, knowledge, know-how, trade secrets, processes, procedures, assays, skills, experience, techniques, data and results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical test data and analytical and quality control data, patentable or otherwise. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444010337"></a>1.88<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Knowledge</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Known</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to AVEO, the actual knowledge of any of the individuals listed on Schedule 1.88 attached hereto. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Law</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Laws</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means all laws, statutes, rules, codes, regulations, orders, decrees, judgments or ordinances of any Governmental Authority, or any license, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Licensed Know-How</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Know-How Controlled by AVEO or its Affiliates as of the Effective Date or during the Term (including any AVEO Inventions and AVEO&#8217;s interest in the Joint Know-How) that is necessary or useful to Exploit a Product in the Field and in the Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Licensed Patents</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Patent Rights Controlled by AVEO or its Affiliates as of the Effective Date or during the Term (including (a) the Patent Rights identified on </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 9.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Licensed Patents) and (b) AVEO&#8217;s interest in the Joint Patent Rights), in each case, that are necessary or useful to Exploit a Product in the Field and in the Territory.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.92</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Licensed Territory</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means worldwide, excluding the North America Territory. </font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Licensed Territory Infringement Action</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.4.2</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the Licensed Territory).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.94<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Losses</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means damages, losses, liabilities, costs (including costs of investigation, defense), fines, penalties, taxes, expenses, or amounts paid in settlement (in each case, including reasonable attorneys&#8217; and experts&#8217; fees and expenses), in each case resulting from an Action by a Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">MAA</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means (a) a marketing authorization application filed with (i) the EMA under the centralized EMA filing procedure or (ii) a Regulatory Authority in any EU country if the centralized EMA filing procedure is not used, or (b) any other equivalent or related regulatory submission, in either case to gain approval to market a Product in any country in the EU, and, in each case, including any amendments thereto, and supplemental applications but excluding Pricing and Reimbursement Approval applications.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Major Market Country</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means each of China, Japan, the United Kingdom, France, Italy, Spain, and Germany.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.97<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Manufacture</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Manufacturing</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means all activities related to the production of a Product, including the production of any of the following to the extent used in a Product: any drug substance produced in bulk form for use as an active pharmaceutical ingredient, drug product, compounded or finished final packaged and labeled form, and in intermediate states, including but not limited to the following activities: reference standard preparation, cell bank preparation, mammalian cell production, purification, formulation, scale-up, packaging, disposition of product, quality assurance oversight, quality control testing (including in-process release and stability testing), storage of product or any component or ingredient thereof and validation activities directly related to all of the foregoing, and data management and recordkeeping related to all of the foregoing. References to a Person engaging in Manufacturing activities will include having any or all of the foregoing activities performed by a Third Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.98<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Marketing Authorization</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the grant of all necessary permits, registrations, authorizations, licenses and approvals (or waivers) required for the Manufacture and Commercialization of a Product for use in the Field and in the Territory, including any Regulatory Approval for sale or marketing, and, where required, Pricing and Reimbursement Approvals.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.99<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Net Sales</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to a Product for any period, the total gross amount billed or invoiced on sales of such Product during such period by CANbridge, its Affiliates, or Sublicensees (other than Distributors and Profit Share Sublicensees) in the Licensed Territory to Third Parties (including Distributors), in bona fide arm&#8217;s length transactions, less the following deductions, in each case related specifically to the Product and actually incurred, paid or accrued by CANbridge, its Affiliates or Sublicensees and not otherwise recovered by or reimbursed to CANbridge, its Affiliates, or Sublicensees:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">trade, cash, price, and quantity discounts actually given to Third Parties;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;">price reductions, rebates or other payments, retroactive or otherwise, imposed by, negotiated with or otherwise paid to Governmental Authorities or other payees;</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">taxes and other governmental charges and fees on sales (such as sales, value added, or use taxes, other than income taxes) to the extent added to the sale price and set forth separately as such in the total amount invoiced and borne by such Third Party;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">amounts repaid or credited by reason of rejections, defects, return goods allowances, recalls or returns, or because of retroactive price reductions, including rebates or wholesaler charge backs;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;">the portion of administrative fees, chargeback payments and rebates (or the equivalent thereof) paid during the relevant time period to group purchasing organizations, Governmental Authorities, trade customers, managed health care organizations or pharmaceutical benefit managers or Medicare prescription drug plans (or analogous plans) relating to such Product; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;">bad debts actually written off which are attributable to sales of Products not to exceed 1% of Net Sales, to the extent such amounts have not been previously deducted;&nbsp;&nbsp;provided, however, that any such amounts that are written off will be added back in a subsequent period to the extent later collected; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;">freight, insurance, import/export, and other transportation charges to the extent added to the sale price and set forth separately as such in the total amount invoiced, as well as any fees for services provided by wholesalers and warehousing chains related to the distribution of such Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Sales will not include transfers or dispositions of Product for charitable, promotional, pre-clinical, clinical, regulatory, or governmental purposes, in all cases, without consideration.&nbsp;&nbsp;Net Sales will include the amount or fair market value of all other consideration received by CANbridge, its Affiliates or Sublicensees in respect of the Product, whether such consideration is in cash, payment in kind, exchange or other form.&nbsp;&nbsp;Net Sales will be calculated only once for the first bona fide arm's length sale of a Product by a CANbridge, its Affiliates or its permitted Sublicensees to a Third Party, and will not include sales between or among CANbridge, its Affiliates, or Sublicensees (other than Distributors or as described in the following paragraph regarding Profit Share Sublicensees).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a sale of a Product by CANbridge or its Affiliates to a Profit Share Sublicensee, then the Net Sales for such Product in a given Calendar Quarter will (A) include the transfer price payment (minus any applicable deductions set forth in clauses (a) through (g) above) for such Product sold to the Profit Share Sublicensee in such Calendar Quarter and (B) exclude the Profit Share Payment and any amounts paid to the Profit Share Sublicensee in connection with its subsequent resale of such Product.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the above, Net Sales will be calculated in accordance with the standard internal policies and procedures of CANbridge, its Affiliates, or Sublicensees, if any, copies of which policies and procedures will be furnished to AVEO upon request, and which must in any case be in accordance with its Accounting Standards. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event a Product is sold in the form of a Combination Product, then the Net Sales for any such Combination Product will be determined by multiplying the Net Sales of the Combination Product during the applicable royalty reporting period, by the fraction, A/(A +B), where A is the weighted (by sales volume) average sale price of the Product when sold separately in finished form in the country in which the Combination Product is sold and B is the weighted (by sales volume) average sale price of the other product(s) which contain the other significantly active ingredient(s) included in the Combination Product when sold separately in finished form in the country in which the Combination Product is sold, in each case during the applicable royalty reporting period or, if sales of both the Product and the other product(s) did not occur in such period, then in the most recent royalty reporting period in which sales of both occurred. In the event that such average sale price cannot be determined for both the Product and all other significantly active pharmaceutical ingredient(s) included in the Combination Product, then the Parties will in good faith discuss and agree on a pro-rata allocation of the Net Sales that reflects the Product's contribution to the Combination Product on an equitable basis; provided, however, that, (i) until such time as the Parties reach agreement upon an appropriate pro-rata allocation, the Parties will use a deemed allocation equal to fifty percent (50%) between the Product and the other product(s) which contain the other significantly active ingredient(s) for purposes of determining Net Sales (which allocation the Parties hereby agree will not be used as a benchmark or point of reference for the actual allocation to be agreed upon by the Parties) and (ii) promptly following the Parties reaching agreement on the appropriate pro-rata allocation, an adjustment will be made in future payments of Net Sales for such Combination Product to account for the difference between the deemed allocation and the agreed-upon allocation.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.100<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Non-Acquired Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.5.2</font><font style="font-family:Times New Roman;color:#000000;"> (Protective Procedures). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.101<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Non-Breaching Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.102<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">North America Territory</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the United States, Canada and Mexico, and their respective territories and possessions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.103<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">North America Infringement Action</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.4.3</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the North America Territory).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.104<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">On-Going Clinical Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.3.7</font><font style="font-family:Times New Roman;color:#000000;"> (On-Going Trials).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.105<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means either AVEO or CANbridge; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Parties</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means AVEO and CANbridge, collectively.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>1.106<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Patent Rights</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the rights and interests in and to (a) all patents and patent applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of any of the foregoing, (b) any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">foreign counterparts, and the like of any of the foregoing, (c) any and all patents that have issued or in the future issue from the foregoing patent applications, including author certificates, utility models, petty patents, innovation patents and design patents and certificates of invention.</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.107<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Person</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship or other business organization or a Governmental Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.108<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Phase II Clinical Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a clinical study in humans of the safety, dose ranging and efficacy of a pharmaceutical Product, as described in federal regulation 21 C.F.R. &#167; 312.21(b) and its foreign equivalents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.109<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Phase IIa Clinical Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a Phase II Clinical Study specifically designed to assess dosing range and requirements. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.110<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Phase III Clinical Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a controlled clinical study, or a portion of a controlled study, in humans of the efficacy and safety of a Product, which study (in its entirety or portion, as applicable), is prospectively designed to demonstrate statistically whether such Product is effective and safe for use in a particular indication in a manner sufficient to file an BLA, MAA or other Regulatory Approval Application to obtain Regulatory Approval, as further defined in federal regulation 21 C.F.R. &#167; 312.21(c) and its foreign equivalents.&nbsp;&nbsp;For clarity, with respect to what is commonly called a phase 2/3 study, the Phase III Clinical Study definition is met upon the first patient, first visit in the portion of such study that is prospectively designed to demonstrate statistically whether such pharmaceutical Product is effective and safe for use in a particular indication in a manner sufficient to file a BLA, MAA or other Regulatory Approval Application to obtain Regulatory Approval, as further defined in federal regulation 21 C.F.R. &#167; 312.21(c) and its foreign equivalents. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.111<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Development Plan</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the written plan for CANbridge&#8217;s Development efforts in connection with the conduct of the POC Study (including a description of the POC Study itself), prepared and finalized by CANbridge in accordance with </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.2</font><font style="font-family:Times New Roman;color:#000000;"> (Development Authorities), as amended from time to time in accordance with this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443933726"></a>1.112<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study Data Package</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a package of information regarding the results of the POC Study containing the information and data described in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 1.112</font><font style="font-family:Times New Roman;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443931605"></a>1.113<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to a Product, a Phase IIa Clinical Study that is appropriately designed (a) to demonstrate efficacy in Esophageal Squamous Cell Carcinoma (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ESCC</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) through relevant primary and/or secondary efficacy endpoints as described in the POC Development Plan and (b) to support generation of efficacy data that would allow movement of such Product into a Phase IIa Clinical Study or Phase III Clinical Study that would support the regulatory strategy of seeking Regulatory Approval for ESCC in the Territory. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.114<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study ROFN</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4</font><font style="font-family:Times New Roman;color:#000000;"> (POC Study ROFN).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.115<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study ROFN Period</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4</font><font style="font-family:Times New Roman;color:#000000;"> (POC Study ROFN).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.116</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Pricing and Reimbursement Approval</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to a Product, the governmental approval, agreement, determination or decision establishing the price or level of reimbursement for such Product, in a given jurisdiction prior to sale of such Product in such jurisdiction.</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443933791"></a>1.117<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Prior CDA</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the Confidential Disclosure Agreement between AVEO and CANbridge, dated 4th February 2015 (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Prior CDA Effective Date</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.118<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Prior CDA Effective Date</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 1.117</font><font style="font-family:Times New Roman;color:#000000;"> (Prior CDA). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.119<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Product</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any product that contains, incorporates, comprises or is derived from any ERBB3 Antibody (a) that is discovered, Developed or Controlled by or on behalf of AVEO or any of its Affiliates prior to or during the Term or (b) the Development, Manufacture or Commercialization of which is Covered by a Licensed Patent. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.120<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">&#8220;Profit Share Payments</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any payments made by a Profit Share Sublicensee to CANbridge or its Affiliates with respect to any Product that are calculated based on a percentage of a Profit Share Sublicensee&#8217;s markup or profit on its resale of such Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.121<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Profit Share Sublicensee</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a Sublicensee in any country in the Territory other than in Europe and Japan that (a) purchases Products from CANbridge or its Affiliate in consideration for a transfer price and (b) pays AVEO or its Affiliate a percentage of its markup or profit on the resale of such Products.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.122<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Qualified Person</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">QP</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a qualified person as defined the Clinical Trial Directive 2001/20/EC and Annex 13 to the European GMP Guide.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.123<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Recall</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a Party&#8217;s removal or correction of a Product following (a) notice or request of any Regulatory Authority or (b) the good faith determination by such Party that an event, incident or circumstance has occurred that required such a recall of such Product.&nbsp;&nbsp;A Recall does not include a market withdrawal or a stock recovery. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.124<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Approval Application</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a BLA, an MAA or other equivalent application to seek Regulatory Approval of a Product for sale or marketing in any country(ies) outside the United States, as defined in the applicable Laws and filed with the Regulatory Authority of such country(ies).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.125<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Approval</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the approval of the applicable Regulatory Authority necessary for the marketing and sale of a Product in the Field in a country(ies), excluding separate Pricing and Reimbursement Approval that may be required.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.126<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Authority</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture, marketing and sale of a Product in a country, including FDA in the United States and EMA in the EU.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444629840"></a>1.127<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Documentation</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the documents set forth on </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exhibit C</font><font style="font-family:Times New Roman;color:#000000;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.128</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Filing</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any documentation comprising or relating to or supporting any filing or application with any Regulatory Authority with respect to a Product, including any documents submitted to any Regulatory Authority, including INDs, Regulatory Approval Applications, and all correspondence with any Regulatory Authority with respect to any Product (including minutes of any meetings, telephone conferences or discussions with any Regulatory Authority).</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.129<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ROFN</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.3</font><font style="font-family:Times New Roman;color:#000000;"> (Right of First Negotiation).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.130<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ROFN Opportunity</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.1</font><font style="font-family:Times New Roman;color:#000000;"> (POC Study ROFN). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.131<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ROFN Period</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.3</font><font style="font-family:Times New Roman;color:#000000;"> (Right of First Negotiation).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.132<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Royalty Term</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.3.2</font><font style="font-family:Times New Roman;color:#000000;"> (Royalty Term).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.133<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Rules</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 13.1</font><font style="font-family:Times New Roman;color:#000000;"> (Arbitration). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.134<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Safety Data</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Adverse Event information from human trials and all results from non-clinical safety studies, including, but not limited to, toxicology and carcinogenity data (if any), with respect to a Product required by one or more Regulatory Authorities to be collected or to be reported to such Regulatory Authorities under applicable Laws, but excluding any information related to the efficacy of the Product. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.135<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sales Milestone Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.1.4</font><font style="font-family:Times New Roman;color:#000000;"> (Sales Milestone Payments).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.136<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sales Milestone Payment</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.1.4</font><font style="font-family:Times New Roman;color:#000000;"> (Sales Milestone Payments).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.137<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Serious Adverse Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SAE</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in 21 C.F.R. &#167; 312.32, and generally means any Adverse Event that (a) results in death, (b) is life-threatening, (c) requires inpatient hospitalization or prolongation of existing hospitalization, (d) results in persistent or significant disability or incapacity or (e) is a congenital anomaly or birth defect.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.138<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Severed Clause</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 14.4</font><font style="font-family:Times New Roman;color:#000000;"> (Severability). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.139<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Significant Development Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any of the following Development events: (a) any material interaction and/or written correspondence between a Party and any Regulatory Authority with respect to any Product; (b) any material event with respect to any Clinical Study involving any Product; and (c) any material result obtained in the conduct of any Clinical Study involving any Product during the period covered by the Development Report.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.140<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.3.3</font><font style="font-family:Times New Roman;color:#000000;"> (Sublicense Requirements).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.141<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Payment</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Sublicense Payments).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.142</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Revenue Percentage</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Sublicense Payments).</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.143<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Revenue</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means all payments received by CANbridge or its Affiliates from a Sublicensee in consideration for a Sublicense, including upfront payments, maintenance fees and development milestone payments, but excluding payments received based on sales of Products, such as royalty payments, sales milestone payments or profit share payments (including Profit Share Payments). For the avoidance of doubt, Sublicense Revenue will not include (a) amounts paid to CANbridge by a Sublicensee (i) in respect of future Development costs or in consideration of services performed by CANbridge, to the extent such Development costs or services represent a transaction for fair market value, or (ii) as a loan or equity investment in CANbridge, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that any portion of such loan or equity investment that does not represent a transaction for fair market value would be included as a Sublicense Revenue and (b) any transfer price payments and/or Profit Share Payments paid to CANbridge by a Profit Share Sublicensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.144<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicensee</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means, with respect to a Party, a Third Party sublicensee of rights granted to such Party under this Agreement or a Third Party licensee of rights with respect to a Product which rights are retained by such Party under this Agreement with respect to such Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.145<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Supply Agreement</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.5</font><font style="font-family:Times New Roman;color:#000000;"> (Supply Terms).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.146<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Technology Transfer</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.1</font><font style="font-family:Times New Roman;color:#000000;"> (Transfer of Licensed Know-How).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.147<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Technology Transfer Plan</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.1</font><font style="font-family:Times New Roman;color:#000000;"> (Transfer of Manufacturing Know-How).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.148<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Term</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.1</font><font style="font-family:Times New Roman;color:#000000;"> (Term).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.149<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Territory</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the Licensed Territory for CANbridge and the North America Territory for AVEO, as applicable. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.150<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any Person other than a Party or any of its Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.151<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Claim</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 10.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (Notice).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.152<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Collaboration Agreement</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.6.1</font><font style="font-family:Times New Roman;color:#000000;"> (Unblocking Rights). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.153<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Partner</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.6.1</font><font style="font-family:Times New Roman;color:#000000;"> (Unblocking Rights).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.154<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Trademark</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.155</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">United States</font><font style="font-family:Times New Roman;color:#000000;">,&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">U.S.</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">US</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">US Territory</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the United States of America and its territories and possessions.</font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.156<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">UPC</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.6</font><font style="font-family:Times New Roman;color:#000000;"> (EU Unitary Patent System).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.157<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">USPTO</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (In the North America Territory).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.158<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Valid Claim</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a claim (including a process, use, or composition of matter claim) of (a) an issued and unexpired patent that has not (i) irretrievably lapsed or been abandoned, revoked, dedicated to the public or disclaimed or (ii) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal or (b) a pending patent application, which claim has not been abandoned or finally disallowed without the possibility of appeal; provided, that, if a pending patent application has been pending for longer than seven years from the date of filing of the initial priority application, then such corresponding claim in such pending patent application will not be deemed to be a Valid Claim.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.159<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Validation of Manufacturing Development</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means the validation, to CANbridge&#8217;s reasonable satisfaction, of the Manufacturing development activities conducted by AVEO prior to the Effective Date, which in any event will occur upon the completion by CANbridge or its designated CMO of an engineering run of Product drug substance using the manufacturing process used by AVEO to manufacture Product drug substance prior to the Effective Date, which engineering run enables CANbridge to perform its planned preclinical studies with respect to the Product.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.160<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Withholding Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.9.2</font><font style="font-family:Times New Roman;color:#000000;"> (Tax Withholding).</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445902989"></a>ARTICLE 2<font style="color:#000000;"><br>GOVERNANCE; JOINT STEERING COMMITTEE</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Formation_Purposes_and_Principles"></a><a name="_Ref443931968"></a><a name="_Toc445902990"></a><a name="_Ref439708264"></a>2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Formation; Purposes and Principles</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Promptly following the Effective Date, but in no event later than [**] days thereafter, AVEO and CANbridge will form a joint steering committee (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">JSC</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) to provide oversight and to facilitate information sharing between the Parties with respect to the activities of the Parties under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Specific_Responsibilities"></a><a name="_Ref439737783"></a><a name="_Toc445902991"></a>2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Specific Responsibilities</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In addition to its overall responsibility to provide oversight and to facilitate information sharing between the Parties with respect to the activities of the Parties under this Agreement, the JSC will:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">review and approve changes to the POC Development Plan proposed by CANbridge on an as-needed basis;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">review and discuss, as necessary, the Parties&#8217; Development and Manufacturing activities related to the Products, including the performance of each Party, or a Party&#8217;s Affiliate or Sublicensee, as applicable, in performing the activities under the POC Development Plan;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">coordinate and share information with respect to the Development and Commercialization of Products; </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">keep each Party reasonably informed of the other Party&#8217;s Development and Manufacturing activities and Commercialization activities and interactions with Regulatory Authorities, by receiving updates from the Party conducting such activities; </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">attempt to resolve in the first instance all matters between the Parties that are in dispute; and</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">perform such other functions as are assigned to it in this Agreement or as appropriate to further the purposes of this Agreement to the extent agreed to in writing by the Parties.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445902992"></a>2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Membership</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The JSC will be composed of an equal number of representatives appointed by each of AVEO and CANbridge.&nbsp;&nbsp;Each individual appointed by a Party as a representative to the JSC will be an employee or contractor of such Party, or an employee or contractor of such Party&#8217;s Affiliate.&nbsp;&nbsp;Each Party may replace any of its JSC representatives at any time upon written notice to the other Party, which notice may be given by e-mail, sent to the other Party&#8217;s co-chairperson.&nbsp;&nbsp;The JSC will be co-chaired by one designated representative of each Party.&nbsp;&nbsp;The co-chairperson of the JSC will cast its Party&#8217;s vote on the JSC and such designee will have the authority to make decisions on behalf of such Party.&nbsp;&nbsp;The co-chairpersons will be responsible for (a) calling meetings, (b) preparing and circulating an agenda in advance of each meeting; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that the co-chairpersons will include any agenda items proposed by either Party on such agenda, and (c) preparing and issuing minutes of each meeting promptly thereafter.&nbsp;&nbsp;Each JSC representative will be subject to confidentiality obligations no less stringent than those in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 8</font><font style="font-family:Times New Roman;color:#000000;"> (Confidentiality and Publicity). </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442609639"></a><a name="_Toc445902993"></a>2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Meetings; Reports</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The JSC will hold meetings [**] during the Term for so long as the JSC exists; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, in the event the Parties enter into a Collaboration Agreement or an Expanded License pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.2</font><font style="font-family:Times New Roman;color:#000000;"> (North America Territory ROFN), the JSC will meet no less frequently than [**]. At least [**] Business Days prior to each meeting of the JSC, each Party will provide a reasonably detailed report describing its Development and Manufacturing activities under the POC Development Plan and this Agreement conducted to date.&nbsp;&nbsp;The JSC may meet in person or by audio or video conference as its representatives may mutually agree.&nbsp;&nbsp;Other representatives of the Parties, their Affiliates and Third Parties involved in the Development, Manufacture or Commercialization of the Products may be invited by the members of the JSC to attend meetings as non-voting observers; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that such representatives are subject to confidentiality obligations no less stringent than those in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 8</font><font style="font-family:Times New Roman;color:#000000;"> (Confidentiality and Publicity); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">further</font><font style="font-family:Times New Roman;color:#000000;">, that each representative appointed by a Party to take action at a meeting will have sufficient authority to execute such action on behalf of such Party.&nbsp;&nbsp;No action taken at a meeting will be effective unless at least one representative of each Party is present or participating.&nbsp;&nbsp;Neither Party will unreasonably withhold attendance of at least one representative of such Party at any meeting of the JSC for which reasonable advance notice was provided. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Decision_Making"></a><a name="_Ref439599056"></a><a name="_Toc445902994"></a><a name="Escalation_to_Executive_Officers"></a><a name="_Ref439599123"></a><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>2.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;"><a name="Escalation_to_Executive_Officers"></a><a name="_Ref439599123"></a>Decision-Making</font><font style="font-family:Times New Roman;color:#000000;">; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Escalation to Executive Officers</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Parties will endeavor in good faith to reach unanimous agreement with respect to all matters within the JSC&#8217;s authority.  </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">Should the JSC not be able to reach agreement with respect to such matter at a duly called meeting of the JSC, either Party may refer such matter to the Executive Officers for resolution, and the Executive Officers will attempt to resolve the matter in good faith.&nbsp;&nbsp;If the Executive Officers fail to resolve such matter within </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> Business Days after the date on which the matter is referred to the Executive Officers (unless a longer period is agreed to by the Parties), then</font><font style="font-family:Times New Roman;color:#000000;"> decisions regarding such matter may be finally determined by CANbridge; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that CANbridge will only exercise such final decision-making authority after the good faith consideration of AVEO&#8217;s position; and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">further</font><font style="font-family:Times New Roman;color:#000000;">, that CANbridge will not be entitled to use such final decision-making authority, and any decision must be unanimous in the event of any disagreement or deadlock at the JSC, with respect to the following matters:</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">any amendment of the POC Development Plan in a manner that fails to satisfy the minimum requirements set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.2</font><font style="font-family:Times New Roman;color:#000000;"> (Development Authorities), unless such amendment is the result of AVEO&#8217;s failure to comply with its obligations under this Agreement; </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">the negation of any consent right or other rights specifically allocated to AVEO under this Agreement or any obligation of CANbridge set forth in this Agreement; or</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">the expansion or narrowing of the responsibilities of the JSC.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clarity, AVEO will have the sole right to make any final decisions related to the Development, Manufacture and/or Commercialization by AVEO of the Product in the North America Territory.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445902995"></a><a name="_Ref398285068"></a>2.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Alliance Managers</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442606559"></a>2.6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Appointment</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party will have the right, but not the obligation, to appoint a person to oversee interactions between the Parties for all matters related to the Development and Commercialization of Products between meetings of the JSC (each, an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Alliance Manager</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).&nbsp;&nbsp;The Alliance Managers will have the right to attend all meetings of the committees as non-voting participants and may bring to the attention of the JSC any matters or issues either Alliance Manager reasonably believes should be discussed and will have such other responsibilities as the Parties may mutually agree in writing.&nbsp;&nbsp;Each Party may replace its Alliance Manager at any time or may designate different Alliance Managers with respect to Development and Commercialization matters, respectively, by notice in writing to the other Party.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Responsibility</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Alliance Managers, if appointed, will have the responsibility of creating and maintaining a constructive work environment within the JSC and between the Parties for all matters related to this Agreement.&nbsp;&nbsp;Without limiting the generality of the foregoing, each Alliance Manager will:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">provide a single point of communication within the Parties&#8217; respective organizations and between the Parties with respect to this Agreement; coordinate cooperative efforts, internal communications and external communications between the Parties with respect to this Agreement; and</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>(b)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">take such other steps as may be required to ensure that meetings of the committees occur as set forth in this Agreement, that procedures are followed with respect to such meetings (including the giving of proper notice and the preparation and approval of minutes) </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed.</font>&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445902996"></a>ARTICLE 3<font style="color:#000000;"><br>LICENSE GRANTS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="AVEO_License_Grant_Right_of_Referen"></a><a name="_Ref439444239"></a><a name="_Toc445902997"></a>3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO License Grant; Right of Reference</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exclusive License Grant</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, including the provisions of </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.2(b)</font><font style="font-family:Times New Roman;color:#000000;"> (Failure to Reach Agreement), AVEO hereby grants to CANbridge an exclusive (even with respect to AVEO and its Affiliates), sublicenseable (subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (CANbridge Right to Sublicense)), royalty-bearing right and license under the Licensed Patents and Licensed Know-How to (a) Develop, Manufacture, Commercialize and otherwise Exploit the Product in the Field in the Licensed Territory, and (b) Develop and Manufacture Products outside the Licensed Territory solely for the purpose of Commercializing such Products inside the Licensed Territory.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440456746"></a>3.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Right of Reference</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms of this Agreement, AVEO hereby grants to CANbridge access to, and a right of reference with respect to, (a) its Regulatory Filings and corresponding documentation to the extent Controlled by AVEO as of the Effective Date, and (b) Safety Data and CMC Data contained or referenced in any Regulatory Filings and corresponding documentation Controlled by AVEO at any time during the Term, in each case ((i) and (ii)), for the sole purpose of Developing and Manufacturing the Product in the Licensed Territory.&nbsp;&nbsp;For clarity, the foregoing will not obligate AVEO to maintain an active IND or Regulatory Approval Application with respect to any Product. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="CANbridge_License_Grant"></a><a name="_Toc445902998"></a><a name="_Ref439444268"></a><a name="_Ref442550299"></a>3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge License Grant; Right of Reference</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442618722"></a>3.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">License Grant</font><font style="font-family:Times New Roman;color:#000000;">. Subject to the terms and conditions of this Agreement, CANbridge hereby grants to AVEO a non-exclusive, royalty-free, sublicenseable (subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.3.2</font><font style="font-family:Times New Roman;color:#000000;"> (AVEO Right to Sublicense)), right and license under the CANbridge Program Patents and CANbridge Program Know-How (a) to Develop, Manufacture, Commercialize, use and otherwise Exploit the Product in the Field in the North America Territory and (b) to Develop Products outside the North America Territory solely for the purpose of Commercializing such Products inside the North America Territory.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO Right of Reference</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms of this Agreement, CANbridge hereby grants to AVEO access to, and a right of reference with respect to, Safety Data and CMC Data contained or referenced in any Regulatory Filing and corresponding documentation Controlled by CANbridge during the Term for the sole purpose of Developing and Manufacturing the Product in the North America Territory. For clarity, the foregoing will not obligate CANbridge to maintain an active IND or Regulatory Approval Application with respect to any Product.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445902999"></a>3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicensing and Subcontracting</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="CANbridge_Right_to_Sublicense"></a><a name="_Ref439451434"></a><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>3.3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Right to Sublicense</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge will have the right to grant Sublicenses (through multiple tiers) to its Affiliates or Third Parties of any and all rights granted to CANbridge by AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">AVEO License Grant; Right of Reference</font><font style="font-family:Times New Roman;color:#000000;">), </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that CANbridge will provide AVEO with written notice of its intent to grant </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">any such Sublicense (or an option to receive a Sublicense) of rights to Commercialize the Product pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">3.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="font-family:Times New Roman;color:#000000;">CANbridge Right to Sublicense</font><font style="font-family:Times New Roman;color:#000000;">) at least </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days, with respect to any country in Europe, and at least </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days, with respect to any country in the Licensed Territory outside of Europe, before it enters into any agreement containing any such Sublicense (or option to receive a Sublicense), and CANbridge will consider in good faith any AVEO proposal for such Sublicense (or option to receive a Sublicense) to be granted to it.&nbsp;&nbsp;In the event that CANbridge grants a Sublicense pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">3.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="font-family:Times New Roman;color:#000000;">CANbridge Right to Sublicense</font><font style="font-family:Times New Roman;color:#000000;">), CANbridge will remain responsible for its obligations under this Agreement and will ensure that each of its Sublicensees complies with all relevant provisions of this Agreement.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="AVEO_Right_to_Sublicense"></a><a name="_Ref439706630"></a>3.3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO Right to Sublicense</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;AVEO will have the right to grant Sublicenses (through multiple tiers) to its Affiliates or Third Parties of any and all rights granted to AVEO by CANbridge pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.2</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">CANbridge License Grant</font><font style="font-family:Times New Roman;color:#000000;">; Right of Reference), </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that in the event that AVEO grants a sublicense pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.3.2</font><font style="font-family:Times New Roman;color:#000000;"> (AVEO Right to Sublicense), AVEO will remain responsible for its obligations under this Agreement and will ensure that each of its Sublicensees complies with all relevant provisions of this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Sublicense_Requirements"></a><a name="_Ref439708299"></a><a name="_Ref443933974"></a>3.3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Requirements</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each license or Sublicense granted by a Party to an Affiliate or a Third Party (including any subcontractor) pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (CANbridge Right to Sublicense) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">3.3.2</font><font style="font-family:Times New Roman;color:#000000;"> (AVEO Right to Sublicense) (a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) will be in writing and will be consistent with the relevant restrictions and limitations set forth in this Agreement.&nbsp;&nbsp;No Sublicense or subcontract will diminish, reduce or eliminate any obligation of either Party under this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443934460"></a>3.3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Performance by CANbridge Sublicensees</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp; CANbridge will promptly provide AVEO with a copy of any fully executed Sublicense agreement covering any Sublicense granted hereunder.&nbsp;&nbsp;Any such Sublicense agreement entered into by CANbridge will contain the following provisions:&nbsp;&nbsp;(a) a requirement that such Sublicensee submit applicable sales or other reports to AVEO to the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement; (b) an audit requirement consistent with that set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.8</font><font style="font-family:Times New Roman;color:#000000;"> (Financial Audits); (c) a requirement that such Sublicensee comply with the confidentiality provisions and restrictions on use of Confidential Information contained in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 8.1</font><font style="font-family:Times New Roman;color:#000000;"> (Confidential Information) with respect to AVEO&#8217;s Confidential Information; and (d) those provisions required by the Existing Third Party License Agreements that are listed on </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 3.3.4</font><font style="font-family:Times New Roman;color:#000000;"> attached hereto.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440976616"></a><a name="_Ref442550473"></a><a name="_Toc445903000"></a>3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exclusivity Covenant</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;During the Term, neither AVEO and its Affiliates nor CANbridge and its Affiliates will directly or indirectly conduct, have conducted, engage in or fund any activity that involves the Development or Commercialization of any ErbB3 inhibitory Antibody product other than the Product pursuant to the terms and conditions set forth in this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903001"></a>3.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Acquisition Transactions</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442608352"></a><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>3.5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Effect of Acquisition Transaction</font><font style="font-family:Times New Roman;color:#000000;">. Notwithstanding anything to the contrary in this Agreement, in the event of an acquisition of a Party or its business (an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Acquired Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) by a Third Party (an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Acquirer</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) after the Effective Date, directly or indirectly, whether by merger, asset purchase or otherwise (each, an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Acquisition Transaction</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), then, as to any such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">Acquirer, (a) any Patent Rights, Know-How, or Regulatory Approvals that are held at the time of such acquisition by the Acquirer, or any Affiliate of the Acquirer that becomes an Affiliate of the Acquired Party as a result of such acquisition, will be deemed not to be Controlled by the Acquired Party, and (b) subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">3.5.2</font><font style="font-family:Times New Roman;color:#000000;"> (Protective Procedures), such Acquirer will not be obligated to comply with the covenants in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">3.4</font><font style="font-family:Times New Roman;color:#000000;"> (Exclusivity Covenant), as applicable, with respect to any program involving the research, development or commercialization of any ErbB3 inhibitory Antibody product conducted by such Acquirer immediately prior to such acquisition (a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Competitive Program</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442550448"></a>3.5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Protective Procedures</font><font style="font-family:Times New Roman;color:#000000;">. Notwithstanding the foregoing, concurrently with the consummation of the Acquisition Transaction, the Acquired Party will prepare, present to the other Party (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Non-Acquired Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) for its review, and implement a plan that outlines the&nbsp;&nbsp;procedures to be implemented to establish an ethical wall to ensure that (a) any information with respect to this Agreement or any Product that is disclosed to the Acquiring Party during due diligence is returned to the other Party or destroyed, (b) subject to subsection (a), all Confidential Information, in both hard and electronic copy, of AVEO and CANbridge that relates to this Agreement or the Product will be kept separate from the Acquirer, (c)</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font><font style="text-decoration:none;letter-spacing:0pt;font-family:Times New Roman;color:#000000;">the Acquirer will not use any Know-How or Patent Rights Controlled by the Acquired Party immediately prior to the Acquisition Transaction at any time during the Term to research, develop and/or commercialize any Competitive Program,</font><font style="font-family:Times New Roman;color:#000000;"> (d) no employees of the Acquired Party or its Affiliates work on any product that is the subject of the Competitive Program for a period of at least one year following such employee&#8217;s conclusion of work on the Development or Commercialization of a Product, and (e) no employees of such Acquirer or its Affiliates as of the date of consummation of the Acquisition Transaction will thereafter conduct any activities that involve the Development or Commercialization of any Product. In addition, the resources devoted by the Acquired Party to, and the efforts of the Acquired Party required for, the conduct of the Competitive Program will not be factored into, or otherwise affect, CANbridge&#8217;s obligations under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections 4.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (Development Diligence) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">5.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Commercialization Diligence). The procedures set forth in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.5.2</font><font style="font-family:Times New Roman;color:#000000;"> (Protective Procedures) will remain in place during the Term of this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903002"></a>3.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Reservation of Rights</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;No rights, other than those expressly set forth in this Agreement, are granted to either Party under this Agreement, and no additional rights will be deemed granted to either Party by implication, estoppel or otherwise, with respect to any intellectual property rights.&nbsp;&nbsp;All rights not expressly granted by either Party or its Affiliates to the other under this Agreement are reserved. Without limiting the generality of the foregoing, AVEO hereby retains the right under the Licensed Patents and Licensed Know-How (a) to Develop, Commercialize and Manufacture all products that do not comprise or contain an ERBB3 Antibody, (b) to perform its obligations under this Agreement, (c) to Develop Products for Commercialization in the North America Territory and (d) to Develop Products outside the North America Territory solely for the purpose of Commercializing such Products inside the North America Territory.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440468121"></a><a name="_Ref440973468"></a><a name="_Toc445903003"></a><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>3.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Bankruptcy Code &#167; 365(n) Election</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;All rights and licenses now or hereafter granted under or pursuant to this Agreement, including pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.1 </font><font style="font-family:Times New Roman;color:#000000;">(AVEO License Grant; Right of Reference) and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.2</font><font style="font-family:Times New Roman;color:#000000;"> (CANbridge License Grant; Right of Reference), are rights to &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">intellectual property</font><font style="font-family:Times New Roman;color:#000000;">&#8221; (as defined in Section&#160;101(35A) of Title 11 of the United States Code, as amended (such Title 11, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Bankruptcy Code</font><font style="font-family:Times New Roman;color:#000000;">&#8221;)).&#160; Each Party, as licensee of such rights </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">under this Agreement, will retain and may fully exercise all of its rights and elections under the United States Bankruptcy Code.&nbsp;&nbsp;In the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Insolvent Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property licensed to it under this Agreement and all embodiments of such intellectual property (including all information related to such intellectual property and rights of reference with respect to Regulatory Approvals), and same, if not already in its possession, will be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon its written request therefore, unless the Insolvent Party continues to perform all of its obligations under this Agreement, or (b) if not delivered or granted under (a) above, following the rejection of this Agreement by or on behalf of the Insolvent Party upon written request therefore by the other Party. The Parties hereto acknowledge and agree that all payments by CANbridge to AVEO under this Agreement, other than royalty payments pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.3</font><font style="font-family:Times New Roman;color:#000000;"> (Royalties), do not constitute royalties within the meaning of Bankruptcy Code &#167;365(n) or relate to licenses of intellectual property under this Agreement.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903004"></a>3.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">No Inconsistent Third Party Agreements</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;During the Term, neither AVEO nor any of its Affiliates will enter into any license of intellectual property pursuant to which AVEO or any of its Affiliates grants to a Third Party rights under or to Know-How and Patent Rights, or otherwise enters into any agreement, that would contravene or be inconsistent or in conflict with the rights of CANbridge or the obligations of AVEO under this Agreement.&nbsp;&nbsp;During the Term, neither AVEO nor any of its Affiliates will amend, modify or terminate any in-license of Third Party intellectual property (including, without limitation, any such in-license that is in effect as of the Effective Date) without the prior written consent of CANbridge (which may be granted or withheld by CANbridge in its absolute discretion) if such amendment, modification or termination would materially adversely affect any of the rights that CANbridge or any of its Affiliates has under this Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903005"></a>ARTICLE 4<font style="color:#000000;"><br>DEVELOPMENT</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903006"></a>4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Responsibilities</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, </font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">including this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 4</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;"> (Development):</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">CANbridge will be solely responsible, at its own expense, for Developing Products for the purpose of obtaining Regulatory Approval and Commercializing Products in the Licensed Territory; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, AVEO will have the right, at its sole cost and expense, to file an IND and conduct Clinical Studies for the Product in any country in the Licensed Territory in any indication in which CANbridge or its Affiliates or Sublicensees does not have an active IND for the same indication in such country, for the sole purpose of obtaining Marketing Authorization and Commercializing the Product in the North America Territory; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;"> </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">further</font><font style="font-family:Times New Roman;color:#000000;">, that such IND and such Clinical Studies for the Product would not reasonably be expected to materially and adversely affect the Development or Commercialization of the Product in the Licensed Territory.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>(b)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">AVEO will be solely responsible, at its own expense, for Developing Products for the purpose of obtaining Regulatory Approval and Commercializing </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">Products in the North America Territory; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that CANbridge will have the right, at its sole cost and expense, to file an IND and conduct Clinical Studies for the Product in any country in the North America Territory in any indication in which AVEO or its Affiliates or Sublicensees does not have an active IND for the same indication in such country, for the sole purpose of obtaining Marketing Authorization and Commercializing the Product in the Licensed Territory; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">that</font><font style="font-family:Times New Roman;color:#000000;">, such IND and such Clinical Studies for the Product would not reasonably be expected to materially and adversely affect the Development or Commercialization of the Product in the North America Territory.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443933698"></a><a name="_Toc445903007"></a><a name="POC_Development_Plan"></a><a name="_Ref439708546"></a>4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Authorities</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440457001"></a>4.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Development Plan</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Development of the Products under this Agreement will be governed by the POC Development Plan. The initial approved POC Development Plan is attached hereto as </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exhibit A</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The POC Development Plan will include, with respect to the Product, the strategy for pre-clinical and clinical studies necessary to demonstrate proof-of-concept for the Product for the treatment of squamous cell esophagus cancer, including a POC Study meeting the requirements set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 4.2.1</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The activities set forth in the POC Development Plan will at all times be designed to be in compliance with all applicable Laws.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444002840"></a>4.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Post-POC Development</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Within [**] days after the date of delivery of the POC Study Data Package CANbridge will prepare and provide to the JSC a post-POC development plan that will include (a) the proposed Development strategy to be used in order to receive Marketing Authorization for the Product in the Field in the Licensed Territory through the date on which such Marketing Authorization is received in any Major Market Country and (b) the expected timelines applicable to the conduct of all Clinical Studies involving the Product.&nbsp;&nbsp;In addition, if AVEO determines to Develop the Product for the North America Territory, AVEO will prepare and provide to the JSC a forward-looking plan summarizing its Development strategy for the Product in the North America Territory for purposes of coordination and information sharing. Notwithstanding the foregoing, if either Party is Developing or Commercializing a product for the same indication as the Product, then the other Party will not be required to provide such Party or the JSC with its post-POC development plan. To the extent there are any material updates to CANbridge&#8217;s post-POC development plan, from time to time CANbridge will promptly provide such updates to AVEO through the JSC.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Principles</font><font style="font-family:Times New Roman;color:#000000;">. The Parties will each conduct the Development of Products both pursuant to and outside of the scope of the POC Development Plan in accordance with the following principles, except to the extent (if any) otherwise expressly provided in the POC Development Plan or this Agreement, and the JSC will take into account and attempt to implement the following principles in its decision-making, including preparation, review and approval of any updates to and amendments of the POC Development Plan:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">Regardless of the specific division of responsibility between the Parties for particular activities at any particular time, the JSC will serve as a conduit for sharing information, knowledge and expertise relating to the Development and Commercialization of the Product.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>(b)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">CANbridge will not conduct, or authorize or cause its Affiliates or any Sublicensees to conduct, any Development activity with respect to the Product if such activity </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">would reasonably be likely to have a material adverse impact on the Development of the Product in the North America Territory. </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">AVEO will not conduct, or authorize or cause its Affiliates or any Sublicensees to conduct, any Development activity with respect to the Product if such activity would reasonably be likely to have a material adverse impact on the Development of the Product in the Licensed Territory. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">Neither Party will conduct any Development activity with respect to the Product without first notifying the other Party of its intent to do so and discussing and coordinating such Development with the other Party&#8217;s Development activities, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">that</font><font style="font-family:Times New Roman;color:#000000;">, if a Party is Developing or Commercializing a product for the same indication as the Product as of the date of any such discussions or coordination activities with the other Party, that Party will implement procedures reasonably acceptable to the other Party to ensure that none of its employees who are actively participating in the Development or Commercialization of the product for the other indication participates in, or has access to the information disclosed in, such discussions or coordination activities. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Development_Efforts_Manner_of_Perfo"></a><a name="_Ref439710003"></a><a name="_Toc445903008"></a>4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Diligence; Manner of Performance; Reports</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Development_Efforts"></a><a name="_Ref442730472"></a><a name="_Ref439595756"></a>4.3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Diligence</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge (directly and through its Affiliates and Sublicensees) will use Commercially Reasonable Efforts to: (a) Develop and Manufacture Products in accordance with the POC Development Plan; and (b) Develop, Manufacture, and obtain Regulatory Approval for the Product in each Major Market Country in the Licensed Territory. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439706874"></a>4.3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Responsibility</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge will be responsible for the day-to-day implementation of the Development activities for which it (or any of its Affiliates) is assigned responsibility under this Agreement and the POC Development Plan, and will keep AVEO reasonably informed as to the progress of such activities.&nbsp;&nbsp;CANbridge will perform its Development obligations under this Agreement in good scientific manner and in compliance with all applicable Laws (including with respect to each such activity that will or would reasonably be expected to be submitted to a Regulatory Authority in support of a regulatory filing or Regulatory Approval Application, then-current Good Laboratory Practice Standards and Good Clinical Practices). </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442550207"></a>4.3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Clinical Studies</font><font style="font-family:Times New Roman;color:#000000;">. Notwithstanding anything to the contrary in this Agreement, CANbridge may terminate or suspend any Clinical Study relating to the Products of which it or its Affiliate or Sublicensee is the sponsor, without the approval or consent of the JSC or AVEO, if (a) a Regulatory Authority, institutional review board or safety data review board for such Clinical Study has required or recommended such termination or suspension or (b) CANbridge believes in good faith that such termination or suspension is warranted because of observed safety risks to the study subjects or patients.</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;color:#000000;"> In either case, CANbridge will promptly notify AVEO in writing of such termination or suspension.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440643033"></a><a name="_Ref442646786"></a><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>4.3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Records; Reports</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party will maintain complete and accurate records (in the form of technical notebooks or electronic files where appropriate) of all work conducted by it with respect to the Development of the Products and all information resulting </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">from such Development work. Such records, including any electronic files where such information may also be contained, will fully and properly reflect all Development work done and results achieved in the Development of the Product in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.&nbsp;&nbsp;Periodically, but no less frequently than </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;">, to the extent that a Party has conducted any Development activities over such </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;">, such Party will deliver to the JSC a report (each, a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Report</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) containing reasonably detailed information regarding its progress with respect to the Development of the Product in such Party&#8217;s Territory, which will include a summary of </font><font style="font-family:Times New Roman;color:#000000;">(a) all Development activities conducted and results obtained with respect to each Product, (b) any Significant Development Events applicable to any Product, (c) a summary of all (i) Know-How conceived or reduced to practice</font><font style="font-family:Times New Roman;"> over such period and (ii) Clinical Data, including Safety Data and CMC Data,</font><font style="font-family:Times New Roman;color:#000000;"> generated by such Party over such period and (d) with respect to CANbridge, (i) reasonable evidence of its satisfaction of the minimum requirements set forth in&nbsp;&nbsp;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">12.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by AVEO) and (ii) a non-binding estimate of the expected timing of any Development Milestone Event and Sales Milestone Event to be achieved with respect to each Product.</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study Data Package</font><font style="font-family:Times New Roman;color:#000000;">. Within [**] days following the database lock of the POC Study, CANbridge will deliver the POC Study Data Package to AVEO. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Notice of Investigation or Inquiry</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;If any Regulatory Authority (a) contacts a Party or its Affiliate with respect to the alleged improper Development, Manufacture or Commercialization of any Product, (b) conducts, or gives notice of its intent to conduct, an inspection at a Party&#8217;s or its Affiliate&#8217;s facilities used in the Development or Manufacturing of Product, or (c) takes, or gives notice of its intent to take, any other regulatory action with respect to any activity of a Party or its Affiliate that could reasonably be expected to adversely affect any Development, Manufacture or Commercialization activities with respect to a Product in the other Party&#8217;s Territory, then such Party will promptly notify the other Party of such contact, inspection or notice.&nbsp;&nbsp;In addition, each Party will provide the other Party with at least [**] days&#8217; advance notice of any meeting with any Regulatory Authority regarding any Regulatory Approval Application for any Product or any such audit or inspection conducted by any Regulatory Authority at any site at which such Product is being Manufactured or Clinical Studies with respect to such Product are being conducted. To the extent any such meeting is between CANbridge and any Regulatory Authority in Europe, then, to the extent that CANbridge reasonably determines that there is space sufficient for AVEO representatives to attend such meeting and such attendance by AVEO will not delay the proposed timing for the meeting, AVEO may elect to send representatives reasonably acceptable to CANbridge to participate in any such meeting at AVEO&#8217;s sole cost and expense.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440976561"></a><a name="_Toc445903009"></a><a name="POC_Study_ROFN"></a><a name="_Ref439708569"></a><a name="Right_of_First_Negotiation_for_NA"></a><a name="_Ref439708331"></a><a name="_Ref439701287"></a>4.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Rights of First Negotiation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440976636"></a><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>4.4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study ROFN</font><font style="font-family:Times New Roman;color:#000000;">. Commencing on the Effective Date until the date of AVEO&#8217;s receipt of the POC Study Data Package (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study ROFN Period</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), AVEO will and hereby does grant to CANbridge a right of first negotiation with respect to any license or co-development agreement under which AVEO would grant to any Third Party any rights to Develop or Commercialize the Product in any country in the North America Territory (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ROFN Opportunity</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). If AVEO determines that it desires to enter into an agreement with a Third Party with respect to such rights during the POC Study ROFN Period, then AVEO will so notify CANbridge and CANbridge will have the option, within [**] days of receipt of such notice from </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">AVEO, to notify AVEO of its desire to negotiate for such contemplated Third Party rights (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">POC Study ROFN</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). Following AVEO&#8217;s receipt of such notice from CANbridge, the Parties will negotiate exclusively in good faith the terms and conditions of an agreement with respect to such contemplated rights for a reasonable period of time, such period not to exceed </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days. If CANbridge exercises the POC Study ROFN and the Parties are unable to reach agreement during such </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> day period (or such longer period as the Parties may agree), then, (a) for the remainder of the POC Study ROFN Period, if any, AVEO will not enter into any agreement with a Third Party with respect to Development or Commercialization of the Product in the North America Territory on terms more favorable, in the aggregate, to the Third Party than the final offer proposed by AVEO to CANbridge during the POC Study ROFN Period and (b) subject to the foregoing, AVEO will thereafter have no obligation to CANbridge with respect to the ROFN Opportunity and will have the right to pursue itself, or to negotiate and execute an agreement with any Third Party with respect to, the ROFN Opportunity.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440457655"></a>4.4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">North America Territory ROFN</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exclusive_Negotiation_Period"></a><a name="_Ref439708339"></a><a name="_Ref439738834"></a>(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exclusive Negotiation Period</font><font style="font-family:Times New Roman;color:#000000;">. During the period not to exceed [**] months following the date of AVEO&#8217;s receipt of the POC Study Data Package, AVEO and CANbridge will exclusively negotiate with each other in good faith (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exclusive Negotiation Period</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) the terms and conditions under which (a) CANbridge and AVEO would enter into a collaboration agreement pursuant to which the Parties would co-Develop the Product in the squamous cell esophagus cancer therapeutic field, including the sharing of the Development costs thereof (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Collaboration Agreement</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), or (b) the North America Territory would become included within the Licensed Territory for all purposes under this Agreement (the</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;color:#000000;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Expanded License</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442623840"></a>(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Failure to Reach Agreement</font><font style="font-family:Times New Roman;color:#000000;">. In the event that the Parties are unable to reach agreement with respect to either a Collaboration Agreement or an Expanded License during the Exclusive Negotiation Period pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.2(a)</font><font style="font-family:Times New Roman;color:#000000;"> (Exclusive Negotiation Period), then, subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.3</font><font style="font-family:Times New Roman;color:#000000;"> (Right of First Negotiation): </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:30.77%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">each Party will have the right to continue the Development of the Product within their respective Territories in accordance with this Agreement; </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:30.77%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">except with respect to Safety Data and CMC Data, CANbridge would not grant to AVEO (i) any access to Clinical Data developed or obtained by CANbridge with respect to the Product in the Licensed Territory or (ii) a right of reference with respect to its Regulatory Filings owned or Controlled by CANbridge or its Affiliates in the Licensed Territory; and </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:30.77%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">except with respect to Safety Data and CMC Data, AVEO would not grant to CANbridge (i) any access to new Clinical Data developed or obtained by AVEO with respect to the Product in the North America Territory or (ii) a right of reference with respect to its new Regulatory Filings owned or Controlled by AVEO or its Affiliates and developed or filed after the Effective Date.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Right_of_First_Negotiation"></a><a name="_Ref439708435"></a><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="text-decoration:none;">4.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Right of First Negotiation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Following any failure to reach agreement pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4.2(b)</font><font style="font-family:Times New Roman;color:#000000;"> (Failure to Reach Agreement), AVEO will be free to pursue itself </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">and/or to negotiate and grant rights to one or more Third Parties under intellectual property rights Controlled by AVEO with respect to Development and/or Commercialization of the Product in the North America Territory; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, if during the </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> month period following the end of the Exclusive Negotiation Period (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ROFN Period</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), AVEO determines that it desires to enter into an agreement with a Third Party with respect to such rights, AVEO will so notify CANbridge and CANbridge will have the right, within </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days of receipt of such notice from AVEO, to notify AVEO of its desire to negotiate for such contemplated Third Party rights (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ROFN</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). Following AVEO&#8217;s receipt of such notice from CANbridge, the Parties will negotiate in good faith the terms and conditions of an agreement with respect to such contemplated rights for a reasonable period of time, such period not to exceed </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days. If CANbridge exercises the ROFN and the Parties are unable to reach agreement during such </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> day period (or such longer period as the Parties may agree), then, (a) for the remainder of the ROFN Period, if any, AVEO will not enter into any agreement with a Third Party with respect to Development or Commercialization of the Product in the North America Territory on terms more favorable, in the aggregate, to the Third Party than the final offer proposed by AVEO to CANbridge during the ROFN Period and (b) subject to the foregoing, AVEO will thereafter have no obligation under this Agreement to negotiate with CANbridge with respect to the Development or Commercialization of the Product in the North America Territory and will have the right to pursue itself, and/or to negotiate and execute an agreement with any Third Party with respect to, the Development or Commercialization of the Product in the North America Territory.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903010"></a>4.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Submissions and Regulatory Approvals</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Ownership_of_Regulatory_Approvals"></a><a name="_Ref439691107"></a>4.5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Ownership of Regulatory Approvals</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge or its relevant Affiliates will have the sole right to file and hold all Regulatory Filings for the Products in the Field in the Licensed Territory and may file and hold Regulatory Filings in the North America Territory, in accordance with the POC Development Plan solely for the purpose of Developing Products for the Licensed Territory.</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;color:#000000;"> AVEO or its relevant Affiliates will have the sole right to file and hold Regulatory Filings in the North America Territory related to the Products for the purpose of Developing and Commercializing the Products in the North America Territory. The Parties will file and hold all Regulatory Filings in eCTD format. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Regulatory_Cooperation"></a><a name="_Ref439691004"></a>4.5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Cooperation</font><font style="font-family:Times New Roman;color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439708656"></a>(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Responsibilities</font><font style="font-family:Times New Roman;color:#000000;">. Subject to applicable Law and this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.5.2</font><font style="font-family:Times New Roman;color:#000000;"> (Regulatory Cooperation), CANbridge will oversee, monitor and manage all regulatory interactions, communications and filings with, and submissions to, Regulatory Authorities with respect to the Products in the Licensed Territory. CANbridge will have final decision making authority regarding all regulatory activities, including the labeling strategy and the content of submissions within such Licensed Territory, subject to the terms and conditions of this Agreement; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, the foregoing will not apply to any Development activities conducted by AVEO in the Licensed Territory as permitted by this Agreement. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a>(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO Responsibilities</font><font style="font-family:Times New Roman;color:#000000;">. Subject to applicable Law and this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.5.2</font><font style="font-family:Times New Roman;color:#000000;"> (Regulatory Cooperation), AVEO will oversee, monitor and manage all regulatory interactions, communications and filings with, and submissions to, Regulatory Authorities with respect to the Products in the North America Territory.&nbsp;&nbsp;AVEO will have final decision making authority regarding all regulatory activities, including the labeling strategy and the content of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">submissions within such North America Territory, subject to the terms and conditions of this Agreement; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, the foregoing will not apply to any Development activities conducted by CANbridge in the North America Territory as permitted by this Agreement. AVEO will also provide reasonable regulatory and administrative support and assistance to CANbridge in connection with the submission of its IND application for the Product in China, including but not limited to, </font><font style="font-family:Times New Roman;color:#000000;">(i) the provision of a notarized authorizat</font><font style="font-family:Times New Roman;color:#000000;">ion letter and business license</font><font style="font-family:Times New Roman;color:#000000;"> and (ii) the provision of a notarized copy of the GLP certificate of AVEO&#8217;s contract research organization responsible for the performance of preclinical experiments on the Product. </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Regulatory Notification</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Solely to the extent that, and for so long as, AVEO has an active IND or Regulatory Approval Application with respect to any Product, the following will apply:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">Each Party will report to the other Party all Adverse Events or Serious Adverse Events with respect to any Product, as the case may be, in its respective territory, within timeframes consistent with its reporting obligations under applicable Laws and in any event no later than [**] hours following receipt of notification by the clinical site of a Serious Adverse Event, which report will, in each case, include the circumstances and nature of such Serious Adverse Event.&nbsp;&nbsp;In addition, to the extent requested by a Party, the other Party will promptly provide to such Party any other information or materials that such Party may require to provide to any Regulatory Authority with respect to any such Serious Adverse Event. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440643184"></a>(b)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">Each Party will promptly notify the other Party upon its determination that any event, incident or circumstance has occurred that may result in the need for a Recall, market withdrawal or stock recovery of a Product (but in no event later than [**] hours and in all cases prior to the execution of such Recall, market withdrawal or stock recovery).&nbsp;&nbsp;For all Recalls, the Parties will reasonably consult with each other with respect to the actions to be taken to address such Recall.&nbsp;&nbsp;Subject to the foregoing, (i) for all Recalls, market withdrawals and stock recoveries that are taken in the Licensed Territory, CANbridge will be responsible for execution, and AVEO will reasonably cooperate in all such efforts and (ii) for all Recalls, market withdrawals and stock recoveries that are taken in the North America Territory, AVEO will be responsible for execution, and CANbridge will reasonably cooperate in all such efforts.&nbsp;&nbsp;All expenses incurred in connection with any Recall (including expenses for notification, destruction and return of the affected Product and any refund to customers of amounts paid for such Product) in the Licensed Territory will be the sole responsibility of CANbridge, and, subject to any allocation of responsibility to CANbridge as a manufacturer of Product that is set forth in the Supply Agreement, all expenses incurred in connection with any Recall in the North America Territory will be the sole responsibility of AVEO. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">The Parties will enter into a pharmacovigilance agreement on reasonable and customary terms that sets forth, among other things, guidelines and procedures for the receipt, investigation, recording, review, communication, reporting and exchange between the Parties of Adverse Event reports (which for the purposes of information exchange between the Parties will include Adverse Events as well as reports of pregnancy, claims of lack of efficacy, overdose, abuse, misuse, medication errors, occupational expose and off-label use), technical complaints, periodic safety update reports and any other information concerning the safety of the Products anywhere in the world and the maintenance of a global safety database with respect to the Products.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903011"></a><a name="_Ref440642292"></a><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Partners</font><font style="font-family:Times New Roman;color:#000000;">.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442784347"></a>4.6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Unblocking Rights</font><font style="font-family:Times New Roman;color:#000000;">. If, at any time during the Term, either Party enters into an agreement (a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Collaboration Agreement</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) with one or more Third Party(ies) (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Partner</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) to Develop and/or Commercialize a Product in the Field in the United States (with respect to AVEO) or a Major Market Country (with respect to CANbridge), respectively, such Party will use Commercially Reasonable Efforts to negotiate the terms of the Third Party Collaboration Agreement regarding intellectual property that are necessary to permit such Party to license or sublicense to the other Party any Patent Rights and Know-How developed in the course of activities pursuant to the Third Party Collaboration Agreement that are necessary or useful for the other Party to Develop, Manufacture and Commercialize Products in its respective territory in accordance with this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Global Coordination</font><font style="font-family:Times New Roman;color:#000000;">. Each Party will use Commercially Reasonable Efforts to include in any Third Party Collaboration Agreement a good faith obligation on such Third Party Partner to participate in discussions with AVEO and CANbridge at least annually to facilitate information sharing and the global coordination of the Development, Manufacture and Commercialization of Products. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903012"></a><a name="_Ref439506213"></a><a name="MANUFACTURE_AND_COMMERCIALIZATION"></a><a name="_Ref442622131"></a>ARTICLE 5<font style="color:#000000;"><br><a name="_Ref439506213"></a><a name="MANUFACTURE_AND_COMMERCIALIZATION"></a><a name="_Ref442622131"></a>MANUFACTURE AND COMMERCIALIZATION</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Manufacture"></a><a name="_Toc445903013"></a>5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Technology Transfer and Manufacture</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Transfer_of_Manufacturing_Know_How"></a><a name="_Ref439560483"></a><a name="_Ref439463734"></a><a name="Manufacturing_Responsibility"></a><a name="_Ref442550865"></a><a name="_Ref439708737"></a>5.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Transfer of Licensed Know-How</font><font style="font-family:Times New Roman;color:#000000;">. Promptly after the Effective Date, AVEO will take such steps as may be reasonably necessary to transfer to CANbridge all Licensed Know-How (including all historical process or analytical development information (</font><font style="font-style:italic;font-family:Times New Roman;color:#000000;">i.e.</font><font style="font-family:Times New Roman;color:#000000;"> all experimentally or literature-derived data used to Develop the Product through the completion of Technology Transfer)) that is necessary or useful to enable the Manufacture and Development of the Product, including the Regulatory Documentation set forth on </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exhibit C</font><font style="font-family:Times New Roman;color:#000000;">, by providing copies or samples of relevant documentation, materials and other embodiments of such Know-How, including data within reports, notebooks and electronic files, and by making available its qualified technical personnel on a reasonable basis to consult with CANbridge with respect to such Know-How (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Technology Transfer</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). Such Technology Transfer will be conducted in accordance with the technology transfer plan attached hereto as </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exhibit C</font><font style="font-family:Times New Roman;color:#000000;"> (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Technology Transfer Plan</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).&nbsp;&nbsp; Each Party will bear its own internal costs incurred in the course of the Technology Transfer to the extent set forth in the Technology Transfer Plan; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">that</font><font style="font-family:Times New Roman;color:#000000;">, any such costs and expenses incurred by either Party that are not included as part of the Technology Transfer Plan will be the sole responsibility of CANbridge.<a name="Manufacturing_Responsibility"></a><a name="_Ref442550865"></a><a name="_Ref439708737"></a> </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Manufacturing Responsibility</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.3</font><font style="font-family:Times New Roman;color:#000000;"> (Right of AVEO to Manufacture) and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.4</font><font style="font-family:Times New Roman;color:#000000;"> (Technology Transfer), CANbridge will have the obligation to Manufacture and supply AVEO with its requirements of Product in connection with the Development and Commercialization of Products by AVEO in the North America Territory pursuant to this Agreement, subject to agreement by the Parties of a commercially reasonable forecasting process to be defined in the Supply Agreement.&nbsp;&nbsp; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442550749"></a><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1.3</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Right of AVEO to Manufacture.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;Notwithstanding the foregoing, if at any time during the Term (a) the per unit price of any Product Manufactured by CANbridge (as opposed to being Manufactured by a Third Party CMO) quoted by CANbridge is higher by </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;">% or more than the lowest binding commitment to supply submitted by a Third Party CMO to AVEO and shared with CANbridge or (b) CANbridge does not have the capacity, or is otherwise unable, to supply AVEO with its requirements of Product in a GMP-compliant manufacturing facility adequate for the Manufacture of such Product, then, in either such case, AVEO will have the right (but not the obligation) to Manufacture such Product itself or have such Product Manufactured by such Third Party CMO and in order to satisfy all of its requirements of such Product. AVEO may exercise its rights under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">5.1.3</font><font style="font-family:Times New Roman;color:#000000;"> (Right of AVEO to Manufacture) with respect to any Product by giving prior written notice to CANbridge.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442550770"></a><a name="_Ref442789086"></a>5.1.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Technology Transfer</font><font style="font-family:Times New Roman;color:#000000;">. Upon receipt by CANbridge of written notice from AVEO under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.3</font><font style="font-family:Times New Roman;color:#000000;"> (Right of AVEO to Manufacture), CANbridge will provide reasonable assistance to enable AVEO to Manufacture or have Manufactured such Product. Such assistance will include, without limitation, engaging in any technology transfer process required in order to enable AVEO or any Third Party CMO engaged by AVEO to Manufacture such Product. If such written notice is the result of a lower Third Party CMO supply price as set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.3(a)</font><font style="font-family:Times New Roman;color:#000000;"> (Right of AVEO to Manufacture), then AVEO will be responsible for the costs and expenses of any such assistance provided by CANbridge under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.4</font><font style="font-family:Times New Roman;color:#000000;"> (Technology Transfer). If such written notice is the result of CANbridge&#8217;s inability to meet AVEO&#8217;s capacity requirements as set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.3(b)</font><font style="font-family:Times New Roman;color:#000000;"> (Right of AVEO to Manufacture), then CANbridge will be responsible for the costs and expenses of any such assistance provided by CANbridge under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.4</font><font style="font-family:Times New Roman;color:#000000;"> (Technology Transfer). </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Supply_Terms"></a><a name="_Ref439708766"></a>5.1.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Supply Terms</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections 5.1.3</font><font style="font-family:Times New Roman;color:#000000;"> (Right of AVEO to Manufacture) and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">5.1.4</font><font style="font-family:Times New Roman;color:#000000;"> (Technology Transfer), AVEO hereby agrees to purchase any and all of its requirements of Product during the Term from CANbridge at a transfer price equal to CANbridge&#8217;s COGS (which amount will be no greater than CANbridge&#8217;s own COGS for the same Product in the Licensed Territory) plus [**]%, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that: CANbridge uses a CMO reasonably acceptable to AVEO for such Manufacture of Products that (a) is comparable in cost to other CMOs in the industry performing similar manufacturing work, and (b) has been inspected by the FDA and inspected by the applicable Regulatory Authority in the EU or by a Qualified Person in the EU authorized to sign the required certificate (as required by Clinical Directive 2001/20/EC and Annex 13 to the European GMP Guide) and, in any such case, found to be in material compliance with all applicable Laws. The Parties will execute a supply agreement containing supply and quality terms and conditions consistent with this Agreement and typical for such agreements (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Supply Agreement</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), including the right of AVEO to audit CANbridge&#8217;s records of COGS applicable to the Manufacture of Products and the requirement that all Products supplied by CANbridge hereunder be Manufactured in accordance with GMP and the applicable Product specifications.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903014"></a>5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commercialization</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444005261"></a>5.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Responsibilities of the Parties</font><font style="font-family:Times New Roman;color:#000000;">.</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">In the Licensed Territory</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge will be solely responsible, at its expense, for Commercializing the Product in the Licensed Territory.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">In the North America Territory</font><font style="font-family:Times New Roman;color:#000000;">. AVEO will be solely responsible, at its expense, for Commercializing the Product in the North America Territory.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444005251"></a><a name="_Ref443920109"></a>(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commercialization Plan</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;At any time prior to the first submission of a Regulatory Approval Application with respect to a Product in any country in the Licensed Territory, CANbridge will prepare and provide to the JSC, a Commercialization plan that will include (i) a launch plan for each Product in each of the Major Market Countries; (ii) the projected commercial infrastructure and sales force to be used with respect to such Product in each of the Major Market Countries; (iii) a [**]-year sales forecast for such Product in the Licensed Territory and for each of the Major Market Countries; and (iv) the projected pricing for the Product in each of the Major Market Countries, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">that</font><font style="font-family:Times New Roman;color:#000000;"> if AVEO is Developing or Commercializing a product (other than the Product) for the same indication as the Product, then CANbridge will not be required to provide AVEO or the JSC with a Commercialization plan for that Product.&nbsp;&nbsp;At any time prior to the first submission of a Regulatory Approval Application with respect to a Product in any country in the North America Territory, AVEO will prepare and provide to the JSC its projected pricing for the Product in the North America Territory. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Compliance by CANbridge</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge will perform its Commercialization obligations under this Agreement in good scientific manner and in compliance in all material respects with all applicable Laws, including, for purposes of clarity, applicable GLPs, GMPs or Good Clinical Practices (and, as appropriate, ICH guidance or other comparable regulation and guidance of any Regulatory Authority in any country or region in the Licensed Territory). </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Reports by CANbridge</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge will keep AVEO regularly informed of the progress of its efforts to Commercialize Products in the Licensed Territory through reports to the JSC not less than [**]. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Importation or Resale of Products</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Parties recognize that it is possible that Products originally sold by a Party (or its Affiliates, Sublicensees or Distributors) in its territory may be imported and resold in the other Party&#8217;s territory.&nbsp;&nbsp;Each Party will take reasonable measures to prevent any such imports and/or sales, to the full extent permitted by applicable Law. Without limiting the foregoing, each Party will, and will cause its Affiliates, Sublicensees and Distributors to, (a) label Products sold by it as being for sale in its territory (or a country thereof); and (b) refrain from selling Products to any entity that such Party or its Affiliates, Sublicensees or Distributors has reason to believe will resell quantities of Product in the other Party&#8217;s territory. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">No Violation</font><font style="font-family:Times New Roman;color:#000000;">. Notwithstanding anything to the contrary contained herein, neither Party (including its Affiliates and Sublicensees) will be obligated to undertake or continue any Commercialization activities with respect to the Products if such Party reasonably determines that performance of such Commercialization activity would violate applicable Law or infringe any Third Party Patent Rights. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442730507"></a><a name="_Ref440644282"></a><a name="_Ref440976664"></a><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>5.2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Commercialization Diligence</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge will (directly and through its Affiliates and Sublicensees) use Commercially Reasonable Efforts</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;color:#000000;">and will cause its Affiliates and Sublicensees to use Commercially Reasonable Efforts to Commercialize the Product in each </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">Major Market Country in the Licensed Territory in which such Product receives Regulatory Approval.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903015"></a><a name="_Ref439597737"></a><a name="_Ref439710842"></a><a name="FINANCIAL_PROVISIONS"></a><a name="_Ref440463919"></a><a name="_Ref440468298"></a><a name="_Ref441245616"></a>ARTICLE 6<font style="color:#000000;"><br><a name="_Ref439597737"></a><a name="_Ref439710842"></a><a name="FINANCIAL_PROVISIONS"></a><a name="_Ref440463919"></a><a name="_Ref440468298"></a><a name="_Ref441245616"></a>FINANCIAL PROVISIONS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Upfront_and_Milestone_Payments"></a><a name="_Ref439597586"></a><a name="_Toc445903016"></a>6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Upfront Payment; Reimbursement of Manufacturing Development Costs; Milestone Payments</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444635060"></a>6.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Upfront Payment</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, CANbridge will pay AVEO a non-refundable, non-creditable payment in the amount of US $1,000,000, which upfront payment will be due and payable to AVEO within [**] Business Days following the Effective Date.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439708858"></a>6.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Reimbursement of Manufacturing Development Costs</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, CANbridge will reimburse AVEO for the costs and expenses incurred by AVEO in connection with the conduct by AVEO of Manufacturing development activities with respect to the Product prior to the Effective Date in the aggregate amount of US $1,000,000, (a) US $500,000 of which will be due and payable to AVEO on the earlier of (i) the date of completion by CANbridge of the Validation of Manufacturing Development, or (ii) 12 months from the Effective Date and (b) the remaining US $500,000 of which will be due and payable to AVEO on the earlier of (i) the date of completion by CANbridge of the Validation of Manufacturing Development or (ii) 18 months from the Effective Date. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Development_Milestone_Payments"></a><a name="_Ref439708799"></a><a name="_Toc444506155"></a>6.1.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Milestone Payments</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, CANbridge will pay to AVEO the following non-refundable, non-creditable one-time milestone payments (each, a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Milestone Payment</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) within [**] days of CANbridge or its Affiliates achieving each of the following milestones in the relevant Territory (each a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Development Milestone Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221;):</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.54%;">
<tr style="height:34.6pt;">
<td valign="middle"  BGCOLOR="#F2F2F2" style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:40.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Development Milestone Event</p></td>
<td valign="middle"  BGCOLOR="#F2F2F2" style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Territory</p></td>
<td valign="middle"  BGCOLOR="#F2F2F2" style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Development Milestone Payment</p></td>
</tr>
<tr style="height:31pt;">
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:40.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:17.65pt;">
<td rowspan="3" valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:40.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:12.75pt;">
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:12.75pt;">
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:15.4pt;">
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:40.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:21.6pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:15.4pt;">
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:40.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:21.6pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:15.4pt;">
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:40.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:35.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:21.6pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.15pt;padding-Right:2.15pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:23.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>Each Development Milestone Payment will be payable only upon the first achievement of the applicable Development Milestone Event, and no amounts would be due for subsequent or repeated achievements.&nbsp;&nbsp;Notwithstanding the foregoing, in the event that CANbridge sublicenses all or any portion of the rights granted to it under <font style="text-decoration:underline;">Section 3.1</font> (<font style="text-decoration:none;">AVEO License Grant; Right of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Reference</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) in (a) the EU, (b) Japan, or (c) the entirety of China, Taiwan and South Korea, then, in lieu of paying the Development Milestone Payments to AVEO in any such country or countries, CANbridge will instead pay to AVEO the payment set forth in </font><font style="text-decoration:underline;">Section </font><font style="text-decoration:underline;">6.2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Sublicense Revenue) below.&nbsp;&nbsp;For purposes of this </font><font style="text-decoration:underline;">Section </font><font style="text-decoration:underline;">6.1.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Development Milestone Payments), the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439448761"></a><a name="_Ref443933906"></a>6.1.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sales Milestone Payments</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, CANbridge will pay to AVEO the following non-refundable, non-creditable one-time sales milestone payments (each, a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sales Milestone Payment</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) within [**] days following the end of the first Calendar Year during the Royalty Term in which the aggregate Net Sales of the Product by CANbridge and its Affiliates in the Licensed Territory achieves each of the following sales thresholds (each a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sales Milestone Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221;): </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:6.84%;width:82.54%;">
<tr>
<td valign="middle"  BGCOLOR="#F2F2F2" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:3.6pt;padding-Bottom:3.6pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales Milestone Event</p></td>
<td valign="middle"  BGCOLOR="#F2F2F2" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:3.6pt;padding-Bottom:3.6pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales Milestone Payment</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Net Sales Greater than or Equal to US $[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:12pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Net Sales Greater than or Equal to US $[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Net Sales Greater than or Equal to US $[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Net Sales Greater than or Equal to US $[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Sales Milestone Payment will be payable only upon the first achievement of the applicable Sales Milestone Event, and no amounts would be due for subsequent or repeated achievements.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Milestone Event Notice</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Within [**] Business Days after a Party becomes aware that a Milestone Event was achieved, it will notify the other Party thereof in writing.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Sublicense_Revenue"></a><a name="_Toc445903017"></a><a name="_Ref439510574"></a>6.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Revenue</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442551013"></a>6.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Payments</font><font style="font-family:Times New Roman;color:#000000;">. In the event that CANbridge sublicenses all or any portion of the rights granted to it under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">AVEO License Grant; Right of Reference</font><font style="font-family:Times New Roman;color:#000000;">) in (a) the EU, (b) Japan, or (c) the entirety of China, Taiwan and South Korea, then CANbridge will pay to AVEO a percentage of all Sublicense Revenue received by it from such Sublicensees within [**] days following the receipt of such Sublicense Revenue, at the percentages set forth below (such percentage, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Revenue Percentage</font><font style="font-family:Times New Roman;color:#000000;">&#8221; and such payment, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sublicense Payment</font><font style="font-family:Times New Roman;color:#000000;">&#8221;):</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:9.27%;width:391.5pt;;">
<tr>
<td style="width:279pt;"></td>
<td style="width:112.5pt;"></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#D9D9D9" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timing of Sublicense Grant </p></td>
<td valign="middle"  BGCOLOR="#D9D9D9" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sublicense Revenue Percentage</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Sublicense granted [**]</p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Sublicense granted [**]</p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Sublicense granted [**]</p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:9.27%;width:391.5pt;;">
<tr>
<td style="width:279pt;"></td>
<td style="width:112.5pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Sublicense granted </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</font></p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Adjustment to Certain Sublicense Revenue</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In the event that (a) any Sublicense Revenue received by CANbridge pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Sublicense Payments) is in the form of a development milestone payment that is attributable to the receipt by the applicable Sublicensee of Regulatory Approval of a Product in any EU country and (b) the amount of the Sublicense Payment due and payable by CANbridge to AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Sublicense Payments) as a result of such development milestone is less than $[**], CANbridge will pay AVEO, in addition to the applicable Sublicense Payment, an amount equal to the difference between such Sublicense Payment and $[**] (such difference, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Additional Payment</font><font style="font-family:Times New Roman;color:#000000;">&#8221;); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, CANbridge will have the right to credit the full amount of the Additional Payment against any other payments that are due and payable by CANbridge under this Agreement to AVEO on and after such date.</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Royalties"></a><a name="_Ref439957208"></a><a name="_Toc445903018"></a>6.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Royalties</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Royalty_Rates"></a><a name="_Ref439510033"></a>6.3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Royalty Rates</font><font style="font-family:Times New Roman;color:#000000;">. Subject to the terms and conditions in this Agreement, on a country-by-country and Product-by-Product basis during the applicable Royalty Term, CANbridge will pay to AVEO royalties on Net Sales of Products (whether by CANbridge, its Affiliates or Sublicensees) in the Licensed Territory, as calculated by multiplying the applicable royalty rates below by the corresponding amount of incremental Net Sales in the Licensed Territory of all Products in each Calendar Year: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:470.9pt;;">
<tr>
<td style="width:362.9pt;"></td>
<td style="width:108pt;"></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#D9D9D9" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Net Sales of Products</p></td>
<td valign="middle"  BGCOLOR="#D9D9D9" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty Rate</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For that portion of aggregate annual Net Sales less than US $[**] </p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For that portion of aggregate annual Net Sales greater than or equal to US $[**] and less than US $[**] </p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For that portion of aggregate annual Net Sales greater than or equal to US $[**] and less than US $[**]</p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For that portion of aggregate annual Net Sales greater than or equal to US $[**]</p></td>
<td valign="top"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, if the Net Sales of the Product in the Licensed Territory in a given Calendar Year totaled $[**], CANbridge would pay to AVEO [**], for a total royalty payment [**] equal to $[**]. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Royalty_Term"></a><a name="_Ref439708948"></a><a name="_Ref443933876"></a><a name="_AEIOULastRenderedPageBreakAEIOU41"></a>6.3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Royalty Term</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Royalties will be due under this</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;"> Section 6.3.2</font><font style="font-family:Times New Roman;color:#000000;"> (Royalty Term) with respect to a Product and country in the Licensed Territory during the period commencing on the First Commercial Sale of such Product in such country and ending upon the later of (a) the expiration of the last Valid Claim within the Licensed Patents Covering the Product in such country, (b) the expiration of regulatory data exclusivity in such country, and (c)&#160;the 10<sup style="font-size:85%; vertical-align:top">th</sup> anniversary of the First Commercial Sale in such country (such period, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Royalty Term</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). Notwithstanding the foregoing, and subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.6.3</font><font style="font-family:Times New Roman;color:#000000;"> (Sales Prior to Receipt of Marketing Authorization), sales of Product prior to receipt of Marketing Authorization for a Product, such as </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">so-called &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">treatment IND sales,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">named patient sales,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; and &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">compassionate use sales,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; will constitute Net Sales subject to the payment of royalties pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.3</font><font style="font-family:Times New Roman;color:#000000;"> (Royalties) if such sale is made at a price greater than the cost of goods for such Product.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903019"></a>6.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Royalty Payments and Reports</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge will pay to AVEO any amounts due pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (Royalty Rates) within [**] days after the end of each Calendar Quarter, and will provide to AVEO concurrently with such payment a statement setting forth (a) the amount of Net Sales of Products in each country in the Licensed Territory during such Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars); (b) the type and amount of permitted deductions from gross sales to determine Net Sales and the total amount of such deductions; (c) the applicable royalty rates for all Products in each country in the Licensed Territory after applying any permitted deductions set forth above; and (d) a calculation of the amount of royalty due to AVEO.&nbsp;&nbsp;Sublicense Payments will be made by CANbridge with respect to each Product that is the subject of a Sublicense agreement [**] days after the end of each Calendar Quarter in which CANbridge receives any Sublicense Revenue from a Sublicensee, and CANbridge will provide to AVEO concurrently with such payment a statement setting forth (y) the amount of Sublicense Revenue received in each country in the Licensed Territory during such Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars) and (z) the total amount of exclusions from Sublicense Revenue to determine the applicable Sublicense Payments.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443931084"></a><a name="_Toc445903020"></a>6.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Profit Share Payments</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In the event that CANbridge receives any Profit Share Payment from Profit Share Sublicensees in any Calendar Quarter during the Royalty Term in any country in the Licensed Territory other than in Europe and Japan, then CANbridge will pay to AVEO [**]% of such Profit Share Payment within [**] days following the end of such Calendar Quarter. CANbridge will provide to AVEO concurrently with such payment a statement setting forth the amount of Profit Share Payments received during such Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars).</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903021"></a>6.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Payment Reductions</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442553423"></a>6.6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Biosimilar Competition</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;If at any time during the Royalty Term there is Biosimilar Competition for a Product in any country in the Licensed Territory in which such Product is then being sold by CANbridge or an Affiliate or Sublicensee, then the applicable royalties in effect with respect to such Product in such country as specified in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (Royalty Rates) will be reduced by [**]%. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Blocking_Third_Party_Intellectual"></a><a name="_Ref439450030"></a>6.6.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Blocking Third Party Intellectual Property</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;With respect to a particular country in the Licensed Territory, CANbridge will be entitled to deduct from royalty payments under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.3</font><font style="font-family:Times New Roman;color:#000000;"> (Royalties) otherwise payable to AVEO in such country [**]% of any Blocking Third Party Intellectual Property Costs paid by CANbridge under a license to Blocking Third Party Patent Rights obtained by CANbridge and applicable to such country. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442599415"></a><a name="_Ref443912330"></a><a name="Maximum_Reduction"></a><a name="_Ref439450194"></a><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>6.6.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sales Prior to Receipt of Marketing Authorization</font><font style="font-family:Times New Roman;color:#000000;">. With respect to sales of a Product in a country in the Licensed Territory prior to the receipt of Marketing Authorization (including, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">treatment IND sales,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">named patient sales,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; and &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">compassionate use sales</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) that are at a price greater than the cost of goods for such Product, then if the actual price received for such Product is lower than the projected sale price in such country set forth in the Commercialization </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">plan provided by CANbridge to the JSC pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">5.2.1(c)</font><font style="font-family:Times New Roman;color:#000000;"> (Commercialization Plan), then CANbridge will be entitled to reduce the royalty payments under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.3</font><font style="font-family:Times New Roman;color:#000000;"> (Royalties) otherwise payable to AVEO with respect to such sale in such country by a percentage equal to the percentage difference between the actual price received for such Product and such projected sale price set forth in the CANbridge Commercialization plan until such time as Marketing Authorization is received.</font><font style="font-family:Times New Roman;color:#000000;"> For example, if the projected sale price in a Commercialization plan for a Product prior to the receipt of Marketing Authorization is $</font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> but the actual price received for such Product is $</font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;">, then the applicable royalty to AVEO for such Product will be reduced by </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;">% until such time as Marketing Authorization is received.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442693164"></a>6.6.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Maximum Annual Reduction</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In no event will the reductions in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections</font><font style="font-family:Times New Roman;color:#000000;"> </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.6.1</font><font style="font-family:Times New Roman;color:#000000;"> (Biosimilar Competition), </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.6.2</font><font style="font-family:Times New Roman;color:#000000;"> (Blocking Third Party Intellectual Property) and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.6.3</font><font style="font-family:Times New Roman;color:#000000;"> (Sales Prior to Receipt of Marketing Authorization) reduce the royalty rates under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.3</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Royalties</font><font style="font-family:Times New Roman;color:#000000;">) in any Calendar Year to less than the greater of (a) [**]% of the royalty rates set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (Royalty Rates) or (b) a rate equal to the sum of the Aggregate AVEO Third Party Royalty Obligation and the Applicable Percentage (as defined below); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that CANbridge will be entitled to carry forward to future Calendar Years any amounts with respect to which CANbridge would have been entitled to make a deduction pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.6.4</font><font style="font-family:Times New Roman;color:#000000;"> (Maximum Annual Reduction) but for such maximum annual reduction.&nbsp;&nbsp;As used herein, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Applicable Percentage</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means (i) [**]% if any portion of the reduction in the royalty rate is pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.6.1</font><font style="font-family:Times New Roman;color:#000000;"> (Biosimilar Competition) and (ii) [**]% if no portion of the reduction in royalty rate is pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.6.1</font><font style="font-family:Times New Roman;color:#000000;"> (Biosimilar Competition). </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref441249526"></a><a name="_Toc445903022"></a><font style="text-decoration:none;">6.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Reimbursement of Third Party Expenses</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;color:#000000;">CANbridge</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;"> will reimburse AVEO for the following milestone payments that AVEO is obligated to pay to Third Parties under the license agreements set forth on </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 1.60 </font><font style="font-family:Times New Roman;color:#000000;">(AVEO In-License Agreements)</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;"> within [**] days of the first achievement of each milestone event set forth below: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:6.84%;width:82.54%;">
<tr>
<td valign="middle"  BGCOLOR="#F2F2F2" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:3.6pt;padding-Bottom:3.6pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Party Milestone Event</p></td>
<td valign="middle"  BGCOLOR="#F2F2F2" style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:3.6pt;padding-Bottom:3.6pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payment</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:12pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[**]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:62.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="padding-left:2.9pt;padding-Right:2.9pt;padding-Top:1.45pt;padding-Bottom:1.45pt;width:37.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Third Party milestone payment set forth in this <font style="text-decoration:underline;">Section 6.7</font> (Reimbursement of Third Party Expenses) will be due and payable (i) only upon the first achievement of the applicable milestone event, and no amounts would be due for subsequent or repeated achievements, and (ii) only if the achievement of such milestone results in AVEO being required to make a milestone payment no smaller than the corresponding amount set forth above to a Third Party pursuant to <font style="text-decoration:none;">an agreement set forth on </font><font style="text-decoration:underline;">Schedule 1.60</font> (AVEO In-License Agreements).</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442550379"></a><a name="_Toc445903023"></a>6.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Financial Audits</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444622564"></a><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>6.8.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Record Keeping</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge and its Affiliates will keep complete and accurate records in accordance with its Accounting Standards of the items underlying (a) the Sales </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">Milestone Payments, (b) the Development Milestone Payments, (c) Net Sales, (d) royalty payments, (e) Sublicense Revenue, (f) Profit Share Payments, (g) its satisfaction of the minimum requirements set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">12.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by AVEO), (h) any other elements thereof required to prepare the reports or calculate payments required under this Agreement (including any payments made under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">6.6.3</font><font style="font-family:Times New Roman;color:#000000;">), and (i) any other payments under this Agreement. AVEO will have the right </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;">, at its own expense, to have an independent, certified public accountant, selected by AVEO and reasonably acceptable to CANbridge, review any such records of CANbridge in the location(s) where such records are maintained by CANbridge upon reasonable prior written notice, during regular business hours and under obligations of confidentiality, for the sole purpose of verifying the basis and accuracy of payments made under this Agreement, within the prior </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> Calendar Year period.&nbsp;&nbsp;The records for any Calendar Year may be audited no more than once.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439709000"></a>6.8.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Audit Period</font><font style="font-family:Times New Roman;color:#000000;">. Upon the expiration of [**] years following the end of any Calendar Year, the calculation of amounts payable with respect to such Calendar Year will be binding and conclusive.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439708981"></a>6.8.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Audit Report</font><font style="font-family:Times New Roman;color:#000000;">. The report prepared by the independent certified public accounting firm, a copy of which will be sent or otherwise provided to each Party by such independent public accountant at the same time, will contain the conclusions of such accounting firm regarding the audit and will specify that the amounts paid pursuant thereto were correct or, if incorrect, the amount of any underpayment or overpayment, and the specific details regarding any discrepancies.&nbsp;&nbsp;No other information will be provided to AVEO without the prior consent of CANbridge unless disclosure is required by Law, regulation or judicial order, and if so determined by AVEO, it will, if permitted, give CANbridge prior notice thereof reasonably sufficient for CANbridge to seek a protective order against or limiting such disclosure.&nbsp;&nbsp;If such report shows any underpayment, CANbridge will remit to AVEO, within [**] days after receipt of such report, (a) the amount of such underpayment and (b) if such underpayment exceeds [**]% of the total amount owed for the period then being audited, the reasonable out-of-pocket costs incurred in conducting such review.&nbsp;&nbsp;Any overpayments will be refunded by AVEO within [**] days of receipt of the audit report or will be deducted from future payments owed to AVEO, in the sole discretion of AVEO.&nbsp;&nbsp;The Parties mutually agree that all information subject to review under this Section is Confidential Information of CANbridge and that AVEO will retain and cause the accountant to retain all such information in confidence in accordance with </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 8</font><font style="font-family:Times New Roman;color:#000000;"> (Confidentiality and Publicity).</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Tax_Matters"></a><a name="_Ref439710414"></a><a name="_Toc445903024"></a>6.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Tax Matters</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.9.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Tax Responsibility</font><font style="font-family:Times New Roman;color:#000000;">. Each Party will be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement, except as expressly set forth in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.9</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Tax Matters</font><font style="font-family:Times New Roman;color:#000000;">).</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439709045"></a><a name="_AEIOULastRenderedPageBreakAEIOU44"></a>6.9.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Tax Withholding</font><font style="font-family:Times New Roman;color:#000000;">. A Party will withhold and deduct from all payments made (or to be made) pursuant to this Agreement by such Party (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Withholding Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), any tax required to be withheld and deducted from such payments under applicable Law and in accordance with this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.9</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Tax Matters</font><font style="font-family:Times New Roman;color:#000000;">).&nbsp;&nbsp;Any amounts so withheld and deducted will be remitted by the Withholding Party on a timely basis to the appropriate Governmental Authority for the account of the other Party and the Withholding Party will provide the other Party reasonable evidence of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">the remittance within </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days thereof. To the extent that amounts are so withheld by the Withholding Party and duly paid over to the appropriate Governmental Authority, such withheld amounts will be treated for all purposes of this Agreement as having been paid to the other Party, in respect of which such deduction and withholding was made.&nbsp;&nbsp;Each Party will furnish to the Withholding Party such forms, certificates and documentation as may be necessary or appropriate, and that are legally required, to obtain any reduction of, credit for, or exemption from the withholding of any tax.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.9.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Retroactive Payments</font><font style="font-family:Times New Roman;color:#000000;">. In the event that a taxing authority retroactively determines that a payment made by a Withholding Party to the other Party pursuant to this Agreement should have been subject to withholding or to additional withholding of taxes, and the Withholding Party remits such taxes to the taxing authority, the Withholding Party will have the right (a) to offset such amount, including any interest and penalties that may be imposed thereon (except to the extent any such interest or penalties result from the gross negligence of the Withholding Party), against future payment obligations of the Withholding Party under this Agreement, (b) to invoice the other Party for such amount (which will be payable by the other Party within [**] days of its receipt of such invoice) or (c) to pursue reimbursement by any other available remedy.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903025"></a>6.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Currency of Payments</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;All payments under this Agreement will be paid in U.S. Dollars by wire transfer to an account designated by the receiving Party (which account the receiving Party may update from time to time in writing</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">)</font><font style="font-family:Times New Roman;color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903026"></a>ARTICLE 7<font style="color:#000000;"><br>INTELLECTUAL PROPERTY OWNERSHIP, <br>PROTECTION AND RELATED MATTERS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Ownership_of_Inventions"></a><a name="_Ref439597639"></a><a name="_Toc445903027"></a>7.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Ownership of Inventions</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442618430"></a>7.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Inventorship</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Ownership of inventions, improvements, developments or discoveries, whether patentable or non-patentable, invented or otherwise developed or generated by either Party or its Affiliates, or any of its or their employees, sublicensees (where permitted), independent contractors or agents during the Term, in the course of Developing, Manufacturing or Commercializing any Product under this Agreement (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Inventions</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), and any and all intellectual property rights therein, will be determined based on the principles of inventorship in accordance with United States patent Laws.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442783596"></a>7.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Ownership</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Any Invention made, conceived, reduced to practice, or otherwise discovered solely by the employees, independent contractors, or agents of AVEO (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO Inventions</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), and all Patent Rights claiming such Invention, will be solely owned by AVEO.&nbsp;&nbsp;Subject to Schedule 7.1.2, any Invention made, conceived, reduced to practice or otherwise discovered by the employees, independent contractors or agents of CANbridge (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Inventions</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), and all Patent Rights claiming such Invention, will be solely owned by CANbridge.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>7.1.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Assignment Obligation</font><font style="font-family:Times New Roman;color:#000000;">.</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;color:#000000;"> Each Party will cause all employees of such Party who perform activities for such Party under this Agreement to be under an obligation to assign their rights in any Patent Rights and Know-How, whether or not patentable, resulting therefrom to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">such Party. With respect to any activities of a Party under this Agreement that are subcontracted to a Person that is not an employee, the Party retaining such subcontractor will include in the applicable subcontract an assignment to such Party of all rights in Patent Rights and Know-How made by such subcontractor resulting from such activities, and in any event will include in the applicable subcontract a license to such Party that is sublicensable to the other Party under this Agreement, of any Patent Rights and Know-How made by such contractor resulting from such activities.&nbsp;&nbsp;</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref403629538"></a>7.1.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Right to Practice Joint Patent Rights and Joint Know-How</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Parties will jointly own any Joint Know-How and Joint Patent Rights.&nbsp;&nbsp;Subject to the rights and licenses granted to, and the obligations (including payment obligations) of each Party under this Agreement, either Party is entitled to practice the Joint Patent Rights and Joint Know-How for all purposes on a worldwide basis and license the Joint Patent Rights and Joint Know-How without the consent of and without a duty of accounting to the other Party.&nbsp;&nbsp;Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses under, the Joint Patent Rights and Joint Know-How, throughout the world, necessary to provide the other Party with such rights of use and Exploitation of the Joint Patent Rights and Joint Know-How, and will execute documents as reasonably necessary to accomplish the foregoing.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Prosecution_and_Maintenance_of_the_L"></a><a name="_Ref439741696"></a><a name="_Toc445903028"></a>7.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Prosecution and Maintenance of the Licensed Patents</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="In_the_Licensed_Territory"></a><a name="_Ref439511823"></a><a name="_Ref439512521"></a>7.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">In the Licensed Territory</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge will have the sole right, at its expense, to prepare, file, prosecute and maintain the Licensed Patents (including any Joint Patent Rights) in all countries in the Licensed Territory.&nbsp;&nbsp;CANbridge will keep AVEO reasonably informed of all steps with regard to and the status of such preparation, filing, prosecution, and maintenance of such Patent Rights, including by providing AVEO with (i) copies of all correspondence and material communications it sends to or receives from the European Patent Office (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">EPO</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) and equivalent patent offices in other jurisdictions in the Licensed Territory, relating to the Licensed Patents, (ii) a draft copy of all applications sufficiently in advance of filing to permit reasonable review and comment by AVEO, and (iii) a copy of applications as filed, together with notice of its filing date and serial number. Before CANbridge submits any material filing, including a new patent application, or response to such patent authorities with respect to the Licensed Patents, CANbridge will provide AVEO with a reasonable opportunity to review and comment on such filing or response and will take into account and consider in good faith AVEO&#8217;s reasonable and timely requests and suggestions regarding the filing, prosecution and maintenance of the Licensed Patents under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (In the Licensed Territory).&nbsp;&nbsp;Without limiting the foregoing, within [**] Business Days following the Effective Date, CANbridge will reimburse AVEO for the costs and expenses incurred by AVEO in connection with the filing and maintenance of the Licensed Patents in March of 2016 in the Licensed Territory.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="In_the_North_America_Territory"></a><a name="_Ref443931563"></a><a name="_Ref439512523"></a><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>7.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">In the North America Territory</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;AVEO will have the sole right, at its expense, to prepare, file, prosecute and maintain the Licensed Patents (including the Joint Patent Rights) in all countries in the North America Territory.&nbsp;&nbsp;AVEO will keep CANbridge reasonably informed of all steps with regard to and the status of such preparation, filing, prosecution, and maintenance of such Patent Rights, including by providing CANbridge with (i) copies of all correspondence and material communications it sends to or receives from the US Patent and Trademark Office (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">USPTO</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) and equivalent patent offices in other jurisdictions in the North America Territory, relating to the Licensed Patents, (ii) a draft copy of all applications sufficiently </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">in advance of filing to permit reasonable review and comment by CANbridge, and (iii) a copy of applications as filed, together with notice of its filing date and serial number. Before AVEO submits any material filing, including a new patent application, or response to such patent authorities with respect to the Licensed Patents, AVEO will provide CANbridge with a reasonable opportunity to review and comment on such filing or response and will take into account and consider in good faith CANbridge&#8217;s reasonable and timely requests and suggestions regarding the filing, prosecution and maintenance of the Licensed Patents under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="font-family:Times New Roman;color:#000000;">In the North America Territory</font><font style="font-family:Times New Roman;color:#000000;">); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, CANbridge&#8217;s rights under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (In the North America Territory) will terminate upon the expiration of CANbridge&#8217;s rights of first negotiation pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">4.4</font><font style="font-family:Times New Roman;color:#000000;"> (Rights of First Negotiation).</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442553495"></a>7.2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Step-In Right</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;If either Party (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Filing </font><font style="font-family:Times New Roman;color:#000000;">Party&#8221;) elects not to continue to prosecute or maintain a Patent Right within the Licensed Patents in its respective Territory pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections 7.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (In the Licensed Territory) and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (In the North America Territory) above, the Filing Party will give the other Party notice thereof within a reasonable period (but not less than [**] days) prior to allowing such Patent Rights to lapse or become abandoned or unenforceable, and the other Party (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Assuming Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) will have the right to prosecute or maintain such Patent Right in the name of the Filing Party.&nbsp;&nbsp;Subject to any rights granted by a Filing Party to a Sublicensee under this Agreement, the Assuming Party will have the right, but not the obligation, to assume responsibility for continuing the prosecution of such Patent Rights in such country or region and paying any required fees to maintain such Patent Rights in such country or region or defending such Patent Rights, all at the Assuming Party&#8217;s sole expense, through patent counsel or agents of its choice.&nbsp;&nbsp;The Assuming Party will not become an assignee of any such Patent Rights as a result of its assumption of any such responsibility.&nbsp;&nbsp;Upon transfer of the Filing Party&#8217;s responsibility for filing, prosecuting and maintaining any of the Patent Rights to the Assuming Party under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Step-In Right), the Filing Party will promptly deliver to the Assuming Party copies of all necessary files related to the Patent Rights with respect to which responsibility has been transferred and will take all actions and execute all documents reasonably necessary for the Assuming Party to assume such prosecution, maintenance and defense); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, CANbridge&#8217;s rights under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Step-In Right) will terminate upon the expiration of CANbridge&#8217;s rights of first negotiation pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 4.4</font><font style="font-family:Times New Roman;color:#000000;"> (Rights of First Negotiation).</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439602261"></a>7.2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Cooperation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party will, and will cause its Affiliates to, reasonably cooperate, with the other with respect to the preparation, filing, prosecution and maintenance of Licensed Patents pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.2</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Prosecution and Maintenance of the Licensed Patents</font><font style="font-family:Times New Roman;color:#000000;">).</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440468667"></a><a name="_Toc445903029"></a><a name="_AEIOULastRenderedPageBreakAEIOU47"></a>7.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Prosecution and Maintenance of the CANbridge Program Patents</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge will have the sole right, at its expense, to prepare, file, prosecute and maintain the CANbridge Program Patents worldwide.&nbsp;&nbsp;CANbridge will keep AVEO reasonably informed of all steps with regard to and the status of such preparation, filing, prosecution, and maintenance of such CANbridge Program Patents in the North America Territory, including by providing AVEO with (a) copies of all correspondence and material communications it sends to or receives from the USPTO and equivalent patent offices in other jurisdictions in the North America Territory relating to the CANbridge Program Patents, (b) a draft copy of all applications sufficiently in advance of filing to permit reasonable review and comment by AVEO, and (c) a copy of applications as filed, together </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">with notice of its filing date and serial number. Before CANbridge submits any material filing, including a new patent application, or response to such patent authorities with respect to the CANbridge Program Patents in the North America Territory, CANbridge will provide AVEO with a reasonable opportunity to review and comment on such filing or response and will take into account and consider in good faith AVEO&#8217;s reasonable and timely requests and suggestions regarding the filing, prosecution and maintenance of the CANbridge Program Patents under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Prosecution and Maintenance of the CANbridge Program Patents).</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439597663"></a><a name="_Toc445903030"></a>7.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Infringement</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Notice"></a><a name="_Ref439709226"></a>7.4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Notice</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party will promptly notify the other in writing of any (a) apparent, threatened or actual infringement by a Third Party of any Licensed Patent, including receipt of any notice filed pursuant to the Biologics Price Competition and Innovation Act of 2009, including notices pursuant to a &#167;351(k) application under the BPCIA, or any analogous law outside the United States, or (b) unauthorized use or misappropriation of any Licensed Know-How by a Third Party of which it becomes aware, and, in each case, will provide the other Party with all available evidence supporting such infringement or unauthorized use or misappropriation (each, an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Infringement</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Enforcement_of_Licensed_Patents_in"></a><a name="_Ref439544804"></a><a name="_Ref442804625"></a><a name="_Ref442553554"></a><a name="_Ref443932021"></a>7.4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Enforcement of Licensed Patents in the Licensed Territory</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge will have the sole right, using counsel of its choosing and at its sole expense, to institute any Action alleging Infringement of the Licensed Patents (including the Joint Patent Rights) in the Licensed Territory (a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Licensed Territory Infringement Action</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).&nbsp;&nbsp;CANbridge will notify and keep AVEO apprised in writing of any such Licensed Territory Infringement Action and will consider AVEO&#8217;s reasonable interests and requests regarding such Licensed Territory Infringement Action; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">that,</font><font style="font-family:Times New Roman;color:#000000;"> if CANbridge does not intend to prosecute a Licensed Territory Infringement Action, or ceases to diligently pursue a Licensed Territory Infringement Action, (a) it will promptly inform AVEO in writing and (b) the Parties will discuss in good faith the possibility of AVEO, at its own expense, initiating such Licensed Territory Infringement Action against the applicable Third Party infringer(s) in CANbridge&#8217;s sole discretion.&nbsp;&nbsp;If in connection with such good faith discussions, AVEO informs CANbridge that it wishes to prosecute any such Licensed Territory Infringement Action against the applicable Third Party infringer(s) and CANbridge determines in its discretion that AVEO may not prosecute such Licensed Territory Infringement Action against any such Third Party infringer(s), then, sales of Biosimilar Products by such Third Party will not be counted to determine whether the market share test in the definition of &#8220;Biosimilar Competition&#8221; has been achieved.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Enforcement_of_Licensed_Patents_NA"></a><a name="_Ref439544826"></a><a name="_Ref443931892"></a>7.4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Enforcement of Licensed Patents in the North America Territory</font><font style="font-family:Times New Roman;color:#000000;">. AVEO will have the sole right, using counsel of its choosing and at its sole expense, to institute any Action alleging Infringement of the Licensed Patents (including the Joint Patent Rights) in the North America Territory (a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">North America Infringement Action</font><font style="font-family:Times New Roman;color:#000000;">&#8221; and, collectively with a Licensed Territory Infringement Action, an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Infringement Action</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).&nbsp;&nbsp;AVEO will notify and keep CANbridge apprised in writing of any such North America Infringement Action and will consider CANbridge&#8217;s reasonable interests and requests regarding such North America Infringement Action. AVEO will have the right to settle or compromise any North America Infringement Action brought pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections 7.4.23</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the North America Territory) without the consent of CANbridge. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.4</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Enforcement of the CANbridge Program Patents</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge will have the sole right, using counsel of its choosing and at its sole expense, to institute any Infringement Action under the CANbridge Program Patents worldwide in its sole discretion.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Cooperation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In any Infringement Action brought under the Licensed Patents pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections 7.4.2</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the Licensed Territory), or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.4.3</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the North America Territory) each Party will, and will cause its Affiliates to, reasonably cooperate with each other, in good faith, relative to the other Party&#8217;s efforts to protect the Licensed Patents and will join such suit as a party, if requested by the other Party. Furthermore, the Party initiating any Infringement Action pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections 7.4.2</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the Licensed Territory) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">7.4.3</font><font style="font-family:Times New Roman;color:#000000;"> (Enforcement of Licensed Patents in the North America Territory) will consider in good faith all reasonable and timely comments from the other Party on any proposed arguments asserted or to be asserted in litigation related to the enforcement or defense of any such Patent Rights. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Allocation of Recoveries</font><font style="font-family:Times New Roman;color:#000000;">. Any settlements, damages or monetary awards recovered by either Party pursuant to any Licensed Territory Infringement Action with respect to the Licensed Patents will, after reimbursing the Parties for their reasonable out-of-pocket expenses in making such recovery (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses), be allocated [**]% to CANbridge and [**]% to AVEO.&nbsp;&nbsp;For clarity, any settlements, damages or monetary awards recovered by AVEO pursuant to any North America Infringement Action with respect to the Licensed Patents will be allocated 100% to AVEO.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442553609"></a><a name="_Ref443931909"></a><a name="_Toc445903031"></a><a name="_Ref439709265"></a>7.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Claimed Infringement</font><font style="font-family:Times New Roman;color:#000000;"><a name="_Ref439709265"></a>.&nbsp;&nbsp;Each Party will promptly notify the other Party if a Third Party brings any Action alleging patent infringement by CANbridge or AVEO or any of their respective Affiliates or Sublicensees with respect to the Development, Manufacture or Commercialization of any Product (any such Action, an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Infringement Claim</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).&nbsp;&nbsp;In the case of any Infringement Claim, CANbridge will have the right, but not the obligation to, control the defense and response to such Infringement Claim in the Licensed Territory, and AVEO will have the right, but not the obligation to, control the defense and response to such Infringement Claim in the North America Territory.&nbsp;&nbsp;Upon the request of the Party controlling the response to the Infringement Claim, the other Party will reasonably cooperate with the controlling Party in the reasonable defense of such Infringement Claim.&nbsp;&nbsp;The other Party will have the right to consult with the controlling Party concerning any Infringement Claim and to participate in and be represented by independent counsel in any associated litigation.&nbsp;&nbsp;If the Infringement Claim is brought against both Parties, then each Party will have the right to defend against the Infringement Claim. The Party defending an Infringement Claim under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.5</font><font style="font-family:Times New Roman;color:#000000;"> (Claimed Infringement) will (a) consult with the other Party as to the strategy for the prosecution of such defense, (b) consider in good faith any comments from the other Party with respect thereto and (c) keep the other Party reasonably informed of any material steps taken and provide copies of all material documents filed, in connection with such defense.&nbsp;&nbsp;The Party controlling the defense against an Infringement Claim will have the right to settle such Infringement Claim on terms deemed reasonably appropriate by such Party, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">that</font><font style="font-family:Times New Roman;color:#000000;">, unless any such settlement includes a full and unconditional release from all liability of the other Party and does not adversely affect the rights of the other Party, any such settlement will be subject to the other Party&#8217;s prior written consent. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440642332"></a><a name="_Toc445903032"></a><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>7.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">EU Unitary Patent System</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Without limiting CANbridge&#8217;s rights under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.4</font><font style="font-family:Times New Roman;color:#000000;"> (Third Party Infringement), CANbridge will have the exclusive right to opt-in and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">opt-out of any Licensed Patent from the jurisdiction of the EU Unified Patent Court, in accordance with the terms of Unified Patent Court Regulation (EU) No 1257/2012 and its applicable Annexes and Rules of Procedure, as amended from time to time and in effect (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">UPC</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). Unless CANbridge has expressly opted-in to the EU Unitary Patent System with respect to a given Licensed Patent, AVEO will not initiate any action to enforce any such Licensed Patent under the EU Unitary Patent System without CANbridge&#8217;s prior written approval.</font>&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903033"></a>7.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Trademarks. </font><font style="font-family:Times New Roman;color:#000000;"> CANbridge will own, and will be solely responsible for, the selection and registration of all Trademarks used exclusively for the Commercialization of the Products in the Licensed Territory. CANbridge will discuss with AVEO in good faith the selection of Trademarks in the Licensed Territory through the JSC and the Parties will coordinate a branding strategy with respect to such Trademarks, subject to CANbridge&#8217;s final decision-making authority in the Licensed Territory.&nbsp;&nbsp;AVEO will discuss with CANbridge in good faith the selection of Trademarks in the North America Territory through the JSC and the Parties will coordinate a branding strategy with respect to such Trademarks, subject to AVEO&#8217;s final decision-making authority in the North America Territory. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903034"></a><a name="_Ref439601931"></a><a name="_Ref439709859"></a><a name="CONFIDENTIALITY_AND_PUBLICITY"></a><a name="_Ref440468755"></a><a name="_Ref440643652"></a>ARTICLE 8<font style="color:#000000;"><br><a name="_Ref439601931"></a><a name="_Ref439709859"></a><a name="CONFIDENTIALITY_AND_PUBLICITY"></a><a name="_Ref440468755"></a><a name="_Ref440643652"></a>CONFIDENTIALITY AND PUBLICITY</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Confidential_Information"></a><a name="_Ref439555929"></a><a name="_Toc445903035"></a>8.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Confidentiality Obligation</font><font style="font-family:Times New Roman;color:#000000;">. During the Term and for a period of [**] years after any termination or expiration of this Agreement, each Party agrees to, and will cause its Affiliates to, keep in confidence and not to disclose to any Third Party, or use for any purpose, except to exercise its rights or perform its obligations under this Agreement, any Confidential Information of the other Party. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Permitted Disclosures</font><font style="font-family:Times New Roman;color:#000000;">. Each Party agrees that it and its Affiliates will provide or permit access to the other Party&#8217;s Confidential Information only to the receiving Party&#8217;s employees, consultants, advisors and Sublicensees, and to the employees, consultants and advisors of the receiving Party&#8217;s Affiliates, in each case on a need to know basis who are subject to obligations of confidentiality and non-use with respect to such Confidential Information no less stringent than the obligations of confidentiality and non-use of the receiving Party pursuant to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 8.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that each Party will remain responsible for any failure by its Affiliates and Sublicensees, and its and its Affiliates&#8217; respective employees, consultants and advisors, to treat such Confidential Information as required under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 8.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">) as if such Affiliates, employees, consultants, advisors and Sublicensees were parties directly bound to the requirements of this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 8.1</font><font style="font-family:Times New Roman;color:#000000;"> (Confidential Information).</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a>8.1.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Confidentiality Limitation</font><font style="font-family:Times New Roman;color:#000000;">. Notwithstanding anything to the contrary herein, each Party may use and disclose the other Party&#8217;s Confidential Information as follows:&nbsp;&nbsp;(a) under appropriate written confidentiality obligations substantially equivalent to those in this Agreement, to its Affiliates, potential and actual permitted Sublicensees, contractors and any other Third Parties, to the extent such use or disclosure is reasonably necessary to perform its obligations or to exercise its rights under this Agreement, (b) to the extent such use or disclosure is consistent with this Agreement, is not prohibited by the Existing Third Party License Agreements and is reasonably necessary for filing or prosecuting the Licensed Patents, (c) to its advisors (including </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">financial advisors, attorneys and accountants), actual or potential acquisition partners, financing sources or investors and underwriters on a need to know basis, in each case under appropriate confidentiality obligations (which may include professional ethical obligations) substantially equivalent to those in this Agreement; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that each Party will remain responsible for any failure by any of the foregoing individuals to treat such Confidential Information as required under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">8.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">) (as if such individuals were parties directly bound to the requirements of this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">8.1</font><font style="font-family:Times New Roman;color:#000000;">, or (d) </font><font style="font-family:Times New Roman;">as required by any court or other</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">governmental body or as otherwise required by </font><font style="font-family:Times New Roman;">applicable L</font><font style="font-family:Times New Roman;">aw</font><font style="font-family:Times New Roman;">s;</font><font style="font-family:Times New Roman;"> provided</font><font style="font-family:Times New Roman;">,</font><font style="font-family:Times New Roman;"> that</font><font style="font-family:Times New Roman;">,</font><font style="font-family:Times New Roman;"> notice is promptly given</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">to the other Party and the disclosing Party cooperates with reasonable requests from the</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">other Party to seek a protective order</font><font style="font-family:Times New Roman;"> or other appropriate remedy to protect the Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Secrecy of Licensed Know-How</font><font style="font-family:Times New Roman;color:#000000;">. AVEO will protect, will cause its Affiliates to protect and will use Commercially Reasonable Efforts to cause its Sublicensees and its and their respective officers, directors, employees, and agents to protect, the secrecy and confidentiality of the Licensed Know-How and AVEO&#8217;s interest in the Joint Know-How using at least the same degree of care as it uses to prevent the disclosure of its own other confidential information of like importance.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Publicity"></a><a name="_Ref439558523"></a><a name="_Toc445903036"></a>8.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Publicity</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Initial_Press_Releases"></a><a name="_Ref439557177"></a>8.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Initial Press Releases</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Promptly following the Effective Date, the Parties will issue a mutually agreed upon press release regarding the subject matter of this Agreement, including a description of the financial terms, a high-level description of the overall scope of the transaction and the scope of planned Development and value of the Agreement in the form attached hereto as </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exhibit B</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439710624"></a>8.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Further Publicity; Publications</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Parties acknowledge the importance of supporting each other&#8217;s efforts to publicly disclose results and significant developments regarding the Product in the Field, and each Party may make such disclosures from time to time, subject to this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 8.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (Further Publicity; Publications).&nbsp;&nbsp;Such disclosures may include achievement of milestones, significant events in the Development process with respect to the Products, Commercialization activities with respect to the Products and the like.&nbsp;&nbsp;Except for the initial press releases described in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 8.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Initial Press Releases):</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439710617"></a><a name="_AEIOULastRenderedPageBreakAEIOU51"></a>(a)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">Whenever either Party elects to make any such public disclosure, it will first notify the other Party of such planned press release or public announcement and provide a draft for review no less than [**] Business Days in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Law, with as much advance notice as possible under the circumstances if it is not possible to provide notice no less than [**] Business Days in advance). Each Party will have the right to review and approve any such planned press release or public announcement proposed by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of Clinical Studies or other studies with respect to the Product, or that includes Confidential Information of the other Party; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that (A) the reviewing Party will attempt to provide such approval as soon as reasonably possible and will not unreasonably withhold such approval; (B) the reviewing Party will provide explanations of its disapproval of such press release; and (C) a Party desiring to make such public disclosure may issue such press release or public announcement without such prior review by the other Party if (i) </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">the entire contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by such Party, and (ii) such press release or public announcement does not materially differ from a previously issued press release or other publicly available information; and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">further</font><font style="font-family:Times New Roman;color:#000000;">, that the other Party will have the right to review, but not approve, any press release or public announcement that the proposing Party determines is required by applicable Law based on the advice of counsel, which public disclosures are subject to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">8.2</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Publicity</font><font style="font-family:Times New Roman;color:#000000;">; Publications).&nbsp;&nbsp;The Party reviewing a press release provided under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">8.2.2(a)</font><font style="font-family:Times New Roman;color:#000000;"> (Further Publicity) will review and approve or disapprove such press release within </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> Business Days after its receipt thereof.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">The principles to be observed in such disclosures will include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of Regulatory Authorities and the need to keep investors informed regarding the business of the Party making such public disclosure.&nbsp;&nbsp;Nothing in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 8.2</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Publicity</font><font style="font-family:Times New Roman;color:#000000;">) will restrict a Party from making a disclosure required by Law as reasonably determined by such Party&#8217;s counsel, including disclosures required by any laws or regulations relating to the public sale of securities; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that such disclosure will include the minimum amount of Confidential Information required by such applicable laws and regulations, and the Parties will seek confidential treatment of Confidential Information to be included in such disclosures to the greatest extent possible under such laws and regulations.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;"> In the event that either Party proposes to publish or present the results of Development or Commercialization carried out on the Product, such publication or presentation will be subject to the prior review by the other Party for patentability and protection of such other Party&#8217;s Confidential Information.&nbsp;&nbsp;Each Party will provide to the other Party the opportunity to review any proposed abstracts, manuscripts or summaries of presentations that cover the results of Development or Commercialization of the Product during the Term.&nbsp;&nbsp;The other Party will respond in writing promptly and in no event later than [**] days after receipt of the proposed material with either approval of the proposed material or a specific statement of concern, based upon either the need to seek patent protection or concern regarding competitive disadvantage arising from the proposal.&nbsp;&nbsp;In the event of any such concern, the submitting Party agrees not to submit such publication or to make such presentation that contains such information until the other Party is given a reasonable period of time to seek patent protection for any material in such publication or presentation that it believes is patentable or to resolve any other issues, and the submitting Party will remove from such proposed publication any Confidential Information of the other Party as requested by such other Party. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903037"></a>ARTICLE 9<font style="color:#000000;"><br>REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903038"></a>9.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Mutual Representations and Warranties</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party represents and warrants to the other Party that, as of the Effective Date:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Organization</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;It is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1.2</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Authority</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;It has full right, power and authority to enter into this Agreement and to perform its respective obligations under this Agreement, it has the right to grant to the other the licenses and sublicenses granted pursuant to this Agreement, and this Agreement and the performance by such Party of this Agreement do not violate such Party&#8217;s charter documents, bylaws or other organizational documents.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Consents</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Except for any Marketing Authorizations, Regulatory Filings, manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization of the Products, all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained by it in connection with the execution, delivery and performance of this Agreement have been obtained.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">No Conflict</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;It is not under any obligation, contractual or otherwise, to any Person that would adversely affect the diligent and complete fulfillment of obligations under this Agreement and the execution and delivery of this Agreement by such Party, and the performance of such Party&#8217;s obligations under this Agreement (as contemplated as of the Effective Date) and the licenses and sublicenses to be granted by such Party pursuant to this Agreement (a) do not conflict with or violate any requirement of Laws applicable to such Party, (b) do not conflict with or violate any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently in effect applicable to such Party, and (c) do not conflict with, violate, breach or constitute a default under any contractual obligations of such Party or any of its Affiliates.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Enforceability</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;This Agreement is a legal and valid obligation binding upon it and is enforceable against it in accordance with its terms, subject to the general principles of equity and subject to bankruptcy, insolvency, moratorium, judicial principles affecting the availability of specific performance and other similar Laws affecting the enforcement of creditors&#8217; rights generally.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439558504"></a><a name="_Toc445903039"></a>9.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Additional Representations and Warranties of AVEO</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;AVEO represents and warrants to CANbridge that, as of the Effective Date:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref441305812"></a><a name="_Ref443931999"></a>9.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Licensed Patents</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;All Licensed Patents as of the Effective Date are listed on </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 9.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Licensed Patents). Except as otherwise noted in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 9.2.1</font><font style="font-family:Times New Roman;color:#000000;">, AVEO is the sole and exclusive owner of the Licensed Patents. With respect to Licensed Patents not solely owned by AVEO, AVEO licenses such Licensed Patents in a manner that permits sublicenses as provided in this Agreement.&nbsp;&nbsp;All Licensed Patents owned by AVEO and, to AVEO&#8217;s Knowledge, all other Licensed Patents, are (i) subsisting and in good standing and (ii) being diligently prosecuted in the respective patent offices in accordance with Law, and have been filed and maintained properly and correctly and all applicable fees have been paid on or before the due date for payment. To AVEO&#8217;s Knowledge, all issued Licensed Patents are valid and enforceable.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Licensed Know-How</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;To AVEO&#8217;s Knowledge, the Development and Manufacture of the Product by or on behalf of AVEO prior to the Effective Date did not misappropriate the Know-How of any Third Party.</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;color:#000000;"> AVEO has sufficient rights under such Licensed Know-How to transfer and license such Licensed Know-How to CANbridge as provided in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 5.1.1</font><font style="font-family:Times New Roman;color:#000000;"> (Transfer of Licensed Know-How). </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.3</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Delivery of Documentation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;True, complete, and correct copies of: (a)&#160;all existing Regulatory Filings relating to the Product and (b) all material adverse information with respect to the safety and efficacy of the Product in AVEO&#8217;s possession and control, in each case ((a) and (b)) have been provided or made available to CANbridge prior to the Effective Date. </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Challenges</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;There are no claims, judgments, or settlements against, or amounts with respect thereto, made against AVEO or any of its Affiliates relating to the Licensed Patents or the Licensed Know-How.&nbsp;&nbsp;Except as otherwise disclosed in writing to CANbridge, no claim or litigation has been brought or, to AVEO&#8217;s Knowledge, threatened by any Person (a) alleging that the Licensed Patents are invalid or unenforceable, (b) asserting the misuse, or non-infringement of any of the Licensed Patents, (c) challenging AVEO&#8217;s Control of the Licensed Patents or (d) alleging misappropriation of the Know-How used in the Development and Manufacture of the Product by or on behalf of AVEO prior to the Effective Date. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Non-Infringement of Third Party IP</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;To AVEO&#8217;s Knowledge, the Development and Manufacture of the Products, as conducted by AVEO prior to the Effective Date, did not infringe any Patent Right or misappropriate or otherwise violate any Know-How of any Person. To AVEO&#8217;s Knowledge, the Development and Manufacture of the Products as specifically described in this Agreement and the POC Development Plan in effect on the Effective Date will not infringe any Patent Right or misappropriate or otherwise violate any Know-How of any Person existing as of the Effective Date.&nbsp;&nbsp;No written claim of infringement of the Patent Rights or misappropriation of the Know-How of any Third Party has been made, or to AVEO&#8217;s Knowledge, threatened, against AVEO or any of its Affiliates with respect to the Development, Manufacture or Commercialization of the Product. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439561840"></a>9.2.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Absence of Litigation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;There are no judgments or settlements against or owed by AVEO or, to AVEO&#8217;s Knowledge, pending litigation against AVEO or litigation threatened against AVEO in writing, in each case related to the Product, including any such litigation any relating to any Regulatory Filings Controlled by AVEO as of the Effective Date.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">US Government Rights</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Except as otherwise disclosed by AVEO in writing to CANbridge, neither AVEO nor any of its Affiliates is or has been a party to any agreement with the U.S. federal government or an agency thereof pursuant to which the U.S. federal government or such agency provided funding for the Development of a Product, and the inventions claimed or covered by the Licensed Patents are not a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">subject invention</font><font style="font-family:Times New Roman;color:#000000;">&#8221; as that term is described in 35 U.S.C. &#167; 201(f).</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Maintenance of Regulatory Filings, Good Laboratory and Clinical Practices</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;AVEO and its Affiliates have generated, prepared, maintained, and retained all Regulatory Filings that are required to be maintained or retained pursuant to and in material compliance with applicable Law, and have conducted in material compliance with applicable Law, including GLP and GCP, (a) all Development of the Product in the Field conducted prior to the Effective Date and (b) all research activities that are material to the receipt of Regulatory Approval for the Product.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Confidentiality of Know-How</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;To the Knowledge of AVEO, no material breach of confidentiality has been committed by any Third Party with respect to the Licensed Know-How and AVEO has used reasonable measures to protect the confidentiality thereof.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.10</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Assignment of Third Party Rights; Third Party Consents</font><font style="font-family:Times New Roman;color:#000000;">.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">AVEO has obtained from each of its employees and agents, and from the employees and agents of its Affiliates, who are participating in the Exploitation of the Product, rights to any and all Know-How created by such employees and agents in the course of his or her employment by or engagement with AVEO that relates to the Product, such that CANbridge will, by virtue of this Agreement, receive from AVEO, without payments beyond those required by </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 6</font><font style="font-family:Times New Roman;color:#000000;"> (Financial Provisions), the licenses and other rights granted to CANbridge under this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">Each Person who has or has had any ownership rights in or to any Licensed Patents purported to be owned solely by AVEO, has assigned and has executed an agreement assigning its entire right, title, and interest in and to such Licensed Patents to AVEO; to AVEO&#8217;s Knowledge, no current officer, employee, agent, or consultant of AVEO or any of its Affiliates is in violation of any term of any assignment or other agreement, in each case, regarding the protection of patents or other intellectual property or proprietary information of AVEO or such Affiliate.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">AVEO and its Affiliates have employed Persons with appropriate education, knowledge and experience to conduct and to oversee the conduct of the pre-clinical and clinical studies with respect to the Product conducted prior to the Effective Date.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;color:#000000;">Prior to the Effective Date hereof, AVEO has obtained all assignments and consents from Third Parties necessary to perform its obligations under this Agreement, including, but not limited to, the consent by Patheon to assign the Patheon manufacturing contract to CANbridge, as set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exhibit C</font><font style="font-family:Times New Roman;color:#000000;"> hereto.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Statements to FDA and Other Regulatory Authorities</font><font style="font-family:Times New Roman;color:#000000;">. Neither AVEO nor any of its Affiliates, nor, to AVEO&#8217;s Knowledge, any of its or their respective officers, employees, or agents has made an untrue statement of material fact or fraudulent statement to the FDA or any other Regulatory Authority with respect to the Development of the Product, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority with respect to the Development of the Product, or committed an act, made a statement, or failed to make a statement with respect to the Development of the Product that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities</font><font style="font-family:Times New Roman;color:#000000;">&#8221;, set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or any analogous laws or policies in the applicable Territory.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Compliance with Law</font><font style="font-family:Times New Roman;color:#000000;">. To AVEO&#8217;s Knowledge, all of the studies, tests and pre-clinical and clinical trials of the Product conducted prior to, or being conducted as of, the Effective Date by or on behalf of AVEO have been and are being conducted in all material respects in accordance with applicable Laws.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref441305721"></a><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="text-decoration:none;">9.2.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">In-licenses</font><font style="font-family:Times New Roman;color:#000000;">. Except as set forth in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 1.60</font><font style="font-family:Times New Roman;color:#000000;">, there are no agreements between AVEO or any of its Affiliates, on the one hand, and any Third Party, on the other hand, pursuant to which AVEO has (i) in-licensed any Patent Rights or Know-how owned or Controlled by such Third Party that are included as part of the Licensed Patents or Licensed Know-How, or (ii) agreed to make any payments (including royalties) to any Third Party or agreed to undertake or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">observe any restrictions or obligations with respect to the Development, Manufacture or Commercialization of the Product.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903040"></a>9.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">No Debarment</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party represents and warrants that neither it nor any of its or its Affiliates&#8217; employees or agents performing under this Agreement has ever been, or is currently: (a) debarred under 21 U.S.C. &#167;&#160;335a; (b) excluded, debarred, suspended, or otherwise ineligible to participate in federal health care programs or in federal procurement or non-procurement programs; (c) listed on the FDA&#8217;s Disqualified and Restricted Lists for clinical investigators; or (d) convicted of a criminal offense that falls within the scope of 42 U.S.C. &#167;&#160;1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible.&nbsp;&nbsp;Each Party further covenants that if, during the Term of this Agreement, it becomes aware that it or any of its or its Affiliates&#8217; employees or agents performing under this Agreement is the subject of any investigation or proceeding that could lead to that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, such Party will immediately notify the other Party. This provision will survive termination or expiration of this Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903041"></a><a name="_Ref439552165"></a><a name="_Ref439695169"></a><a name="INDEMNIFICATION_DAMAGES"></a>ARTICLE 10<font style="color:#000000;"><br><a name="_Ref439552165"></a><a name="_Ref439695169"></a><a name="INDEMNIFICATION_DAMAGES"></a>INDEMNIFICATION; DAMAGES</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="General_Indemnification_By_AVEO"></a><a name="_Ref439595429"></a><a name="_Toc445903042"></a>10.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Indemnification by AVEO</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;AVEO will indemnify and hold harmless CANbridge, its Affiliates and their respective directors, officers, employees and agents (collectively, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">CANbridge Indemnified Parties</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), from, against and in respect of any and all Losses incurred or suffered by any CANbridge Indemnified Party to the extent resulting from:&nbsp;&nbsp;(a) any breach of any representation or warranty made by AVEO in this Agreement, or any breach by AVEO of any covenant or agreement in this Agreement; (b) the negligence or intentional misconduct of AVEO or any of its Affiliates or Sublicensees, or any of their respective directors, officers, employees and agents, in performing AVEO&#8217;s obligations or exercising AVEO&#8217;s rights under this Agreement; (c) activities conducted by AVEO or its Affiliates related to the Development, Manufacture, or other Exploitation of the Products anywhere in the world prior to the Effective Date; and (d) the Development, Commercialization, Manufacture, or other Exploitation of any Products in the North America Territory during the Term or anywhere in the world after the termination (but not the expiration) of this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="General_Indemnification_By_CANbridge"></a><a name="_Ref439595441"></a><a name="_Toc445903043"></a>10.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Indemnification by CANbridge</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;CANbridge will indemnify and hold harmless AVEO, its Affiliates and their respective directors, officers, employees and agents (collectively, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">AVEO Indemnified Parties</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), from, against and in respect of any and all Losses incurred or suffered by any AVEO Indemnified Party to the extent resulting from:&nbsp;&nbsp;(a) any breach of any representation or warranty made by CANbridge in this Agreement, or&#160;any breach by CANbridge of any covenant or agreement in this Agreement, (b) the negligence or intentional misconduct of, or violation of Law by, CANbridge, any of its Affiliates or Sublicensees, or any of their respective directors, officers, employees and agents, in performing CANbridge&#8217;s obligations or exercising CANbridge&#8217;s rights under this Agreement, or (c) the Development, Commercialization, Manufacture or other Exploitation of any Product in the Licensed Territory during the Term.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439595527"></a><a name="_Toc445903044"></a><a name="_Ref439595383"></a>10.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Claims for Indemnification</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Notice_10_3_1"></a><a name="_Ref439595471"></a><a name="_AEIOULastRenderedPageBreakAEIOU56"></a>10.3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Notice</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;An Indemnified Party entitled to indemnification under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Sections 10.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Indemnification by AVEO</font><font style="font-family:Times New Roman;color:#000000;">) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">10.2</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Indemnification by CANbridge</font><font style="font-family:Times New Roman;color:#000000;">) will give prompt </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">written notification to the Indemnifying Party from whom indemnification is sought of the commencement of any Action by a Third Party for which indemnification may be sought (a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Third Party Claim</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) or, if earlier, upon the assertion of such Third Party Claim by a Third Party; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that failure by an Indemnified Party to give notice of a Third Party Claim as provided in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">10.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="font-family:Times New Roman;color:#000000;">Notice</font><font style="font-family:Times New Roman;color:#000000;">) will not relieve the Indemnifying Party of its indemnification obligation under this Agreement, except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give notice.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Defense</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Within [**] days after delivery of a notice of any Third Party Claim in accordance with </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 10.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (Notice), the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party Claim with counsel reasonably satisfactory to the Indemnified Party.&nbsp;&nbsp;If the Indemnifying Party does not assume control of such defense, the Indemnified Party may control such defense.&nbsp;&nbsp;The Party not controlling such defense may participate therein at its own expense.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Cooperation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Party controlling the defense of any Third Party Claim will keep the other Party advised of the status of such Third Party Claim and the defense thereof and will reasonably consider recommendations made by the other Party with respect thereto.&nbsp;&nbsp;The other Party will reasonably cooperate with the Party controlling such defense and its Affiliates and agents in defense of the Third Party Claim, with all out-of-pocket costs of such cooperation to be borne by the Party controlling such defense.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Settlement</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Indemnified Party will not agree to any settlement of such Third Party Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld.&nbsp;&nbsp;The Indemnifying Party will not, without the prior written consent of the Indemnified Party, which will not be unreasonably withheld, agree to any settlement of such Third Party Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the Indemnified Party.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903045"></a><a name="_Ref439601954"></a><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="text-decoration:none;">10.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Insurance</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party, at its own expense, will maintain liability insurance (or self-insure) with respect to its activities under this Agreement in an amount consistent with industry standards.&nbsp;&nbsp;Each Party will provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request.&nbsp;&nbsp;Without limiting the foregoing, during the Term and thereafter for the period of time required below, each Party will maintain on an ongoing basis comprehensive general liability insurance in the minimum amount of $[**] per occurrence and $[**] annual aggregate combined single limit for bodily injury and property damage liability; and Products liability insurance (including contractual liability coverage on such Party&#8217;s indemnification obligations under this Agreement) in the amount of at least $[**] per occurrence and as an annual aggregate combined single limit for bodily injury and property damage liability; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that (a) prior to the initiation of any Clinical Study, the Party responsible for such Clinical Study will secure and maintain in full force and effect clinical trial insurance in compliance with applicable Law in those countries where such Clinical Study is conducted, and (b) commencing not later than [**] days prior to the reasonably anticipated First Commercial Sale of a Product, and thereafter for the period of time required below, each Party will obtain and maintain on an ongoing basis Products liability insurance (including contractual liability coverage on such Party&#8217;s indemnification obligations under this Agreement) in the amount of at least $[**] per occurrence and as an annual aggregate combined </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">single limit for bodily injury and property damage liability.&nbsp;&nbsp;All of such insurance coverage may be maintained through a self-insurance plan that substantially complies with the foregoing limits and requirements and may be satisfied through one or more policies, including an umbrella policy; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that such self-insurance is determined to be investment quality by a recognized rating agency such as Moody&#8217;s or Standard &amp; Poor&#8217;s.&nbsp;&nbsp;Not later than </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days following receipt of written request from a Party, the other Party will provide to the requesting Party a letter(s) affirming appropriate self-insurance and/or a certificate of insurance evidencing such coverage in accordance with this Agreement.&nbsp;&nbsp;Each Party will maintain such insurance or self-insurance coverage without interruption during the Term and for a period of six years thereafter, and, if applicable, will provide certificates and/or letters evidencing such insurance coverage without interruption as reasonably requested during the period of time for which such coverage must be maintained.&nbsp;&nbsp;Each Party will be provided at least </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days&#8217; prior written notice of any cancellation or material decrease in the other Party&#8217;s insurance coverage limits described above.&nbsp;&nbsp;Notwithstanding the foregoing, either Party&#8217;s failure to maintain adequate insurance will not relieve that Party of its obligations set forth in this Agreement.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc443316714"></a><a name="_Toc443317130"></a><a name="_Toc443318046"></a><a name="_Toc444169279"></a><a name="_Toc444182196"></a><a name="_Toc444244373"></a><a name="_Toc444506185"></a><a name="_Toc445903046"></a><a name="_Ref444009319"></a>ARTICLE 11<font style="text-decoration:none;color:#000000;"><br><a name="_Ref444009319"></a>LIMITATION OF LIABILITY</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439601868"></a><a name="_Toc445903047"></a>11.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">No Consequential or Punitive Damages.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;EXCEPT AS SET FORTH IN </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SECTION 11.2</font><font style="font-family:Times New Roman;color:#000000;"> (Exclusion from Liability Limitation), NEITHER PARTY NOR ANY OF ITS AFFILIATES WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE OR MULTIPLE DAMAGES OR FOR ANY LOST PROFITS ARISING OUT OF THIS AGREEMENT, IN EACH CASE HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439601850"></a><a name="_Toc445903048"></a>11.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Exclusion from Liability Limitation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;THE LIMITATIONS AND DISCLAIMER SET FORTH IN </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SECTION 11.1</font><font style="font-family:Times New Roman;color:#000000;"> (No Consequential or Punitive Damages) WILL NOT APPLY TO A CLAIM (A) FOR WILLFUL MISCONDUCT; (B) FOR A BREACH OF </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SECTION 3.4</font><font style="font-family:Times New Roman;color:#000000;"> (Exclusivity Covenant), OR (C) FOR AN INTENTIONAL BREACH BY AVEO OF </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SECTION 4.4</font><font style="font-family:Times New Roman;color:#000000;"> (Right of First Negotiation) OR (D) FOR A BREACH OF </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 8</font><font style="font-family:Times New Roman;color:#000000;"> (Confidentiality and Publicity); OR (E) FOR INDEMNIFIABLE LOSSES PURSUANT TO </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SECTION 10.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Indemnification by AVEO</font><font style="font-family:Times New Roman;color:#000000;">), OR </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SECTION 10.2</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Indemnification by CANbridge</font><font style="font-family:Times New Roman;color:#000000;">).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903049"></a><a name="_Ref439595568"></a><a name="_Ref439597460"></a><a name="_Ref439597720"></a><a name="TERM_AND_TERMINATION"></a><a name="_Ref440468851"></a>ARTICLE 12<font style="color:#000000;"><br><a name="_Ref439595568"></a><a name="_Ref439597460"></a><a name="_Ref439597720"></a><a name="TERM_AND_TERMINATION"></a><a name="_Ref440468851"></a>TERM AND TERMINATION</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Term"></a><a name="_Ref439709413"></a><a name="_Ref443934080"></a><a name="_Toc445903050"></a>12.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Term</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Unless terminated earlier in accordance with this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 12</font><font style="font-family:Times New Roman;color:#000000;"> (Term and Termination), this Agreement will become effective as of the Effective Date and will continue in full force until the last to expire Royalty Term in the Licensed Territory (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Term</font><font style="font-family:Times New Roman;color:#000000;">&#8221;). Upon the expiration (but not termination) of this Agreement, the licenses granted pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">AVEO License Grant; Right of Reference</font><font style="font-family:Times New Roman;color:#000000;">) will become perpetual, irrevocable, and fully paid-up. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Early_Termination"></a><a name="_Ref439710882"></a><a name="_Toc445903051"></a>12.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Early Termination</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Termination_for_Material_Breach"></a><a name="_Ref439595689"></a><a name="_Ref440462607"></a><a name="_Ref440977637"></a><a name="_Ref443930998"></a><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><a name="_Ref439597041"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2.1</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Termination for Material Breach</font><font style="font-family:Times New Roman;color:#000000;">.</font><font style="font-family:Times New Roman;color:#000000;"><a name="_Ref439597041"></a>&nbsp;&nbsp;</font><font style="font-family:Times New Roman;color:#000000;">Upon (a) any material breach of this Agreement by AVEO or (b) any material breach of this Agreement by CANbridge (the Party so allegedly breaching being the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Breaching Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), the other Party (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Non-Breaching Party</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) will have the right, but not the obligation, to terminate this Agreement in its entirety by providing 45 days written notice to the Breaching Party in the case of a material breach of a payment obligation and 90 days written notice to the Breaching Party in the case of any other material breach, which notice will, in each case (x) expressly reference this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="font-family:Times New Roman;color:#000000;">Termination for Material Breach</font><font style="font-family:Times New Roman;color:#000000;">), (y) reasonably describe the alleged breach which is the basis of such termination, and (z) clearly state the Non-Breaching Party&#8217;s intent to terminate this Agreement if the alleged breach is not cured within the applicable cure period. Notwithstanding the foregoing, (i) if the alleged material breach by CANbridge is that it has failed to use Commercially Reasonable Efforts to Develop or Commercialize the Product in a particular country in the Licensed Territory under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">4.3.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="font-family:Times New Roman;color:#000000;">Development </font><font style="font-family:Times New Roman;color:#000000;">Diligence) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">5.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Commercialization Diligence) other than a Major Market Country in the EU, then AVEO will have the right to terminate this Agreement solely with respect to such country (and not in its entirety); (ii) if the alleged material breach by CANbridge is that it has failed to use Commercially Reasonable Efforts to Develop or Commercialize the Product in a Major Market Country in the EU, then AVEO will have the right to terminate this Agreement solely with respect to the EU; (iii) if such material breach (other than a payment breach), by its nature, is curable, but is not reasonably curable within the applicable cure period, then such cure period will be extended if the Breaching Party provides a written plan for curing such breach to the Non-Breaching Party and uses Commercially Reasonable Efforts to cure such breach in accordance with such written plan; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that no such extension will exceed 90 days without the consent of the Non-Breaching Party; and (iv) if the Breaching Party disputes that it has materially breached this Agreement, the dispute will be resolved pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 13</font><font style="font-family:Times New Roman;color:#000000;"> (Dispute Resolution), and this Agreement may not be terminated during the pendency of such dispute resolution procedure. The termination will become effective at the end of the notice period unless the Breaching Party cures such breach during such notice period; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that the Non-Breaching Party may, by notice to the Breaching Party, designate a later date for such termination in order to facilitate an orderly transition of activities relating to the Product. If, as a result of the application of such dispute resolution procedures, the Breaching Party is determined to be in material breach of this Agreement (an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Adverse Ruling</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), then if the Breaching Party fails to cure such material breach within 60 days after such ruling (whether or not such actions are specified by the Adverse Ruling) (or 10 days after such ruling in the case of a payment breach), then the Non-Breaching Party may terminate this Agreement upon written notice to the Breaching Party as provided in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach).</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Termination_by_CANbridge_Unilater"></a><a name="_Ref439597110"></a><a name="_Ref440977677"></a><a name="_Ref439958418"></a><a name="_Ref442554395"></a><a name="_Ref442554396"></a><a name="_Ref442789722"></a>12.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Termination by CANbridge for Convenience</font><font style="font-family:Times New Roman;color:#000000;">.<a name="_Ref439958418"></a> <a name="_Ref442554395"></a><a name="_Ref442554396"></a><a name="_Ref442789722"></a>CANbridge may, upon 180 days prior written notice to AVEO, unilaterally terminate this Agreement for convenience and without cause.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444637196"></a><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>12.2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Termination by AVEO</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Until the delivery of the POC Study Data Package to AVEO, AVEO may, upon 90 days prior written notice to CANbridge, unilaterally terminate this Agreement if CANbridge has failed to expend at least $[**] for or devote at least one FTE to (or any combination thereof, based on an FTE rate equal to $[**] per FTE) the conduct of Manufacturing and Development of any Product for use in the Field in the Licensed Territory in any Calendar Year prior to delivery of such POC Study Data package to AVEO. Such minimums </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">will be prorated for any partial Calendar Years commencing upon the Effective Date and ending upon the date of delivery of the POC Study Data Package to AVEO. </font><font style="font-family:Times New Roman;color:#000000;"> Notwithstanding the foregoing, AVEO will not have the right to terminate this Agreement if a failure to meet the minimums set forth in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">12.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by AVEO) is a result of a regulatory delay not attributable to any act of or failure to act by CANbridge, a Force Majeure Event, a failure or early termination of any Clinical Study, or a determination by the JSC or an agreement by the Parties to halt Development activities for the Product in the Licensed Territory.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref444637228"></a>12.2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Termination for Challenge</font><font style="font-family:Times New Roman;color:#000000;">. AVEO may terminate this Agreement in its entirety, effective upon 30 days&#8217; notice to CANbridge, if CANbridge or any of its Sublicensees commences or conducts legal proceedings, or assists any Third Party in commencing or conducting legal proceedings, to challenge the validity, enforceability, or ownership of any Licensed Patents (other than to assert its own rights as an owner with respect to any Patent Rights), including by (a)&#160;filing a declaratory judgment action in which the applicable Licensed Patents is alleged to be invalid or unenforceable, (b) citing prior art pursuant to 35 U.S.C. &#167;301, filing a request for re-examination of the applicable Licensed Patents, or provoking or becoming party to an interference with the applicable Licensed Patents pursuant to 35 U.S.C. &#167;135 or (c) filing or commencing any re-examination, opposition, cancellation, nullity or similar proceedings against the applicable Licensed Patents, or petitioning for any form of administrative or judicial (or arbitration) review of the applicable Licensed Patents, including post-grant review, inter partes review, or opposition proceedings.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Effects_of_Termination"></a><a name="_Toc445903052"></a><a name="_Ref439597323"></a>12.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Effects of Termination</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Effects of Termination Generally</font><font style="font-family:Times New Roman;color:#000000;">. Upon termination of this Agreement in its entirety pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2</font><font style="font-family:Times New Roman;color:#000000;"> (Early Termination), the Parties&#8217; rights and obligations under this Agreement generally, including under the POC Development Plan, will terminate and neither Party will have any further rights or obligations under this Agreement from and after the effective date of termination, except as set forth in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.3</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Effects of Termination</font><font style="font-family:Times New Roman;color:#000000;">); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, if this Agreement is terminated with respect to a particular country only (other than a Major Market Country), then such rights and obligations will terminate only to the extent they relate solely to the terminated country. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Accrued Obligations</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Expiration or termination of this Agreement for any reason will not release either Party from any obligation or liability which, on the effective date of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Survival"></a><a name="_Ref439597608"></a><a name="_AEIOULastRenderedPageBreakAEIOU60"></a>12.3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Survival</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;This </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.3.3</font><font style="font-family:Times New Roman;color:#000000;"> (Survival), the provisions set forth in the following Sections, as well as, to the extent applicable, any other Sections or defined terms referred to in such Sections or Articles or necessary to give them effect, will survive any expiration or termination of this Agreement in its entirety: </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 3.7</font><font style="font-family:Times New Roman;color:#000000;"> (Bankruptcy Code &#167;365(n) Election); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.1</font><font style="font-family:Times New Roman;color:#000000;"> (Ownership of Inventions); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.3</font><font style="font-family:Times New Roman;color:#000000;"> (Prosecution and Maintenance of the CANbridge Program Patents); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 8</font><font style="font-family:Times New Roman;color:#000000;"> (Confidentiality and Publicity); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 10</font><font style="font-family:Times New Roman;color:#000000;"> (Indemnification; Damages); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 11</font><font style="font-family:Times New Roman;color:#000000;"> (Limitation of Liability); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 12</font><font style="font-family:Times New Roman;color:#000000;"> (Term and Termination); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 13</font><font style="font-family:Times New Roman;color:#000000;"> (Dispute Resolution); </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 14</font><font style="font-family:Times New Roman;color:#000000;"> (Miscellaneous), to the extent applicable; and, to the extent that any obligations have accrued prior to termination for any reason under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 12</font><font style="font-family:Times New Roman;color:#000000;"> (Term and Termination) or otherwise extend beyond the effective date of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">termination (as expressly set forth therein), the payment provisions in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 6</font><font style="font-family:Times New Roman;color:#000000;"> (Financial Provisions). Furthermore, any other provisions required to interpret the Parties&#8217; rights and obligations under this Agreement, including applicable definitions in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 1</font><font style="font-family:Times New Roman;color:#000000;"> (Definitions), will survive to the extent required.&nbsp;&nbsp;Except as otherwise expressly provided in this Agreement, all rights and obligations of the Parties under this Agreement, including any licenses granted under this Agreement, will terminate upon expiration or termination of this Agreement in its entirety or solely with respect to the terminated country, as the case may be, for any reason.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Regulatory_Filings_and_Regulatory"></a><a name="_Ref439597905"></a>12.3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Transfer of Regulatory Filings and Regulatory Approvals</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Promptly following the effectiveness of any termination by AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach) or by CANbridge pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by CANbridge for Convenience), or by AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by AVEO) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.4 </font><font style="font-family:Times New Roman;color:#000000;">(Termination for Challenge) and upon AVEO&#8217;s written request, CANbridge will, at CANbridge&#8217;s sole cost and expense, assign and transfer to AVEO all Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing Authorizations for Products that are held by or under authority of CANbridge or its Affiliates or Sublicensees as of the effective date of termination, with respect to the terminated country or the Licensed Territory, as the case may be, and will take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights under such Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing Authorizations to AVEO.&nbsp;&nbsp;If applicable Law prevents or delays the transfer of ownership of any such Regulatory Filing, filing for Pricing and Reimbursement Approval or Marketing Authorizations to AVEO, CANbridge will grant, and does hereby grant, to AVEO an exclusive and irrevocable right of access and right of reference to such Regulatory Filing, filing for Pricing and Reimbursement Approval and Marketing Authorizations for the Products in the Licensed Territory or the terminated country, as the case may be, and will reasonably cooperate to make the benefits of such Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing Authorizations available to AVEO or its designee(s).&nbsp;&nbsp;AVEO will have the right to grant licenses or sublicenses (as applicable) under the rights granted to it under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.3.4</font><font style="font-family:Times New Roman;color:#000000;"> (Transfer of Regulatory Filings and Regulatory Approvals) to its Affiliates and Third Parties, through multiple tiers. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Transfer of Clinical Data</font><font style="font-family:Times New Roman;color:#000000;">. Promptly following the effectiveness of any termination by AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach) or by CANbridge pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by CANbridge for Convenience), or by AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by AVEO) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.4</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Challenge) and upon AVEO&#8217;s written request, CANbridge will, at CANbridge&#8217;s sole cost and expense, transfer to AVEO its entire right, title, and interest in and to all preclinical and clinical data, Clinical Data, Safety Data and all other supporting data, including CMC Data and pharmacology, toxicology, chemistry and biology data, in CANbridge&#8217;s Control as of the effective date of such termination related to, and to the extent necessary or reasonably useful for AVEO to continue the Development, Manufacture and/or Commercialization of, Products.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Survival_of_Sublicenses"></a><a name="_Ref439597940"></a><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>12.3.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Survival of Sublicenses</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In the event of a termination of this Agreement for any reason, the terms of this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.3.6</font><font style="font-family:Times New Roman;color:#000000;"> (Survival of Sublicenses) will apply with respect to any CANbridge Sublicense existing as of the effective date of such termination in the terminated territory, but only if the applicable Sublicensee did not contribute to any material breach of this Agreement that was the cause of the termination by AVEO of this Agreement and is not otherwise </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">in material breach of the applicable Sublicense agreement at such time: (a) all of such Sublicensee&#8217;s obligations under the applicable Sublicense agreement to CANbridge will remain in effect as obligations to AVEO and will be enforceable solely by AVEO as a third party beneficiary; (b) such Sublicensee&#8217;s rights under the Sublicense agreement that do not exceed and are consistent with AVEO&#8217;s obligations to CANbridge under this Agreement, whether in scope, duration, nature or otherwise, will survive termination; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that the foregoing will in no way be interpreted to increase the scope, duration, territory or other aspect of the rights sublicensed to such Sublicensee; and (c) all of CANbridge&#8217;s rights under such Sublicense agreement will remain in effect, may be exercised solely by AVEO and will inure to the exclusive benefit of AVEO</font><font style="font-family:Times New Roman;color:#000000;">.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="On_Going_Trials"></a><a name="_Ref439709539"></a>12.3.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">On-Going Trials</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In the event that any Clinical Study with respect to a Product has been Commenced and is on-going as of the effective date of the termination of this Agreement in its entirety (an &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">On-Going Clinical Study</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) for any reason other than a termination by CANbridge pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach), CANbridge will, at CANbridge&#8217;s sole cost and expense, as AVEO may request, (a) promptly transition to AVEO or its designee some or all of such On-Going Clinical Studies and the activities related to or supporting such trials including by, inter alia, requiring any Third Party with which CANbridge has an agreement with respect to the conduct of Clinical Studies for Products (including agreements with CMOs, contract research organizations, clinical sites and investigators), to cooperate with AVEO in order to accomplish the transfer to AVEO of similar rights as held by CANbridge under its agreements with such Third Parties, (b) continue to conduct such On-Going Clinical Studies for a period requested by AVEO up to a maximum of twelve months after the effective date of such termination, or (c) terminate such On-Going Clinical Studies in a manner consistent with applicable Laws; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that in the event that AVEO, CANbridge, an institutional review board or independent safety board reasonably determines that an On-Going Clinical Study being run by CANbridge or any of its Affiliates would pose an unacceptable safety risk for subjects or patients participating in such On-Going Clinical Study, CANbridge will not be obligated to continue such Clinical Study.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Return of Confidential Information</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Within [**] days after the effective date of termination of this Agreement in its entirety, each Party will, and cause its Affiliates to (a) destroy, all tangible items solely comprising, bearing or containing any Confidential Information of the other Party that are in such first Party&#8217;s or its Affiliates&#8217; possession or Control, and provide written certification of such destruction, or (b) prepare such tangible items of the other Party&#8217;s Confidential Information for shipment to such other Party, as such other Party may direct, at the first Party&#8217;s expense; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, in any event, (x) each Party may retain one copy of the Confidential Information of the other Party to the extent necessary to perform its obligations that survive expiration or termination of this Agreement; and (y) such first Party may retain one copy of such Confidential Information of the other Party for its legal archives.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Transition_Manufacturing_Inven"></a><a name="_Ref439595311"></a><a name="_Ref442553884"></a><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>12.3.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Transition; Manufacturing; Inventory</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Following the effectiveness of any termination by AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.1</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Material Breach), or by AVEO pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.3</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by AVEO) or </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.4</font><font style="font-family:Times New Roman;color:#000000;"> (Termination for Challenge) or by CANbridge pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.2.2</font><font style="font-family:Times New Roman;color:#000000;"> (Termination by CANbridge for Convenience), CANbridge and its Affiliates will (a) continue to Manufacture and supply AVEO with its requirements of Product in accordance with </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 5</font><font style="font-family:Times New Roman;color:#000000;"> (Manufacture and Commercialization) </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">and the Supply Agreement for period requested by AVEO (not to exceed </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> months after the Term; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, to the extent AVEO requests a period of more than </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> months, the obligation of CANbridge to Manufacture and supply AVEO with its requirements of Product under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">12.3.9</font><font style="font-family:Times New Roman;color:#000000;"> (Transition; Manufacturing; Inventory) for such additional </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> month period will be subject to the Parties agreeing in good faith on a reasonable premium to the transfer price to be paid by AVEO for such Product) and (b) reasonably cooperate with AVEO and its designees to facilitate a smooth, orderly and prompt transition to AVEO or its designees of the activities with respect to Products, including any ongoing Development and Commercialization activities with respect to Products, for a period requested by AVEO (not to exceed </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> months after the Term; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that, to the extent AVEO requests a period of more than </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> months for such transition activities, the obligation of CANbridge to provide such activities under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">12.3.9</font><font style="font-family:Times New Roman;color:#000000;"> (Transition; Manufacturing; Inventory) for such additional </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> month period will be subject to the Parties agreeing in good faith on a reasonable payment to be made by AVEO for such activities).</font><font style="font-family:Times New Roman;color:#000000;"> For the period that is </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days following the effective date of the termination of this Agreement,</font><font style="font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;color:#000000;">CAN</font><font style="font-family:Times New Roman;color:#000000;">bridge</font><font style="font-family:Times New Roman;color:#000000;"> will retain the right to sell, distribute or otherwise dispose of its Product inventory in its or its Affiliates or Sublicensees possession as of the effective date of termination, subject to CANbridge&#8217;s continuing obligation to make Sales Milestone Payments and royalty payments in accordance with </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 6</font><font style="font-family:Times New Roman;color:#000000;"> (Financial Provisions) with respect to Net Sales derived from such distribution, sale and disposition.</font><font style="font-family:Times New Roman;color:#000000;"> Without limiting the foregoing, upon the written request of AVEO, CANbridge will promptly, and in any event within </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> days after such request (i) take such steps as may be reasonably necessary to assign to AVEO CANbridge&#8217;s rights under any Supply Agreement between CANbridge and any Third Party that relates to any Product (and not any other product) to the extent permitted by the terms of such Supply Agreement; (ii) consent to the supply by the Third Party manufacturer to AVEO of AVEO&#8217;s requirements of such Products, to the extent permitted under the terms of the Supply Agreement; or (iii) provide AVEO or its designee with reasonable assistance in order to facilitate (A) the transfer to AVEO of the Manufacturing processes (including CMC Data) for such Products and any related manufacturing technology, in each case used by CANbridge or such CANbridge Third Party manufacturer with respect such Products, and (B) the qualification of AVEO&#8217;s or its designee&#8217;s facility as required by any Regulatory Authority in order for AVEO or its designee to Manufacture quantities of such Products.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Cooperation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party will cause its Affiliates and Sublicensees to comply with the obligations in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 12.3</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Effects of Termination</font><font style="font-family:Times New Roman;color:#000000;">).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903053"></a><a name="_Ref439709963"></a><a name="_Ref439738099"></a><a name="ALTERNATIVE_DISPUTE_RESOLUTION"></a><a name="_Ref440464091"></a><a name="_Ref440469089"></a><a name="_Ref440644296"></a><a name="_Ref442622586"></a>ARTICLE 13<font style="color:#000000;"><br><a name="_Ref439709963"></a><a name="_Ref439738099"></a><a name="ALTERNATIVE_DISPUTE_RESOLUTION"></a><a name="_Ref440464091"></a><a name="_Ref440469089"></a><a name="_Ref440644296"></a><a name="_Ref442622586"></a>DISPUTE RESOLUTION</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref443933889"></a><a name="_Toc445903054"></a><a name="_Ref440654544"></a><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>13.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Dispute Resolution Escalation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Parties recognize that disputes as to certain matters arising out of or in connection with this Agreement may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedited manner by mutual cooperation. To accomplish this objective, any and all disputes between the Parties arising out of or in connection with this Agreement will first be referred to the JSC for resolution. Should the JSC not be able to reach agreement at a duly called meeting of the JSC within [**] after the date on which the matter is referred to the JSC, then either Party may refer such matter to the Executive Officers for resolution and the Executive Officers will attempt to resolve the matter in good faith.&nbsp;&nbsp;If the Executive Officers fail to resolve such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">matter within </font><font style="font-family:Times New Roman;color:#000000;">[**]</font><font style="font-family:Times New Roman;color:#000000;"> Business Days after the date on which the matter is referred to the Executive Officers (unless a longer period is agreed to by the Parties), then either Party may submit the dispute to the ICC for final resolution by binding arbitration in accordance with </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">13.2</font><font style="font-family:Times New Roman;color:#000000;"> (Arbitration).</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442623202"></a><a name="_Toc445903055"></a>13.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Arbitration</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Except as set forth in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 13.2</font><font style="font-family:Times New Roman;color:#000000;"> (Arbitration), each dispute, difference, controversy or claim arising in connection with or related or incidental to, or question occurring under, this Agreement or the subject matter hereof will be referred to and finally resolved by arbitration in accordance with the Rules of Arbitration (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Rules</font><font style="font-family:Times New Roman;color:#000000;">&#8221;) of the International Chamber of Commerce (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ICC</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), by an arbitral tribunal composed of three arbitrators, all of whom will have previous judicial experience, appointed by agreement of the Parties in accordance with said Rules.&nbsp;&nbsp;If, at the time of the arbitration, the Parties agree in writing to submit the dispute to a single arbitrator, said single arbitrator will be appointed by agreement of the Parties, or, failing such agreement, by ICC in accordance with said Rules.&nbsp;&nbsp;The foregoing arbitration proceedings may be commenced by either Party by notice to the other Party.&nbsp;&nbsp;Unless otherwise agreed by the Parties hereto, all such arbitration proceedings will be held in New York, New York, U.S.A.;</font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;"> </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that proceedings may be conducted by telephone conference call with the consent of the Parties and the arbitrator(s).&nbsp;&nbsp;All arbitration proceedings will be conducted in the English language.&nbsp;&nbsp;The arbitrator(s) will consider grants of equitable relief and orders for specific performance as co-equal remedies along with awards of monetary damages. The arbitrator(s) will have no authority to award punitive damages.&nbsp;&nbsp;The allocation of expenses of the arbitration, including reasonable attorney&#8217;s fees, will be determined by the arbitrator(s), or, in the absence of such determination, each Party will pay its own expenses.&nbsp;&nbsp;The Parties hereby agree that the arbitrator(s) has authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrator(s) deem reasonable and necessary with or without petition therefore by the Parties as well as the final ruling and judgment. All rulings by the arbitrator(s) will be final.&nbsp;&nbsp;Notwithstanding any contrary provision of this Agreement, any Party may seek equitable measures of protection in the form of attachment of assets or injunctive relief (including, without limitation, specific performance and injunctive relief) in any matter relating to the proprietary rights and interests of either Party from any court of competent jurisdiction, pending a decision by the arbitral tribunal in accordance with this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 13.2</font><font style="font-family:Times New Roman;color:#000000;"> (Arbitration).&nbsp;&nbsp;The Parties hereby exclude any right of appeal to any court on the merits of such matter.&nbsp;&nbsp; The provisions of this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 13.2</font><font style="font-family:Times New Roman;color:#000000;"> (Arbitration) may be enforced and judgment on the award (including without limitation equitable remedies) granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the Parties or any of their respective assets.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903056"></a>13.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Jury Waiver</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES TO ARBITRATE AS SET FORTH IN </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">SECTION 13.2</font><font style="font-family:Times New Roman;color:#000000;"> (Arbitration). THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903057"></a><a name="_Ref440469266"></a>ARTICLE 14<font style="color:#000000;"><br><a name="_Ref440469266"></a>MISCELLANEOUS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Assignment_Successors"></a><a name="_Ref439711187"></a><a name="_Toc445903058"></a>14.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Assignment; Successors</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1.1</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Assignment</font><font style="font-family:Times New Roman;color:#000000;">. This Agreement and the rights and obligations of each Party under this Agreement will not be assignable, delegable, transferable, pledged or otherwise disposed of by either Party without the prior written consent of the other Party; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that either Party may assign or transfer this Agreement, without such consent (but with written notice to the other Party), (a) to an Affiliate or (b) to a Third Party that acquires all or substantially all of the business or assets of such Party or at least 50% of the combined voting power of such Party, whether by merger, consolidation, reorganization, acquisition, sale or otherwise.&nbsp;&nbsp;If this Agreement is assigned or transferred to an Affiliate, the assigning or transferring Party will remain responsible (jointly and severally) with such Affiliate for the performance of such assigned or transferred obligations. No assignment or transfer of this Agreement or a Party&#8217;s rights or obligations under this Agreement will be valid and effective unless and until the assignee agrees in writing to be bound by the terms and conditions of this Agreement.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:15.38%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref439711133"></a>14.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Successors</font><font style="font-family:Times New Roman;color:#000000;">. Any permitted assignment of the rights and obligations of a Party under this Agreement will be binding on, and inure to the benefit of and be enforceable by and against, the successors and permitted assigns of the assigning Party.&nbsp;&nbsp;The permitted assignee or transferee will assume all obligations of its assignor or transferor under this Agreement.&nbsp;&nbsp;Any assignment or attempted assignment by either Party in violation of the terms of this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 14.1.2</font><font style="font-family:Times New Roman;color:#000000;"> (Successors) will be null, void and of no legal effect.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Choice_of_Law"></a><a name="_Ref439709721"></a><a name="_Toc445903059"></a>14.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Choice of Law</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;This Agreement will be governed by and interpreted under the laws of the State of New York, other than any principle of conflict or choice of laws that would cause the application of the laws of any other jurisdiction; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that all questions concerning (a) inventorship of Patent Rights under this Agreement will be determined in accordance with </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 7.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Ownership of Inventions</font><font style="font-family:Times New Roman;color:#000000;">) and (b) the construction or effect of Patent Rights will be determined in accordance with the laws of the country or other jurisdiction in which the particular patent has been filed or granted, as the case may be.&nbsp;&nbsp;The Parties agree to exclude the application to this Agreement of the United Nations Conventions on Contracts for the International Sale of Goods.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Notices"></a><a name="_Ref439711152"></a><a name="_Toc445903060"></a>14.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Notices</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Any notice or report required or permitted to be given or made under this Agreement by one Party to the other will be in writing and will be deemed to have been delivered (a) upon personal delivery, (b) on the second Business Day (at the place of delivery) next following deposit with a reputable, internationally recognized overnight courier that maintains records of delivery and (c) in the case of notices provided by telecopy (which notice will be followed immediately by an additional notice pursuant to clause (a) or (b) above if the notice is of a default under this Agreement), upon completion of transmission, with transmission confirmed, to the addressee&#8217;s facsimile machine, as follows (or at such other addresses or facsimile numbers as may have been furnished in writing by a Party to the other as provided in this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 14.3</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Notices</font><font style="font-family:Times New Roman;color:#000000;">)). This </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 14.3</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Notices</font><font style="font-family:Times New Roman;color:#000000;">) is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.05%;width:481.8pt;;">
<tr>
<td style="width:216.5pt;"></td>
<td style="width:265.3pt;"></td>
</tr>
<tr style="height:17.5pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to AVEO:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="Background-color:#D3D3D3;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO Pharmaceuticals, Inc.</p></td>
</tr>
<tr style="height:12.6pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One Broadway, 14th Floor</p></td>
</tr>
<tr style="height:12.6pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA 02142</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Attn<font style="font-style:normal;">: Michael Bailey, Chief Executive Officer</font></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.05%;width:481.8pt;;">
<tr>
<td style="width:216.5pt;"></td>
<td style="width:265.3pt;"></td>
</tr>
<tr style="height:12.6pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax:&nbsp;&nbsp;[**]</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.6pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.</p></td>
</tr>
<tr style="height:12.6pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One Financial Center</p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, MA&nbsp;&nbsp;02111</p></td>
</tr>
<tr style="height:12.6pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Attn<font style="font-style:normal;">:&nbsp;&nbsp;John J. Cheney, Esq.</font></p></td>
</tr>
<tr style="height:13.3pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax:&nbsp;&nbsp;[**]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.6pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:90.2pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to CANbridge:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="Background-color:#BFBFBF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CANbridge Life Sciences Ltd.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303A, Building E</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wangjing Pioneer Park</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No. 2 LizeZhongEr Road</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chaoyang District, Beijing, China</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Attn<font style="font-style:normal;">: Chief Executive Officer </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: [**]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:76.9pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ropes &amp; Gray LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800 Boylston Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prudential Tower</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts 02199-3600</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Attn<font style="font-style:normal;">: David M. McIntosh</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: [**]</p></td>
</tr>
<tr style="height:19.7pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Severability"></a><a name="_Ref439709758"></a><a name="_Toc445903061"></a>14.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Severability</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;If, under applicable Law, any provision of this Agreement is invalid or unenforceable, or otherwise directly or indirectly affects the validity of any other material provision of this Agreement and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (such invalid or unenforceable provision, a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Severed Clause</font><font style="font-family:Times New Roman;color:#000000;">&#8221;), it is mutually agreed that (a) this Agreement will endure except for the Severed Clause, (b) this Agreement will be construed and enforced as if such Severed Clause had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the Severed Clause or by its severance herefrom, and (d) in lieu of such illegal, invalid, or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid, and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the Parties.&nbsp;&nbsp;To the fullest extent permitted by applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid, or unenforceable in any respect.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Integration"></a><a name="_Ref439960991"></a><a name="_Toc445903062"></a><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>14.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Integration</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;This Agreement, together with all schedules and exhibits attached hereto, constitutes the entire agreement between the Parties with respect to the subject matter of this Agreement and supersedes all previous arrangements between the Parties with respect to the subject matter hereof, whether written or oral, including the Prior CDA.&nbsp;&nbsp;In the event of a conflict between the POC Development Plan or any schedules or attachments to this Agreement, on the one hand, and this Agreement, on the other hand, the terms of this Agreement will govern. Each </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement.</font><font style="font-family:Times New Roman;color:#000000;"> </font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903063"></a>14.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Waivers and Amendments</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The failure of any Party to assert a right under this Agreement or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. Notwithstanding the authority granted to the JSC under this Agreement, (a) no waiver will be effective unless it has been given in writing and signed by the Party giving such waiver, and (b) no provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903064"></a>14.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Independent Contractors; No Agency</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Neither Party will have any responsibility for the hiring, firing or compensation of the other Party&#8217;s or such other Party&#8217;s Affiliates&#8217; employees or for any employee benefits with respect thereto.&nbsp;&nbsp;No employee or representative of a Party or its Affiliates will have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on such other Party, without such other Party&#8217;s written approval.&nbsp;&nbsp;For all purposes, and notwithstanding any other provision of this Agreement to the contrary, each Party&#8217;s legal relationship under this Agreement to the other Party will be that of independent contractor, and the relationship between the two Parties will not constitute a partnership, joint venture, or agency, including for all tax purposes.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903065"></a>14.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Affiliates</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;To the extent that this Agreement imposes obligations on Affiliates or Sublicensees of a Party, such Party will cause its Affiliates and its Sublicensees to perform such obligations.&nbsp;&nbsp;Either Party may use one or more of its Affiliates to perform its obligations and duties or exercise its rights under this Agreement; </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">however</font><font style="font-family:Times New Roman;color:#000000;">, that each such Affiliate or Sublicensee will be bound by the corresponding obligations of the applicable Party and </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">further</font><font style="font-family:Times New Roman;color:#000000;">, that, subject to such Party&#8217;s assignment to an Affiliate pursuant to </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 14.1</font><font style="font-family:Times New Roman;color:#000000;"> (</font><font style="text-decoration:none;font-family:Times New Roman;color:#000000;">Assignment; Successors</font><font style="font-family:Times New Roman;color:#000000;">), such Party will remain liable under this Agreement for the prompt payment and performance of all of its obligations under this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442804847"></a><a name="_Toc445903066"></a>14.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Force Majeure</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Neither Party will be responsible to the other for, or be deemed to have defaulted under or breached this Agreement for, any failure or delay in performing any of its obligations under this Agreement or for other nonperformance under this Agreement (excluding, in each case, the obligation to make payments when due) if such delay or nonperformance is caused by or results from events beyond the reasonable control of the non-performing Party, including strike, fire, flood, earthquake, hurricanes, accident, war, acts of war (whether war be declared or not), insurrections, riots, civil commotion, strikes, lockouts, or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), act of terrorism, act of God or acts, omissions or delays in acting of the government of any country or of any local government, or by cause unavoidable or beyond the reasonable control of such Party (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement) (a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Force Majeure Event</font><font style="font-family:Times New Roman;color:#000000;">&#8221;).&nbsp;&nbsp;In such event, the Party affected will promptly (and, in any event, within [**] days) notify the other Party in writing of such Force Majeure Event, stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect.&nbsp;&nbsp;The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing Party and will use Commercially Reasonable Efforts to resume performance of its obligations. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903067"></a><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.10</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">No Third Party Beneficiary Rights</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;This Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, other than, to the extent provided in </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 10</font><font style="font-family:Times New Roman;color:#000000;"> (Indemnification; Damages), the Indemnified Parties.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903068"></a>14.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Non-exclusive Remedy</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Except as expressly provided herein, the rights and remedies provided herein are cumulative and each Party retains all remedies at law or in equity, including the Parties&#8217; ability to receive legal damages or equitable relief, with respect to any breach of this Agreement.&nbsp;&nbsp;Neither Party will be required to terminate this Agreement due to a breach of this Agreement by the other Party.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903069"></a><a name="_AEIOULastRenderedPageBreakAEIOU67"></a>14.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Interpretation</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Article and Section headings used herein are for reference and convenience only, and will not enter into the interpretation of this Agreement.&nbsp;&nbsp;Except as otherwise explicitly specified to the contrary, (a) references to an Article, Section, Exhibit or Schedule means an Article or Section of, or a Schedule or Exhibit to this Agreement and all subsections thereof, unless another agreement is specified; (b) references in any Section to any clause are references to such clause of such Section; (c) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto; (d) references to a particular Law mean such Law as in effect as of the relevant time, including all rules and regulations thereunder and any successor Law in effect as of the relevant time, and including the then-current amendments thereto; (e) words in the singular or plural form include the plural and singular form, respectively; (f) unless the context requires a different interpretation, the word &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">or</font><font style="font-family:Times New Roman;color:#000000;">&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">and/or</font><font style="font-family:Times New Roman;color:#000000;">&#8221;; (g) the terms &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">including,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">include(s),</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">such as,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">e.g.</font><font style="font-family:Times New Roman;color:#000000;">&#8221; and &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">for example</font><font style="font-family:Times New Roman;color:#000000;">&#8221; mean including the generality of any description preceding such term and will be deemed to be followed by &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">without limitation</font><font style="font-family:Times New Roman;color:#000000;">&#8221;; (h) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day; (i) &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">monthly</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means on a calendar month basis, (j) &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">quarter</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">quarterly</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means on a Calendar Quarter basis; (k) &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">annual</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">annually</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means on a Calendar Year basis; (l) &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">year</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means a 365 day period unless Calendar Year is specified; (m) &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">$</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">dollars</font><font style="font-family:Times New Roman;color:#000000;">&#8221; means U.S. Dollars; (n) references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement; (o) all words used in this Agreement will be construed to be of such gender or number as the circumstances require; (p) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative manner; (q) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (r) the words &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">hereof,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">herein,</font><font style="font-family:Times New Roman;color:#000000;">&#8221; &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">hereby</font><font style="font-family:Times New Roman;color:#000000;">&#8221; and derivative or similar words refer to this Agreement (including any Exhibits or Schedules); (s) neither Party or its Affiliates will be deemed to be acting &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">on behalf of</font><font style="font-family:Times New Roman;color:#000000;">&#8221; the other Party under this Agreement, except to the extent expressly otherwise provided; (t) there will be no double-counting in calculating Development costs or any components thereof; and (u) provisions that require that a Party, or the JSC hereunder &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">agree</font><font style="font-family:Times New Roman;color:#000000;">&#8221;, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">consent</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">approve</font><font style="font-family:Times New Roman;color:#000000;">&#8221; or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;color:#000000;">the like will be deemed to require that such agreement, consent or approval be specific and in writing in a written agreement, letter or approved minutes, but, except as expressly provided herein, excluding e-mail and instant messaging.</font>&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903070"></a>14.13<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Further Assurances</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903071"></a>14.14<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Ambiguities; No Presumption</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel.&nbsp;&nbsp;Accordingly, in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement will not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:10pt;text-indent:7.69%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc445903072"></a>14.15<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Execution in Counterparts; Facsimile Signatures</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart.&nbsp;&nbsp;Signatures provided by facsimile transmission or in Adobe&#8482; Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of this page intentionally blank.]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized representative under seal, in duplicate on the Effective Date.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO PHARMACEUTICALS, INC.</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Michael Bailey</font>______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Michael Bailey</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;President and CEO</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">CANBRIDGE LIFE SCIENCES, LTD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____<font style="text-decoration:underline;">/s/ James Xue</font>______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;James Xue</p>
<p style="margin-bottom:60pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President and CEO</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;margin-left:5.77%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.60</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> &#8211; Existing Third Party License Agreements</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Research and Commercialization License Agreement between EvoGenix PTY Limited and AVEO Pharmaceuticals, Inc., Dated September 25, 2007</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">First Amendment to Research and Commercialization License Agreement between EvoGenix Pty Limited and AVEO Pharmaceuticals, Inc., between AVEO Pharmaceuticals, Inc. and Cephalon (formerly EvoGenix), dated September 26, 2012</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;color:#000000;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Second Amendment to the Research and Commercialization License Agreement between AVEO Pharmaceuticals, Inc. and Cephalon Australia, dated September 26, 2013</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Option and License Agreement by and between AVEO Pharmaceuticals, Inc. and Biogen Idec International GMBH, Dated March 18, 2009.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Amendment No. 1 to Option and License Agreement by and between AVEO Pharmaceuticals, Inc. and Biogen Idec International GMBH Dated March 18, 2014</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Services Agreement between AVEO Pharmaceuticals, Inc. and Selexis SA, Dated April 12, 2010</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Amendment No. 1 to Services Agreement between AVEO Pharmaceuticals, Inc. and Selexis SA, Dated October 1, 2010 </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Commercial License Agreement between Selexis SA and AVEO Pharmaceuticals, Inc., Dated May 31, 2011. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;margin-left:5.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;margin-left:5.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;margin-left:5.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;margin-left:5.77%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.88</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> &#8211; List of AVEO Individuals for Purposes of Knowledge</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:18.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:20.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">President and Chief Executive Officer </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:18.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:20.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Chief Financial Officer </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:18.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:20.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Chief Medical Officer</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:18.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:20.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Vice President of Corporate Development and Alliance Management </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:18.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:20.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Senior Corporate Counsel </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:18.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:20.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Symbol';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Vice President of Technical Operations</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;text-indent:-20.19%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:60pt;margin-left:38.46%;text-indent:-30.77%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.88</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.112</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">- Information to be Included in the POC Study Data Package</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:10pt;margin-bottom:0pt;margin-left:16.03%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.112</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3.4</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">- Provisions Required by the Existing Third Party License Agreements to be Included in Sublicense Agreements</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option and License Agreement by and between AVEO Pharmaceuticals, Inc. and Biogen Idec International GMBH of March 18, 2009 and Amendment No. 1 thereto of March 18, 2014 (&#8220;<font style="text-decoration:underline;">Biogen Agreement</font>&#8221;)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.14. <font style="text-decoration:underline;">Blocked Payments</font>. If, by reason of applicable laws or regulations in any country, it becomes impossible or illegal for CANbridge to transfer, or have transferred on its behalf, royalties or other payments to AVEO that would result in a payment to Biogen, then CANbridge will promptly notify AVEO of the conditions preventing such transfer and such royalties or other payments will be deposited in local currency in the relevant country to the credit of Biogen in a recognized banking institution designated by Biogen or, if none is designated by Biogen within a period of 30 days, in a recognized banking institution selected by CANbridge, and identified in a notice given to AVEO.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.16. <font style="text-decoration:underline;">Records and Audits</font>.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:9999999;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Royalties</font><font style="font-family:Times New Roman;color:#000000;">. CANbridge will keep complete and accurate records of the underlying revenue and expense data relating to the calculations of Net Sales and payments required by </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 6</font><font style="font-family:Times New Roman;color:#000000;"> (Financial Provisions). Biogen will have the right, [**] at its own expense, to have a nationally recognized, independent, certified public accounting firm, selected by it and reasonably acceptable to CANbridge, review any such records of CANbridge in the location(s) where such records are maintained by CANbridge upon reasonable notice (which will be no less than [**] prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">ARTICLE 6</font><font style="font-family:Times New Roman;color:#000000;"> (Financial Provisions) within the [**] period preceding the date of the request for review. CANbridge will receive a copy of each such report concurrently with receipt by Biogen. Should such inspection lead to the discovery of a discrepancy to Biogen&#8217;s detriment, CANbridge will pay the amount due within [**] after its receipt from the accounting firm of the certificate any undisputed amount of the discrepancy. Biogen will pay the full cost of the review unless the underpayment of royalties is greater than 5% of the amount due for the entire period being examined, in which case CANbridge will pay the reasonable cost charged by such accounting firm for such review. Any overpayment of royalties by CANbridge revealed by an examination will be paid back by Biogen to CANbridge within [**]. The records of CANbridge for any Calendar Year may be audited no more than once, whether by Biogen or AVEO, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">provided</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">that</font><font style="font-family:Times New Roman;color:#000000;"> if AVEO is the auditing Party under </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Section 6.8.1</font><font style="font-family:Times New Roman;color:#000000;"> (Record Keeping), AVEO will have the right to share the applicable audit report with Biogen, and if Biogen is the auditing Party under this </font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Schedule 3.3.4</font><font style="font-family:Times New Roman;color:#000000;"> (Performance by CANbridge Sublicensees), Biogen will have the right to share the applicable audit report with AVEO. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1. <font style="text-decoration:underline;">Confidential Information</font>. CANbridge will keep in confidence and not disclose to any Third Party, or use for any purpose, <font style="color:#000000;">except to exercise its rights or perform its obligations under this Agreement, any Confidential Information of Biogen in accordance with the terms and conditions of </font><font style="text-decoration:underline;color:#000000;">ARTICLE 8</font><font style="color:#000000;"> (Confidentiality and Publicity). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.3.4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Services Agreement between AVEO Pharmaceuticals, Inc. and Selexis SA, of April 12, 2010 and Amendment No. 1 to Services Agreement between AVEO Pharmaceuticals, Inc. and Selexis SA, of April 12, 2010 (the &#8220;</font><font style="text-decoration:underline;">Selexis Agreement</font><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1(b) In the event that AVEO discloses to CANbridge (i) sequence information pertaining to the Selexis Genetic Elements, (ii) Selexis Vector Maps, or (iii) Protocols associated with Selexis proprietary Gene Cloning or Selexis proprietary Transfection Methods, and CANbridge desires to&nbsp;&nbsp;disclose such information to a CMO that has not been engaged to prepare portions of the CMC documentation to be filed with the applicable regulatory authorities where, in the reasonable opinion of CANbridge, the CMO requires access to such documentation, or if CANbridge desires to disclose any Confidential Information of Selexis (as defined in the Selexis Agreement) to a potential Collaboration Partner (as defined in the Selexis Agreement) then CANbridge will so notify AVEO and AVEO will promptly notify Selexis of the identity of the parties and confirm that they have been bound by obligations of confidentiality and nonuse with respect to such Confidential Information that are no less stringent than the obligations set forth in the Selexis Agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Confidential Information</font>. CANbridge will keep in confidence and not disclose to any Third Party, or use for any purpose, <font style="color:#000000;">except to exercise its rights or perform its obligations under this Agreement, any Confidential Information of Selexis in accordance with the terms and conditions of </font><font style="text-decoration:underline;color:#000000;">ARTICLE 8 </font><font style="color:#000000;">(Confidentiality and Publicity).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercial License Agreement between AVEO Pharmaceuticals, Inc. and Selexis SA, of May 31, 2011</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Confidential Information</font>. CANbridge will keep in confidence and not disclose to any Third Party, or use for any purpose, <font style="color:#000000;">except to exercise its rights or perform its obligations under this Agreement, any Confidential Information of Selexis in accordance with the terms and conditions of </font><font style="text-decoration:underline;color:#000000;">ARTICLE 8</font><font style="color:#000000;"> (Confidentiality and Publicity).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Commercialization License Agreement between EvoGenix Pty Limited and AVEO Pharmaceuticals, Inc. Dated September 25, 2007, and the First Amendment thereto, between AVEO Pharmaceuticals, Inc. and Cephalon (formerly EvoGenix, dated September 26, 2012 (the &#8220;<font style="text-decoration:underline;">EvoGenix Agreement</font>&#8221;)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4(c) All Improvements made by any sublicensee through the exercise of its rights under the EvoGenix Agreement will be the property of EvoGenix. For clarity, the Improvements will be licensed by EvoGenix to AVEO under the EvoGenix Agreement as Improvements to the Licensed Technology, as defined therein and provided below, licensed to CANbridge hereunder as Licensed Patents or Licensed Know-How, as defined in this Agreement and as applicable, and further sublicensed to the applicable sublicensee.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a>&#8220;<font style="text-decoration:underline;">AVEO Results</font>&#8221; means (a) any antibodies resulting from the Research, including the immunoglobulin molecule (such as IgG), whether in monospecific or any other form, any immunoglobulin fragment (such as Fv, Fab, F(ab') or F(ab')<sub style="font-size:85%; vertical-align:bottom">2</sub>), any fusion protein of an immunoglobulin or immunoglobulin fragment and any single chain antibody (such as scFv), and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any derivative of any of the foregoing, (b) any nucleic acids encoding any of the foregoing, (c) cells expressing any of the foregoing, and (d) any uses of any of the foregoing. AVEO Results include Products. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Designated Target</font>&#8221; means each Target with respect to which AVEO elects to conduct Research pursuant to clause 2.2, but excluding any Restricted Target.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Improvement</font>&#8221; means any development, modification, adaptation, or improvement of the Licensed Technology (including the discovery of new uses of the Licensed Technology) that is made by or on behalf of AVEO during the Term. Notwithstanding the foregoing, "Improvement" shall not include any Target or AVEO Results or any development, modification, adaptation, or improvement or other Intellectual Property subsisting in, claiming or covering any Target or AVEO Results, but shall include Intellectual Property subsisting in, claiming or covering new, modified or improved applications of the Licensed Technology to Targets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Know-How</font>&#8221; means drawings, specifications, designs, research and development results, test results and other technical information and Confidential Information that are (a) Controlled by EvoGenix at any time during the term of this Agreement and (b) provided by EvoGenix to AVEO hereunder or otherwise necessary or useful in connection with the Research or Commercialization of actual or potential Products, and any material form in which the above materials or information are contained or embodied, or from which they can be reproduced. For the avoidance of doubt, Know-How does not include the AVEO Results.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Licensed Technology</font>&#8221; means: (a) the Patent Rights and/or (b) the Know-How. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Target</font>&#8221; means a single human or non-human antigen and its isoforms. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Patent Rights</font>&#8221; means </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) the patents and patent applications described in Part A of Schedule 1 of the EvoGenix Agreement;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) all patent applications that may be filed which are based on, or claim priority from, or are divided from or are continuations of, any patent application described in Schedule 1 of the EvoGenix Agreement;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) all patents which may be granted pursuant to any of the patent applications referred to in the foregoing paragraph (a) or (b); and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) all patents and patent applications covering Improvements licensed to AVEO under the EvoGenix Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Product</font>&#8221; means any product (a) that is directed to, inhibits or modulates the expression or activity of a Designated Target and (b) that is or includes:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) a protein that is engineered or produced by or on behalf of AVEO using the Licensed Technology, regardless of the intended use of such protein; and/or</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) any composition of matter, chemical entity or other substance based on, derived from or incorporating all or part of any such protein, including without limitation all analogs, homologs of and binding regions derived from any such protein.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Research</font>&#8221; means, with respect to any Designated Target, the research, manufacture and development of pharmaceuticals, including Products, utilizing all or part of the Licensed Technology, provided, however, that &#8220;Research" shall only include the humanisation of murine antibodies using the Licensed Technology to the extent conducted by AVEO 's Personnel at AVEO's premises or by a subcontractor appointed by AVEO).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Restricted Target</font>&#8221; means the Targets specifically set forth in <font style="text-decoration:underline;">Schedule 4</font> to the EvoGenix Agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5(d) If by reason of applicable laws or regulations in any country, it becomes impossible or illegal for CANbridge to transfer, or have transferred on its behalf, milestones, sales-based or other payments to AVEO that result in a payment to EvoGenix, CANbridge will promptly notify AVEO of the conditions preventing such transfer and such payments shall be deposited in local currency in the relevant country to the credit of EvoGenix in a recognized banking institution designated by EvoGenix or, if none is designated by EvoGenix within a period of 30 days, in a recognized banking institution selected by CANbridge, and identified in a notice given to AVEO. If so deposited in a foreign country, CANbridge will provide reasonable cooperation to EvoGenix so as to allow EvoGenix to assume control over such deposit as promptly as practicable.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Confidential Information</font>. CANbridge will keep in confidence and not disclose to any Third Party, or use for any purpose, <font style="color:#000000;">except to exercise its rights or perform its obligations under this Agreement, any Confidential Information of EvoGenix in accordance with the terms and conditions of </font><font style="text-decoration:underline;color:#000000;">ARTICLE 8</font><font style="color:#000000;"> (Confidentiality and Publicity) and in accordance with Section 10 of the EvoGenix Agreement: regarding all documents and other materials in any medium in CANbridge&#8217;s possession, power or control which constitute Confidential Information (as defined in the EvoGenix Agreement) CANbridge will return to AVEO (i) any EvoGenix Confidential Information forming part of the Know-How as defined in the EvoGenix Agreement upon termination of this Agreement or the EvoGenix Agreement, and (ii) all other Confidential Information of EvoGenix upon demand by EvoGenix. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.2.1</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">- POC Study Requirements</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">The POC Study will meet the following criteria:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**].</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 4.2.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule 7.1.2- EvoGenix Improvements</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 4.4(c) of the <font style="color:#000000;">Research and Commercialization License Agreement between EvoGenix PTY Limited and AVEO Pharmaceuticals, Inc., dated September 25, 2007 (&#8220;EvoGenix Agreement&#8221;)</font> any Inventions that are Improvements (as defined in the EvoGenix Agreement) made by CANbridge through exercise of its rights under that portion of the Licensed Patents or Licensed Know-How that are in-licensed by AVEO pursuant to the terms of the EvoGenix Agreement will be the property of EvoGenix. For clarity, any such Improvements that are owned by EvoGenix will be licensed by EvoGenix to AVEO under the EvoGenix Agreement and included as Licensed Patents and/or Licensed Technology under this Agreement and will be licensed to CANbridge hereunder.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Improvement</font>&#8221; means any development, modification, adaptation, or improvement of the Licensed Technology (including the discovery of new uses of the Licensed Technology) that is made by or on behalf of AVEO during the Term. Notwithstanding the foregoing, "Improvement" shall not include any Target or AVEO Results or any development, modification, adaptation, or improvement or other Intellectual Property subsisting in, claiming or covering any Target or AVEO Results, but shall include Intellectual Property subsisting in, claiming or covering new, modified or improved applications of the Licensed Technology to Targets</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 7.1.2 - 1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2.1</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">- Licensed Patents</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">AVEO Patents Relating to AV203</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:526.5pt;;"></table></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 9.2.1 - 1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:526.5pt;;">
<tr>
<td style="width:68.4pt;"></td>
<td style="width:72pt;"></td>
<td style="width:64.8pt;"></td>
<td style="width:93.6pt;"></td>
<td style="width:54pt;"></td>
<td style="width:85.5pt;"></td>
<td style="width:88.2pt;"></td>
</tr>
<tr>
<td style="width:68.4pt;"></td>
<td style="width:72pt;"></td>
<td style="width:64.8pt;"></td>
<td style="width:93.6pt;"></td>
<td style="width:54pt;"></td>
<td style="width:85.5pt;"></td>
<td style="width:88.2pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">AVEO No.</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Filed</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Application No.</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Publication or Patent No.</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p></td>
</tr>
<tr>
<td colspan="7" valign="top"  BGCOLOR="#D9D9D9" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td colspan="7" valign="top"  BGCOLOR="#D9D9D9" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 9.2.1 - 2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patents In-Licensed From EvoGenix</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:13.88%;"></td>
<td style="width:21.37%;"></td>
<td style="width:46.18%;"></td>
<td style="width:11.32%;"></td>
<td style="width:9.56%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Docket No./ Country</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Application or Patent Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Priority Date</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 9.2.1 - 3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patents In-Licensed From Selexis</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:510.5pt;;">
<tr>
<td style="width:70.3pt;"></td>
<td style="width:101.6pt;"></td>
<td style="width:234pt;"></td>
<td style="width:59.75pt;"></td>
<td style="width:44.85pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Docket No./ Country</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Application or Patent Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Priority Date</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:3.5pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A- 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="text-decoration:underline;">Exhibit A: POC Development Plan</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the Securities and Exchange Commission.&nbsp;&nbsp;A total of three pages were omitted. [**]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="text-decoration:underline;">Exhibit B: Initial Press Release</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#FF0000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DRAFT &#8211; NOT FOR RELEASE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CAMBRIDGE, Mass., USA and BEIJING, China &#8211; March XX, 2016 &#8211;<font style="font-weight:normal;"> AVEO Oncology (AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced an exclusive license agreement in which AVEO has granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO&#8217;s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CANbridge plans to develop AV-203 first in esophageal squamous cell cancer (ESCC), the most prevalent form of esophageal cancer.&nbsp;&nbsp;According to the World Health Organization, esophageal cancer is the eight most common cancer globally, with over 450,000 cases diagnosed each year. To date, AVEO has completed a Phase 1, open-label, dose-escalation study of AV-203 in patients with advanced solid tumors. In this study, AV-203 was found to be generally safe and well-tolerated, with an early signal of activity consistent with preclinical data showing the potential for heregulin, the only known ligand for ErbB3, to serve as a biomarker predictive of AV-203 anti-tumor activity.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, CANbridge Life Sciences will pay AVEO up to $134 million in upfront and potential reimbursement and milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.&nbsp;&nbsp;AVEO is also eligible for a tiered royalty, ranging from a low double-digit up to a low-teen percent on net sales of AV-203 in the agreement&#8217;s territories. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CANbridge Life Sciences will be responsible for costs associated with the execution of a development plan that includes additional manufacturing requirements as well as pre-clinical and clinical studies necessary to demonstrate proof-of-concept for AV-203 as a treatment for squamous cell esophagus cancer, including a Phase IIa proof-of-concept study meeting mutually agreed upon criteria.&nbsp;&nbsp;Following completion of the proof-of-concept studies, AVEO and CANbridge will negotiate a possible agreement under which they may co-develop AV-203, with each party bearing a percentage of the cost of global development activities based on respective geographic rights.&nbsp;&nbsp;If the parties fail to reach such an agreement, CANbridge may continue the development of AV-203 on its own in markets outside of the United States, Canada and Mexico. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;With an exclusive license to AV-203 outside of North America, CANbridge will be expanding outside of Asia for the first time,&#8221; said James Xue, CANbridge Chairman and CEO. &#8220;Pre-clinical work shows that AV-203 has the potential to treat ESCC, the most common type of esophageal cancer in Asia, with fifty percent of worldwide diagnoses occurring in China. Esophageal cancer is also prevalent in other parts of the world, particularly developing countries. As part of our globalization strategy, we plan to develop AV-203 in Asia first, then bring it to other territories where patients with this form of disease have few treatment options.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54483985_21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a growing body of clinical data which suggests that heregulin-driven ErbB3 signaling drives resistance to standard therapy in a variety of tumors overexpressing HER3,</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; said Michael Bailey, president and chief executive officer of AVEO. &#8220;</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This agreement allows us to further advance AV-203 development in this setting</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">together with a motivated partner in CANbridge that is led by a deeply experienced team hailing from Genzyme, Synageva and other life sciences innovators.&nbsp;&nbsp;Importantly, it allows us to retain North American rights for future development, giving us the opportunity to explore a third late-stage drug candidate at a point where our lead development candidate, tivozanib, may be nearing the commercialization stage in North America</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#8221;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About CANbridge Life Sciences</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CANbridge Life Sciences, Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan).&nbsp;&nbsp;CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses, or obtains exclusive rights to commercialize, drug and device products that are approved in their home markets for commercialization in China and North Asia.&nbsp;&nbsp;CANbridge has an agreement with EUSA Pharma, to commercialize Caphosol&#174; in China for the prevention and treatment of oral mucositis caused by cancer treatments, and a license with Apogenix to develop, manufacture and commercialize immune-oncology therapy, APG101, for the treatment of glioblastoma multiforme in China, Macao, Hong Kong and Taiwan, where it will be developed as CAN008.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Led and backed by a highly-seasoned executive team, with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CANbridge is privately-held and headquartered in Beijing, China.&nbsp;&nbsp;For more on CANbridge Life Sciences, please go to <font style="text-decoration:underline;">www.canbridgepharma.com</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About AVEO </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). For more information, please visit the company&#8217;s website at <font style="text-decoration:underline;">www.aveooncology.com</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A- 2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AVEO </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CANbridge Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James Xue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+8610.8414.8018</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;781.995.0074</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deanne Eagle</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Planet Communications</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917.837.5866</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Pitts, Argot Partners</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(212) 600-1902<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">aveo@argotpartners.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">###</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A- 3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="text-decoration:underline;">Exhibit C: Technology Transfer Plan and Transfer of Regulatory Documents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Technology Transfer Plan</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This plan describes the transfer to CANbridge of all historical process or analytical development information that is necessary or useful to enable the Manufacture of the Product.&nbsp;&nbsp;The transfer consists of three parts: (1) providing access to electronic copies of relevant documentation listed below, (2) the physical transfer or assignment of technology inventory listed below, and (3) the assignment of the Patheon (formerly Laureate) manufacturing contract covering the ongoing drug product stability and reference standard stability program, which assignment is subject to the prior written consent of Patheon.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO will provide electronic copies of the following documents, which have been deemed necessary or useful to enable the Manufacture of Product:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**] </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Table: Current Technology Inventories</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:89.67%;">
<tr>
<td style="width:33.29%;"></td>
<td style="width:33.3%;"></td>
<td style="width:23.08%;"></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LOCATION</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INVENTORY</p></td>
</tr>
<tr style="height:21.6pt;">
<td rowspan="3" valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:36pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:36pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Transfer of Regulatory Documents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.15%;width:93.77%;">
<tr style="height:15pt;">
<td rowspan="2" valign="middle"  style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Importancy</p></td>
<td colspan="2" valign="middle"  style="width:49.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Document</p></td>
<td rowspan="2" valign="middle"  style="width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prepared by </p></td>
<td rowspan="2" valign="middle"  style="width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Check if provided</p></td>
<td rowspan="2" valign="middle"  style="width:9.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="middle"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Content</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="middle"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.88%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:12.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.38%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.1</p></td>
<td valign="middle"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.88%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:12.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.38%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.2</p></td>
<td valign="middle"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.88%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:12.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.38%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.4</p></td>
<td valign="top"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.88%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:12.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.38%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.15%;width:93.77%;">
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</font></p></td>
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.5</p></td>
<td valign="top"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.88%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:12.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.38%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="top"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.88%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:12.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.38%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:11.9%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td valign="top"  style="width:37.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.88%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:12.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.38%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td colspan="6" valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;">*All regulatory documents will be electronic since the submission was done electronically</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;">
<tr style="height:15pt;">
<td valign="middle"  style="width:15.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1</font></p></td>
<td colspan="5" valign="middle"  style="width:84.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">List of preclinical study reports in the IB, including source documents (see details in the list based on the <font style="text-decoration:underline;">IB Edition 3 </font>dated on <font style="text-decoration:underline;">29 July, 2013</font>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td rowspan="2" valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Importancy</p></td>
<td colspan="3" valign="middle"  style="width:63.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Document</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prepared by </p></td>
<td rowspan="2" valign="middle"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Original file number in I.B.</p></td>
<td valign="middle"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Content</p></td>
</tr>
<tr style="height:36pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.1.1</p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:37.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.1.2 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:31.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.1.3 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:40.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.1.4 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:38.25pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.1.5 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:50.25pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.1.6 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:50.25pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.1.7 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:48pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.1 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:62.25pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.2</p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:42pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.3 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:48pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.4 </p></td>
<td valign="middle"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:47.25pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.5 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="middle"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-3</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;">
<tr style="height:42.75pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</font></p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.6 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:39.75pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.7 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:43.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.1.2.8 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:39.75pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.2.1.1 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:46.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.2.1.2 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:47.25pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.2.1.3 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:48pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.3.2 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:44.25pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.3.4.1 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:45.75pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.3.4.2 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:37.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">4.3.5.1 </p></td>
<td valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#FF0000" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FFFFFF;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check &amp; get back</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:6.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:31.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:26.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td colspan="3" valign="middle"  style="width:63.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Phase I clinical study related documents kept by the sponsor (see details in the list per FDA GCP guidance)&nbsp;&nbsp;</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td colspan="3" valign="middle"  style="width:63.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> Documents before the phase I study started </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td rowspan="2" valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Importancy</p></td>
<td colspan="3" valign="middle"  style="width:63.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Document</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prepared by </p></td>
<td rowspan="2" valign="middle"  style="width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Title of document</p></td>
<td valign="middle"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Purpose</p></td>
</tr>
<tr style="height:39.75pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:14.25pt;">
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;">
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</font></p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:57.75pt;">
</tr>
<tr style="height:28.5pt;">
<td rowspan="5" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="5" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="5" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="5" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="5" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:60pt;">
<td valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.5pt;">
<td rowspan="8" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="8" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="8" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="8" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="8" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:73.5pt;">
<td valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:60.75pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:14.25pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:49.5pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:42.75pt;">
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-5</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;">
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</font></p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:41.25pt;">
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:6.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:31.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:26.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td colspan="3" valign="middle"  style="width:63.78%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Documents during the Clinical Conduct of the Trial</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:63.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to having on file the above documents, the following should be added to the files during the trial as evidence that all new relevant information is documented as it becomes available.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td rowspan="2" valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Importancy</p></td>
<td colspan="3" valign="middle"  style="width:63.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Document</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prepared by </p></td>
<td rowspan="2" valign="middle"  style="width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:6.6%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Title of document</p></td>
<td valign="middle"  style="width:26.06%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Purpose</p></td>
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:42pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="3" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="3" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="3" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="3" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="3" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:150pt;">
<td valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-6</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;">
<tr style="height:57pt;">
<td rowspan="8" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</font></p></td>
<td rowspan="8" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="8" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="8" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="8" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:11pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:11pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:11pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:67.5pt;">
<td valign="middle"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:42.75pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td rowspan="2" valign="middle"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:71.25pt;">
<td valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="top"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:120.75pt;">
<td valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:46.5pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:49.5pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:43.5pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="middle"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:41.25pt;">
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-7</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;">
<tr style="height:32.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</font></p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:52.5pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:36pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:30.75pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:35.25pt;">
</tr>
<tr style="height:14.25pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:82.5pt;">
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:6.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:31.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:26.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td colspan="4" valign="middle"  style="width:76.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Documents after Completion of the Trial<br>After completion the trial, all of the documents identified in sections 2.2.1 and 2.2.2 should be in the file together with the following:</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:63.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After completion the trial, all of the documents identified in sections 2.2.1 and 2.2.2 should be in the file together with the following:</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td rowspan="2" valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Importancy</p></td>
<td colspan="3" valign="middle"  style="width:63.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Document</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prepared by </p></td>
<td rowspan="2" valign="middle"  style="width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:6.6%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="middle"  style="width:31.12%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Title of document</p></td>
<td valign="middle"  style="width:26.06%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Purpose</p></td>
</tr>
<tr style="height:15pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:53.25pt;">
</tr>
<tr style="height:33pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:77.25pt;">
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-8</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.73%;width:101.35%;">
<tr style="height:21pt;">
<td rowspan="2" valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</font></p></td>
<td rowspan="2" valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td rowspan="2" valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="top"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td rowspan="2" valign="middle"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:65.25pt;">
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:6.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:31.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:26.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:15.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td colspan="4" valign="middle"  style="width:76.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Other Clinical Related Documents<br>After completion the trial, all of the documents identified in sections 2.2.1 and 2.2.2 should be in the file together with the following:</p></td>
<td valign="middle"  style="width:8.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td rowspan="2" valign="middle"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Importancy</p></td>
<td colspan="3" valign="middle"  style="width:63.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Document</p></td>
<td rowspan="2" valign="middle"  style="width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prepared by </p></td>
<td rowspan="2" valign="middle"  style="width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td colspan="2" valign="middle"  style="width:57.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Content</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:28.5pt;">
<td valign="middle"  BGCOLOR="#92D050" style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clear</p></td>
<td valign="middle"  style="width:6.6%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="width:31.12%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:26.06%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:12.26%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVEO</p></td>
<td valign="top"  style="width:8.86%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C-9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
